var title_f27_47_28400="Salpingectomy";
var content_f27_47_28400=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Total salpingectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 402px; height: 301px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Technique of total salpingectomy at laparotomy; (B) Excision and suture ligation of the mesosalpinx at laparotomy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_47_28400=[""].join("\n");
var outline_f27_47_28400=null;
var title_f27_47_28401="Uterosacral vault suspension";
var content_f27_47_28401=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50966&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50966&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Uterosacral ligament vault suspension",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 296px; height: 367px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Dissection of the bladder off the anterior vaginal wall (and underlying fascia) is performed and permanent or delayed-absorbable sutures are used to unite the anterior and posterior fascia before anchoring the vaginal apex to the proximal uterosacral ligaments.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter L Rosenblatt, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_47_28401=[""].join("\n");
var outline_f27_47_28401=null;
var title_f27_47_28402="Patient information: Antibiotic-associated diarrhea (C. difficile infection) (The Basics)";
var content_f27_47_28402=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16200\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"         Digestive system",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?9/5/9299\">",
"         Patient information: Diarrhea in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/34/34338\">",
"         Patient information: Diarrhea in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/16/37121\">",
"         Patient information: What are clinical trials? (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?35/29/36308\">",
"         Patient information: Acute diarrhea in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/1/27\">",
"         Patient information: Acute diarrhea in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/52/19267\">",
"         Patient information: Antibiotic-associated diarrhea caused by Clostridium difficile (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Antibiotic-associated diarrhea (C. difficile infection) (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/antibiotic-associated-diarrhea-c-difficile-infection-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H21736751\">",
"      <span class=\"h1\">",
"       What is antibiotic-associated diarrhea?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Diarrhea describes bowel movements that are runny or watery, and happen 3 or more times in a day. There are different causes of diarrhea. Antibiotic-associated diarrhea can happen when people are taking or have just finished taking certain antibiotic medicines. Most often, this type of diarrhea is caused by an infection with bacteria called &ldquo;C. difficile.&rdquo; C. difficile normally lives in the intestines (",
"      <a class=\"graphic graphic_figure graphicRef66110 \" href=\"UTD.htm?28/27/29107\">",
"       figure 1",
"      </a>",
"      ). When people are on antibiotics, the C. difficile in their intestines can overgrow.",
"     </p>",
"     <p>",
"      People can get antibiotic-associated diarrhea even if they don&rsquo;t take antibiotics. They can get C. difficile infection if they touch infected people or surfaces and then don&rsquo;t wash their hands.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H21736758\">",
"      <span class=\"h1\">",
"       What are the symptoms of antibiotic-associated diarrhea?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most common symptoms are:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Watery diarrhea (3 or more bowel movements for 2 or more days)",
"       </li>",
"       <li>",
"        Mild belly cramps",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People can also have more severe symptoms, such as:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood or pus in their bowel movements",
"       </li>",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Belly pain, nausea, or loss of appetite",
"       </li>",
"       <li>",
"        Dehydration &mdash; This is when the body loses too much water. It can cause people to have dark yellow urine and feel thirsty, tired, dizzy, or confused.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Sometimes people have C. difficile infection but don&rsquo;t have any symptoms. These people can still spread the infection to others.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H21736765\">",
"      <span class=\"h1\">",
"       Is there a test for antibiotic-associated diarrhea?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse can test you for C. difficile infection by doing tests on a sample of your bowel movement. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H21736772\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to get better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To help yourself get better, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Drink a lot of liquids that have water, salt, and sugar. Good choices are water mixed with juice, flavored soda, and soup broth. If you are drinking enough, your urine will be light yellow or almost clear.",
"       </li>",
"       <li>",
"        Try to eat a little food. Good choices are potatoes, noodles, rice, oatmeal, crackers, bananas, soup, and boiled vegetables.",
"       </li>",
"       <li>",
"        Ask your doctor if you should take &ldquo;probiotics.&rdquo; Probiotics are bacteria that are good for the intestines.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H21736779\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse if you have:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Many runny or watery bowel movements in a day",
"       </li>",
"       <li>",
"        Blood or pus in your diarrhea",
"       </li>",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Severe belly pain or a swollen belly",
"       </li>",
"       <li>",
"        Nausea",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You should also see your doctor or nurse if you have any of the symptoms of dehydration listed above.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H21736786\">",
"      <span class=\"h1\">",
"       How is antibiotic-associated diarrhea treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you are taking an antibiotic that could be causing your diarrhea, your doctor will stop it. He or she might switch you to another antibiotic.",
"     </p>",
"     <p>",
"      He or she will also treat your C. difficile infection with medicines. If your symptoms are severe, you might need to be treated in the hospital.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H21736793\">",
"      <span class=\"h1\">",
"       Can antibiotic-associated diarrhea be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sometimes. To help reduce your chances of catching or spreading C. difficile infection, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Wash your hands frequently with soap and water, especially after you use the bathroom and before you eat. Do not rely on alcohol-based hand rubs, because they have not been proven to prevent the spread of C. difficile.",
"       </li>",
"       <li>",
"        Follow the rules about washing hands and wearing gloves, if you visit someone in the hospital who has C. difficile infection",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H21736800\">",
"      <span class=\"h1\">",
"       What happens if my diarrhea comes back?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your diarrhea comes back after treatment, let your doctor or nurse know. He or she will probably use medicines to treat it again. But you might need to take the medicines for longer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H21736807\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/5/9299?source=see_link\">",
"       Patient information: Diarrhea in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/34/34338?source=see_link\">",
"       Patient information: Diarrhea in children (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/16/37121?source=see_link\">",
"       Patient information: What are clinical trials? (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/52/19267?source=see_link\">",
"       Patient information: Antibiotic-associated diarrhea caused by Clostridium difficile (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/29/36308?source=see_link\">",
"       Patient information: Acute diarrhea in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/1/27?source=see_link\">",
"       Patient information: Acute diarrhea in children (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?27/47/28402?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16200 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-B2F8B938AB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_47_28402=[""].join("\n");
var outline_f27_47_28402=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21736751\">",
"      What is antibiotic-associated diarrhea?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21736758\">",
"      What are the symptoms of antibiotic-associated diarrhea?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21736765\">",
"      Is there a test for antibiotic-associated diarrhea?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21736772\">",
"      Is there anything I can do on my own to get better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21736779\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21736786\">",
"      How is antibiotic-associated diarrhea treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21736793\">",
"      Can antibiotic-associated diarrhea be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21736800\">",
"      What happens if my diarrhea comes back?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21736807\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16200\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"      Digestive system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/29/36308?source=related_link\">",
"      Patient information: Acute diarrhea in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/1/27?source=related_link\">",
"      Patient information: Acute diarrhea in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/52/19267?source=related_link\">",
"      Patient information: Antibiotic-associated diarrhea caused by Clostridium difficile (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/5/9299?source=related_link\">",
"      Patient information: Diarrhea in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/34/34338?source=related_link\">",
"      Patient information: Diarrhea in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/16/37121?source=related_link\">",
"      Patient information: What are clinical trials? (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_47_28403="CBD stones MRCP I";
var content_f27_47_28403=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F68692&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F68692&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Common bile duct stones",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 288px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEgAUADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDqvjvr+mx3Wjx6ZqlhHrMIkKQeYsypFnCNsH97jA/wr5q8S6201zqWzS7G7upoybqaayAaPH8aHqOv6V9SaB4X0mT4iT6NefDLSNN0a2aRbPUXUF7naq4ZRjnOSSScj65ryW9+HOo6vr3/AAmE2n+GjpbvDNFpcOoPgxcAx+Wo3FmBLEbhzx04pgfOxGADxyM9a3vB2l6fqWpD+2NQt7OzjILCR9pkyeg9vU/5H2vD8KfAD+PNXV/DVoJ5LaDbBJAVtVibeGaIDCiQlDn+6FUjGTnN8R/C7wFpXhAXGkeF9OvmtrmNLFZZJA8908/lBJZM5ePcyjByMA9RSA8S8T/B5NU0yTWvCVzZ3scSiWeK1lUJsAzhMDAOB1/+vXPa34NsbLVbHV7CCGLw4bUyTM8nnBXCnI5zuPIIHt+fUfGnX4PCPxaFl8MrBNJurKBY78WEWI7iQ4cqIsFMKpHO3OSc9BXe6jZn4g/CPTbLRd0VzqEim5llQHycHLlgoA9fSmB8mWttJPucK4gQr5soQssYJxk4pv2mb7H9l8w/Z/M83Z23Yxn8q7z4radoXhbUv+Ef8MXMlwY0VdQmYk+ZIOQPTjnoK89pAFdNpfijVdO8PyWtjJbwxLIqsRbozuGDE5Yg8cD39+K5yKN5ZFjiRnkY4VVGST7Cuh0LRylrd6hqNhNLBCjCJSCA8oONpA+bAP8AI0AXTqlvfaRNfXcwudRLeVHYSktECSBlEzkfL3z1pY/BmtaPG91rumfY7IxFhPPtbHHBVc4Y5xwQa5CQMsjB12tnlcYxWnqmr3OrSW02qXTTiIeWsIyNigDHtz+fH0oAopHK0qsY1G7B+YBVwfyAFdNYePNUt9EvtImS3nsLiAxJH5Sp5BPRlIGe/f8AOuVmRo5WWSMxsDyhBG3255ppwD8vIx3oA7vR7/X7C20y/wBb1LU7TRQx8iRHJMpJztODnbweTn2rpYvHcEd/Ncr4klSxkG0Wf2Tec4xkuwzXkDO7LhnYjOcE961JNcnm0wWE6KYBGEBjAViQcqScHOPw+tAHsWka9oenaJezWni9ioO1vPt0abcf+eYK5YD15q0+jyQ20WrzeKNLSdo98d7PCkYkRugYrjnpXhtja29/fW1vE8kQKgO0hDEt3CgD8hXWPHomg+GbZtY0q+utddm8gzPthWMHoyHnuT9aYHTyfDWDU9I/tXW/Gnh/TnmLSRs6gC4PbawIzxXA6t4J1zS9Ml1K5spBp6vtWcjAdScBx7Hj86k8P6zbWL21zqN091HG5AsHiMiRjqGBLYHQcCtu++JWu3emGO51KG5tIJwttYSwAptHIfGcjt3NAHnVFdJr/iI65ab5dK0m3mDYeW3j8uRyehxn29+1Zmm6d/aEMwhmhS5j+YJLIqeYuOi56t7UgM6iilNACUvbr+FJSjGeelABVmGzlub2K1s8XM0pCoIweSe3IH+FVqvS6tfSWKWZnK2yjAjRQgx74Az170Aa2reCNd0awa81a1itIMZUyTxkufQAE5Nc1S0lABSmkrW0rT9U1u8to7OGW4ZSsSsU3IgHQE4xj2NAFfS9MvdRkxZW8koztLBMqufWvZfD/hbwfZaBpwurSfUvEMFwkt2sMhGxCf4hnG0fril0WDSvAHhW7g1i8SDXLiUHCnDovTIA5wK94+DXhTQtY8D3kkd5NqtvqEh36gQI5ZezLkcjHSmAmt/Brw/4lg0240aLT4LSSTzLkmHcXQ8kJ6H3NeraBoOleHrMWmiafbWNuMfJBGFBx64q5YWcGn2UFpZxiK3gQRxoOiqBgCp6QBRiiigAqNYIl3YiQbzub5RyfWpKKAPkf47aTb/Dm88OfZPHHi6+v3lZdl7q7ObWEgKzrsCsvBxjuPoa5yH4e6PeeCbbxJ4G1jU5PEa69HpcDQBIIg7lWXy9o3gqjqSxfqG4Aq98f4PFrQaXq/xG0/wtYiO+lhhXS4WNxdlBw7FycxHaMZIPIyo7T+Crzx/dfBWzg8Hr4VXT7vUWtYxbeYmowXLyE5LcRowBBDZyqbfSgD0J/hbqNv4xtdH1fxv8QbqxvtLDS3lvqRVPOQt5okLZ2xYZNqnccuck18yePPEmoL4kmstK8S67e6Jpl3u0qS6vXfYIztSWPnCnjKlQOPSvZfix4z+J/wAN7zTY9e1nRdQlvtLex8uGGUqNrKWmIYKDIcgbhwQOVGAa4n4f6d4c+ImkzaXrd5b6Zr8I22jY2B1AOFX2Hp/9agDytdTuJ9YOoalc3tzcSPvmm+0ETSE9SZDk59zmvtD9m3UvCx8L6jpHhae8uo48yzyXEWCCwJweBnr1xXyH4j8L6n4Vubi11WzYSk+WswXdCRwdyv6nB9MCvX/2TdcurDxHqVqbO6lh1CNUV4ISUVl65AG3pjrigDy3xzapY+OdVtJ1keza5Yq52h5PTbIVOBn8K5vT7aC81FYpLhbO2YkmSU7ti9eemT27V9I/GH4ZaprPju6v7TSNV/sr7JtMsVvEVV8knAY5H1Az6GvnKGySW8ntri5itPs6Pl5lZdxUngjrnnGMdulADtOs2n1e1tLVpoZml2+aeCATwwXgjA5xk16prXjKfwJe22l22j2UkEREwuc/vJ89y23g5+ted+C7OOfxBpjx6na20qXCErPvXOG6KQpByPUjk4x3Nz4kXE97401GZGkn+zkKXEYAQD6cYz60Aa3jKfSPFevC8g1r97cR5WE2hiCNju2SD3GfaqWn+H/EurNB4gtnivnWfZAzyDMhQ/wg444PpUXg3W5L7xRpcWtP59su6MMIkLR5H3gcD0HXtmvRvFfhm68M6lZ61bandanYorSQS4UW8B2niQL/ADUHpTA8kmgkTxHPF4smubeRm/0h/vN2PQdR9OmPwqXxPqWlSzW9toltssIQBIxXY1wQepPXHpnnk12Vs+geIrF9R1+Z1lhfNxdW8TsEOeAoIyexwwIGaXQ/DeneIdJuF0O5vrsPcBbi3jihjkZQQQ2SoGB16+tAHK6Fpqah4V1A2+FuA6+dPONscaDkANk56eg6/Sq1n4ZF7q1vZ2Wo29wsi/PLGMiM89u496958C/CPQ9ThuNE1TXp2CyeYlqr7Cq+5Awxz9ee1ewaB8KvA/h2MT6bHGJVAQyScscf3h1zQB4f8IPhDcXWiXup3MMU95DMRbPB85ZgO2QMDP8An088+L2m6/pM8MHijVbWe/eQu9lEBug4IBzjOMV9o+HdZ0SxtNYXTJbaK0swS80YbbuwSfY/hXw/8SvE41vxbqOqRzi4uZi0XngDGw5HAI9CRn3oA42ymjt7qOWaIzIvJTeUz+I5FW9PtP7QgnjBhS7BEiNLIQ0vX5FHQk9c1RhRnY4DbVGXKjJA7mvdP2c/CU3iiS7v73ShdxWSeXBdXQ/cxDqQACCzdaQHjFlp91Npt3eRpF9miwHMhAJPBwvfPTpiqCozkhAWIGTgdAOtfTus638NoNctNJt7GLVp7R2kYxK20yDso7nr611OkXHgTR9DnvPFGk2GjxX7syKWG9yR3UEkHinYD44Y5VfUcYAA4p5SVoBJ5Z8pTs3hcDPJwT3Neo+KdY0Y2+uW3g7wuIrISbZnnYOVGeGCA7gO4OcflXmElvKLjycCSXjAjYSZ47Fcg0gIKKKvNYmLVIrSRkm3OgJt3D5DY4B9eaAKajcVUsACep6Cp0s5nultlX/SHYKq5GD+OcVpnQpIPEiabcEAFurcBhjOM+/SvS9O0Pw9o1i//CUxWkE8sJ+zW9xJ5m0dcq4x3PQ80AedDwfrQto7lrVVtnkERlLgqrE4wcZP5Ck1Kyg8P3EsLy2d7dbNksDIxVCecq3HQY755rQ8R+JijJpnhq5lh0qNAnXG5u5BPIHTnjvXO6WthK0qai80ZZfkkjXdtb3HftQBWthE1zGbgstuXAkKdQuece+M17P8KtOnsNelslu400yb95AzYZ+RyTt6HGOteYxQ3NoLaGTSd0lpOLh5VU7nQkYUnpjg/wCc13nheeHRNZkvZI4rO5vNvlW9nIbiQZzneg6nntjrTQHpHwP8DxXPxX1m/wDEFmuo20TFbdtTYPKSf4tnQjtyOB6V9VWNla2FuLextobaBckRwxhFGfYcV458ILB5vFl3d6xBD9qgiC2km4pMUOMl4+35mvaqTAKKKKACiiigAooooA/Pr40fE6b4i3tjeR2Z0+FLVbd4GuRMXYNuJ6DaM/QmtL4bfGCy8D+B4dGh8P3F3fR6l/af2hr8JGZNoUfII87dqqCuTk5ORwB49RQB794+8WX3xs/sezsNLSw0+0eeZnkuzM5mkwSu5lXCqSQAMjA6jAAzNNtvh14DkI8TQya3rcG1lhtpCyK3oxBC5/H0rx2G9uoIykNzPGhBBVJCBg9RgULbq1g9wsnzo4VkIxwQcEHPPTpigD7+8Lan4S8feEbFbLQ0uNPvk8uWCRUJgGOd3zE8V2vhfw3pXhfSodP0W0jt7eJdowPmI9z1NfKP7MNzfab4p0hBNCLa7VovLR/vLgtuYf3s8V9jUAFfKP7W3g/RLG80zVLS1ZL2/mKz+TgYAHXHbJ7nivq6vBf2k9MttauLS3Ej/are1aRxE2WCEkD5e+eetAHyroXhJp/E2j2F+5igu5wGlRt2F67eOh9/f259F/aM0q00bxBY6bodhtkubfMsyKWdgDjt1966L4b+F10SS3mhDTWCASEXWASTyVBHSvetY8Kaf4q0+DUbWExXUa/KG5IOOme9MR8DJp9/BcpYRRDzrxRt4wxXn16dDkV9F/s8Jd3Glv4b17LwTErEjjIQdwc12sPhaLR9UF5NBa3EC58wkYaHPp61bU6XFeeXYTCR1PmwgKFYOexPpRYDl/i58N10mC0Fk/kaazCOVYMRhl7Kx7D8vrWL8OreXS11E2UVrPZmX97PMnkhBgfKhP3/AMK9h+Id1Z6l4Kmgu/IlZYwLkSPtjjHrkc5r518cfELT7HwZZeHdKsZIYlk3SBD8lwo7hz8w/L/GgDu5bfTvGd5NF4fvLmz1K1OyWaHhIR/v4wD7HmtfUPEF7olvY2lpJbX+oBljnk2F3dc4JIB9O9eP+A/FuqtrEEdjHbLYzqGaIOQFPoTjLN26DpX0NoPguG91ix1bXkkS9jTKADCqM/7PU/WgDlvitr9p4O8HTf2bAI7vVmEIikby0BPVgpHTnmvH/CPwbuvE9nFIsMtqiMBLdK++ORT1IJHX2Fe2eOvBl3418YwnTdOuJIrNTGt9Ou2NCeuA2Mn6CvYNH0D+zPCVlpSyPJJboPnwAXb37d6APK/hr8EfBnhya6uLmd9UuEwd9xtAQdTwKzvGfjm5ksb3TfBf9kaR4esf+Pq8mmCzTLg7hHGAM/Umuo8W+F/EniPWzAlg2n6QinIjuI9tw3YnDbh+VeXXn7O3irV9YE95qmmWlmrDZEAznHvx1oA4vSviRoGk6lImkaTBe6jKipbanNHt2OT0MePX379qtaRZib4kreeNmh1P7faMIWhj5t36j93zjqec/wA69fj8AfDLwvqemaZ4nmjv9akRpBDKPkdu77QOD+Na8dl8L9S1+OVdKt/t7qYg0sTKRjI470AfJOrtNf6pd6B4X0y5b96wmkgiLTTgHjcB0XJ7nv8AgU8P/DLxXqN44W0OniHkz3LFFB9ARk5r6E8XeIrL4T6ebTw94dsrEXLn/TAQAwPcepHp7CvN9E8d2ghmuo9Re7ubhi0sUoPmhuvC9x9KAOd8NeCtei1C80qOwsby2H+ukDctxj5Xxnv0+tdJ4c+G114auWv727sooblWUB4t7QnsqsT1qvb+INama5aC4gj1Vw0kdisq58sf3iDgE/XvXKeKvGHiHWfDs1tritElvOpthu2FGByT1y3GOR9e1AyfW/FFxoEosomtb2cMxkklTovYYHQ+9cHqt9/aD+fLNcPOWOUkO5VB5wpz+mKoU+ZleVmjjEaHogJOPzpAKspVSg2shGPmQEj6E9K0PD1u0t8ZUuEt/symZmKbyFHUgdDis0gKFIYMSORjp1//AF1PYWwvLmGAOsbSPgu7BVRe5JJ+v5e9AHb2mq3ky2N4t/M0Qm2MjQLvuBnkKAeePxFet6Nb2dvfxW2i67GsojNzJBLbqTHnPcfN614Esb6a/nvfq0dqzLaeWd3mHPVccAc5P5elanhrWdXbxZBfvfsl00IDywxCVnjyPlIQHB9zgjvTA+p/2c9c1bXtZ1u4uktl0+Fjbo8gb7RIwPUEjlOPXrXvVfJHwX8VWh+KV00eoFbG1tjkS3KojnnJRDgk88/yFexaT8XLTX9YlsdGh8xUdovMzn5wcHigR6rRUFhJJLZxPNjzGUFsdM1PSGFFFMlkESFmzgdh1NAD6q3N/bW5ImnRD7n9KxJfFccfiGHTDbyAMMtIw4X0rxr453k2n6kst5dT2cyyCRZIiRHNGOvGOTTsB8a0vTqDgikq0sCkRr9ojDMT5i54QDnOeh78DnjHWkB6L8F/hFqfxKvpnScWOkWxHnXTKSX5+6g7nGeTwK+uvCfwQ8CeHLaJY9FhvrhCG+0Xo81y3qM8D6Cue/ZMv9NuPhmLawW3Se3uGWfywA0h4w7DrkjHWvbKAOD1j4YaDcXWmXmkWyaVeafcpcRtajYr7TkowHVTV/xF8RvCXhu8az1vXbK0vFAJgd/n/Kutrynx98MNF8ReMItZvtOa8lCbSiqdi8dWHRz9aAPTrC8t9QsobuzlWW3mUOkinIYHvXIeKtDlvPMtUQ3Elwm+SeVeFI6dP5Vp+CdCl8OaeunQhI9MiXEEO4sye3oF9BXRSAlSAOe1AHkNh4VuJXEuq3U8Qx5XlI22NsfxYrs9JutC0O1uf+JjAZbWPMsfmjKDr0NcJ8UdN8SWGm7tJs9R1m8aQ+TGkxOeerduO1eHTeDfEenWl22u6TqMclw32hrtrbLIwOdhk6lfbp19aYj3+++IPhDxaX0W6tXdpxwZYxjPYg9zXnUXgDxBo/jN57a7/tTS5QW3sOYAOQu0DJP/ANavBtO8V6rBrFz5/wBkWVSEDCZYvJxn7p79+le0fCj4oazpGmSC6s5bmOZiyPJJvkP0B7e9ADPDGheKte8e6nZzQXa6c/FyGBVAOmMdear+Nvhpqn/CURyG3dnt4SieXCR9pU9jxyBk19A+EfEE9/JYSRaQ1vHdqTJvGJB/tH29q7eSKOQgyIrFehIzigD5v+Efwz1HSfE1vcanbabbxlMtbxRDc49c+tfRdnZW9mm22iCD6k/zqWOJIxiNAvbin0hhRRnnFVdUv4NMsJry6YiKJdxCjJPsB3NAE+8shKDB/wBoYrzjxheXqW1zcrfeTg8hTvRR7N/D9apz/EjSvEcjWEF1c6bGw2i4ZcYY8Y57j0rzD4g3dxoMy6bHrb65ZTg5RwEZSf4jtxkUxHH+K/Fe5Yr27jIa2mZRqEE4cjnlCc888Vwmo/FLWG15720aN4lj8qJZk5C9+h9auzeCHT7c1zbxm3mXfp7CVwgY/wAJGfp/niuYsfCgvYrwR3JiuLHi4EgBUn/ZOc4+ooGbF14+1zXdBhtNQt7bUbWyk8xo5V3FVJ7ZOe+M84qta61vt9WTT9I02zl8j5NoBuEz1Kt14HbjFbHw8v4NDS7sL68sHsblPM3k5DseNoPbGB+dcbfEWfiJn01JmuI52IWVRtHOFxg8j/61IDOCqk0T2FzK8+wu5x5ZQgEnBzzxmoZ7m5u2jWeaWdl+VNzFjz6U+/S5tr+ZbhDDOSSyqcY3dQMdsGqvAI7j2oAlgjSQSeZMsRVCyhgTvPpx0/Goav3l0LizijitoIYojtLL9+Q9i3r36Adao4OSOh96ABTgg4Bx606R/NkkchFLEttUYAyegHar89ibWws5476FpLxWDQI+GRd2PmPTBI7+lUJEMcjo+NykqcEEZHuOtAD9z28pCho3AKsGHqMHg+xpsUskL74ZHjcZG5Tg88GmqNzBeAScZJwKkmaISIbXzVAVclyM7sckY6DPSgDoNDsoY9PuNXkMZNupKKD8qvjC5HXdn8K9N+FHxE0Hwhomn219bJLc3UryT3EDEyIcn5nz7V4bTpNnmN5e7Znjd1/GgD7n8C/GTRX0+5Op3kz/AL0/Z1WLLMvbGOtYmv8Ax90gRXsl/bata2aO0cESJ5Us5x78gfXFfIVpqskOqWt3NGsqQSLIIPupxjoBwOnYV1PxC8T6B4mhS5srLVINU3AM09xviC4wQB26Dpj/ABYHvHww+PWhaNO+l6uuqW+nyOZI5btvMMRc5C9Scc59K6P4gftHeFrCzuLXQpLq7vxgK8cXyqeucngj6HvXxTW54O8Man4v1yLSdFiWS6dS/wA7bVVR1JPYdPzpAdT45+LXiDxXrlrqpkNhc26bF8huD7kd65GTxLrcwfztVvZC5yWeZmb8CeR+FdT8QfhVr/gbS7fUdaNuLS4cRRujElpMEkYx6A815/QB21p4T1G38NL4h0S8trxHDQyRLEDIueDtVgSe/OAa5OBHdvKjt2MygghYy5Y57g9PTgV3Gl/DzGhT6x4j1q20Ow3bYIbj5p5z6eWOVOB3q/p7+BZdX0i0me/1HdtikeVQqxleFA2KpIPTJz70wOq+AupeK/D/AI5t7i30FnsZ08qe2s4VTzF/v57lc9M+tfattMJ4ElCSR7hnbIu1h7EV8i+MvjVqfhl/7Og8N6dp91bgfYmSUSqE7OQGyp9v/wBdcRqf7RHxCv4kj/tO3tgG+byLZV3r/dOcnH0waQH3hJcRxzxxMw3v0HeqPiHXLLw/pr3+pyGO2T7zgZwPU15r8LJbjQPAS+K/Gl4qXF1B55jfI8sHkAbiTkivn74tfFRvGvjmK0eS6k8OWvzw21g4Vp3xuBYkEH6YoA+ob7xfJ4i8Izax4Cv7G4jgY+a8mWG0csOOhxVHwH8RYtVvWs9WvLUSyH/R2Q4D+1eF/C/xNJZ+B9etLFpLW0kkc+RK6yImR8yjABB+tcPf6VqSLaXmm2Xladbzo9syllkBU8gr1bPtimB974Gc9+lUtb02DWNIu9OuxmC5jMbe2e9Y3w58Rx+KfCdlqC5Wbb5c0bIUZHXg5U8jOM/jXTHOOOtID5I0r4Ca9e63DHc2NrbabayPG7yS7vMUH5SO5yADnPtz1r1Pwf8AA3T9JmmfVL17ld37lYsptX+63/1sV7GqhVAUYA7UtAFLSdLstItFttOgSCEdl7/U96u0VU1SSOOwlaaIzR4wyDuPf2oAgXV4p742tmjTuoy7ggIo+vetI+9c9oWsaO6yx2qwW0kfEka4BHtmuN+J/wAS7fR9PfT9NieTUrlCqknb5Q6bj6+1AHpUdxEzh2aMb22Rnd9/6fjmvB/jl4q8QaZqNzbWenusIjAMyfvFdTxg46GuJ1DxRd3OkwDUru7CwYjihizuBJ/1nX9a6DR/izp9nfReGtXtJ5MQBopwokaU8/fB+nc0xHgGm+ONUt5SZbtbaaGQuIpIztwOq46it68+IgnWPWJ4Uaa4HkTLbxbfL46ZJxnFdV4qtfD+vTyDWLXTNP1G6Y4miIQbR0JwBg49K898T+Ff7O025SDXLc6VAPMh3qqfanx0XH3jx1NAzV16/wBD1Xwvp+rrfXkeoQTNHFb20oMyKepPp0/zmvK7khriVgzuCxIZ/vMM9T71pade2lnBt8iS4mlGHVm8sKc8bWByffpWcJCshO/hhtYgZ+Xpjn2pAWLdrSOGeV9zSZAigbJH+8xGM4GRj1PpReqsAs5IEkhkeMSHJ6Nk4Kn04BHp70hhhexnusBCHWOONWzzjJJB5xgfmaggmWIS7okkLIVUvn5M9x70AI8hmkaSeQl25Jxkk1HRx+NWY9PvZNPlvo7S4exicJJcLExjRj0BbGAT6UAV1cqCFwM4Occj6HtVqwspL0TFA22GPedqbieQMfXk/lWja2y6ZYyXd1/Z8lw67Y7aYs0kZP8AEU6dORn1Fafh5ra/0O7spdCnurhCZFurPK5Gc4k7YHbj8KAOYuirsJi0eZMnZGu3bzjkdBnrxTrIKZJGKEgqUQ7NwDkHaD7nBH69q9NuPBXgz7DCP+EqRdWnh8xFZlEIbptPGRz6nnBrjNJvY9Cuzbyak8kDtmX7GFdVZfunLqQe/T9aAMO/trm0umhvYHgnXGUdNhHpxUYglMBnETmENtMm07QfTPrV7xFqlxrGqy3V3cvcsflWR1AO0dAQAK9I0b/k2DxB/wBjFD/6KWgDyWrcem3ktm92ltKbZRkylcL+B7/hVVEaRgqKzMTgADJNdr4a+HnirVJVFtp99a7k8yF2jZQzdh6j60AcRRXVJ8P/ABU0F/N/Yd4sdiSs5ddu0j0z976jNc7fWVxYT+TdxNFLgNtb0NAFeuu+Ffix/BnjWx1YY8gHyp8gn92xG7gemAfwrkaKAPqn9oXxrpfjf4fNbeHb63nSzlSeRYXByB1BzzgZzxzxXytXpXw5n0rULWGx1GzspbiKQgvNa7z5R6Ev0GCcYrN0zwvbHxvdWd8kg0qFmcOM7dmRgbvof0pgc1bXs99rBmvXFzcXJ2NLOnmnLcbgO5Hao0unsCv2Frm0uwGSZhJgn24AI6dKgeC4tldnjaMK5iYkYIYdR7GrGhy6dDqCPrME09ntbKQths44PUd/ekBn16n8Gvhxc+I9TttW1eCOPw9bv5jfaH2C6I/gX15Az+X0z/h34Kh1PSrrxJqzCPRrCYB95xvA5Ix37Dj3r1u2+Jmm+Ntf07TrSwnj0+xXNnp6osYuXHAbqBgY6UwIfjN8SX1e0+xKbCGEP5ENlP8A8ssA/OT6cDsPrXgusaNDppsYLfUIbrUZGxIsD5WM5G0ZwOa+gdB+GnhTx/4h8R2FxqF3F4kTErRyjaYMgAYxwVGR3714Lrul3Fp4sutE1GFHvLaeSCSS3KgyMM4brt7Dj696ANnStJlg8Svp3iC3vvs7xCW7js22pjHDFVwOcfma9n+D+lab47uLqSG11GzOmERt59wxVQADu6/erhfAnjzw/wCHtDOj61p0i6zdSGO+1E/vAUz8oZsljgcYArW+HfjXTfC9xrfh3QElupb6Ysjo4MDLtH3Tncfp9aAPpzw5rulQarb6VpFuTHIh824bClmHQn+99a7evgDxf4111tSmisHfS/sOFWGJHxgYI5xnPXOeP1r6z+BnxAk8aeFoF1fy4tdgUCdFYESL2kHJ69/Q0gPTKKKwfHU9/beEdUm0lgl6sJ8tj27Ej3xnFAHn3xJ+Ki6ZqselaJ5chDFJ5i+Bv6BF+nc1neDviCbG+bR/ELtOsnzefuJQFuiivC9Wg+0akIowl1dxsX+1zthIz33LkE9/881p6NBfTStd3E7ShAQsqRmCNvQKzZGKYj3WG1gvdfv2tvNzbQ+Y6gKBz05HU/nXz7rviH7KmoXlzasbhpmMUxbdIi/7YY4A9hXqFhrdxomkTX13qelAxxYkS1G9wPXaGJY141cRjWPtEtppd/qmm3Nx5pvBESwbdnDLjgCgCvJrj3/hC6nuLv7XOoPnAAKQv+zjBHBzzVW302S78LT3/wBrN09tD5qSqdghQdt33ifXrV2Pw3dXOpC6eFHkPyKkA8r5emHHPHua5gm80abWbK5hlco254EmPlovXI45GOvTpQM6HW9W0pPC+jyy6bNfMclppGABAGOh55Pr/hXA6lqj6qSJ22oo/dKT8seOwAx+ZzU8c1pqIzMs6rGNiiSXMcQIPQ446e/41hHbtJGQc8DHGPrSAlkupXtooC37qMllUDoT1Pr2rX8E6YdZ8TWdp5kCb33M07hQQOTgnvjpWOvnTiOJdzhAdqjt3NbOn+H9QJtZ4/LjaYCSFnwVx6nPTH0NAFjxyuif8JG0Gg213ZWsR8lxcsG+YHBYbeoPNYCWk0rzC3ikmWLO5kQnA9T6fjXrEPga/wBbsYYbSWPWtXRd81umNoj68PwQfw7Vb1nStD0DwxHYazrMC6neFmMGnE/uW9JDgEnoOQaYHkDS2baeqfZ2S7DAeYrHaV9SCfvfkK97+BPg3xD4j8GeL/Dt1YSpoGp2gezu5wEVLpG3RNtPz4bPJAPC14fDbq2oRRWtxkI2yS4WEBVGeCMdTweeCa9++HnxG1HQ/Eul3k1teJoXl/ZrhZHX/U9fNKZ+UqRkY6gkd6QHkHxE8NR+Cdf1PQNTuP7Q1eER7rhAwVCUVwBn72Qw5/StPwbbppHhO81K21GY61Kv7rSoUyZozx5hOTwOTjFelftLaPp0vxEN9Havqd/qVrE1vCkhSPYq437xgdvWuT8G+FL3RPDF/wCILk/ZkmiMLRKPmjHOTlun4GmB5ba6VLf3EYicyM/MyovzxnPPy5GfwrrdN0+PRLyyupLKC3bbiaW/UNCpznMeWyX9vb61S121sF0awg0hWikVWlJuU2TTbv7pXhuo4z2FYljo2p6t9ltrBJrweZ5YWNJGELMRw3GF9ePekBL4o1G1vr6dxZRK5cMk8MZgEidcmPnrnOc5/lX1/wCG9Z0Nf2Yv7cTTLB0t9NfdE8CYa5jBiVm45YsBz15r521f4d+JSY9E0TT7y+kSNTctLCF8voQqOwAK55wpPT8/QNB0DxDP+zzf+GZNF1iAzatGNrQHO3gkgYzs8xFPI/iPOKAPCj4qv0ST7GltYu7AlrSIRfKM/LgdR0rTb4g+M59M2Lrmp/Z4FEZMZwqKeB8w6Gu78M/s8+Mb6SRNQ05tPmidWSSaVDFIvpgZOfr+Vd3pfwCn0jSr6w1TxYLKOdd0kMMaPkEY5yM4/KgD57tvEmralMlvqfiLU4o2XZ5jXDsv/Ahnn61H4et9dfzjolrPPFM3kPMsBZSScDLEYU8+3WvbU/Z20/UbtLfRvGNtOEQySAxLuOemCDx+Oa+nPBfg/TtB8EWmhR2VtFEIAkwiTAdiOX5yck85oA+W9Q/Zr8S23gkajHd2V7qaQb106KHaw3YJHmfxsB6j6Guu0D9mSz1DwjZ/bdZmgu5UErFbSMMrEDKkkbsAjpnua+mbKH7NaQQDcwiQIGJycAY5qcDHSgD5Osv2dtf8L+JYDpt9aanptzlJGcNE8YHIBXkEcdf5V0fjz4W6/c+GZbbSNJt5b6crEQJgqohOC2e4xzX0dSOu5GXJGRjI7UAfleqyKolUMFDYDgcA9evrXqfwR+FFx448UmLXUu9P0a1jE9zIyGNnXsqlhgZxyecCqfwS1XS9M1p31/S7fVLTcpgiuJVVEnOQrYPf39q9o+KfjP8A4Q7TLcygSaxqpBfT4n8uOOIjuw6jtmmB57+0TqHh+0ey0DwdPbjR7NfL8i3f5TIM7nyPvcggk9Tn0ryzw5rCaOk86I4vgMQTqwzEfVfQ98/5NzxBZ2tz4iuLTw1atcPcYXyY03iI8EhPx79uanvdIS2tbTSdXT+ztbiDMrXJCwiPJb5jz8xOR0x0pAReG9c1s+KZtVt9burXX3VvLn5Z53wBsYngZA78cD2rEhu7yLV5L5/3t3HIZZTJzls8lvXk1Xu51uCshVhO2TKxbhyT1AxxS6dNDbXsM1zbi5hRtzRFtof2JoAkkvGfU3ublEdZJ/OliU4RuckcduSPxr274GeC2uDN4hktImMp22ixSZMZPoPX/CvJkns4fEEerwWko0szb9kkS7VbqUABxx2/D617F4Q1jV5r6zHgzT302zDC6Fvbx73Lju6n+H6U0B13ir4H+L9f15dUWewgZlVThz8wHILr0z69c1R0zRtd+GPjew1DWbizLxvkiEkRvCww/fr3r3vS9R8UazocMNzpb6ZdygJJd71wo7sqE7gTU1r8OfDMQLXFh9uuD965vJDLK31Y0AdRY3cF9Zw3VpIstvMgdHXoQaW9tYr20mtrlN8MqlGX1Bqto2k2mjWotdPRorUHKxbsqn0z0q/SA+SviD8PNU0LXro2kLmKRiLaRV8zzR1BYeorF18zwaJGmsTLcygYls3by/Jx0YAZFfYep2CX8ARmKMpyrgZIry+9+DVrd308v2qOKJ8lUSPOSeuc0xHi3gq2/wCEgnihvbJLK3kQoI1GS3tu9a1rzwfqOiQ3kdmJoLSUBXSGThUHTJz1+le52ngiLRNOt7TSrO0lQgpM0i4Kr32+9ZGieHbSLXf7NNjc/wBkqpIEoI/eHvz17UAeJjw7Lc6VDc2VnJHFH8r+Q7MTg8mRjg59hmsbWPBNve3st3ay7iYtjpNkbf8AeHUivqCz8GjTdKvoLV7jY8jPHH5mWwfesGDwRGL4vewXDTFOGdvNcg/3iO3tQB8man8NZVukdLmCG0chfMjDMqHHU5Oals/A9rbzS3i2s2p2cX7uSFJFDhieCoJGR+dfZl34Y0230/A02A+Svz7lBVs+tc39g8PaINllplhHcsrSqWxj8KAPCtD8K6VoFguookmnTTDbLFdoZflPQZXcAfxqtp2hX2owXrR6ZOptuVu3UNiPrhNua9TudF/tVlTUtRjttMmJmNvEQjbuowOuPasvwz4rsrC31pb64iS1sZP9GWKQItwPf39qYHP+GfBl95lrrmmfbdEuJfl2RRndOvXMoxjt9eayvGngO+vvEst+r2cU0yhHMqBSx7YBx+dem2PjefW9esVsp7Wz057cu4aYHc/Zf9k0QxavrrRWFx4dM0UlwVldpMyAZ4fd6UAeQWnw41pdJSwihkmbzgfPQq/lHOc8Hp35px8Eal/bWqWbST3F7+72W9tCzvJ05bH3fxwK+p/DXw8tNIZmlu7iYHpGrbVH17mpP+Eo8M6Le6hZwbRe2YzMAuW59W60gPHbPwH498SSafbaraw2lhYwCFGuiC2wEkAAc5Gcc+1dbffBaHWVtovEniG+XTYlC/2dC4jjf6sOTWZr/wAYtUGvWtrayaPZ6ZM203Lz5bn+Edg1VdV1DydRCz3eqaleXRH2UbuU/wCAdMe9AHUa34W+Hfg6806fWIrZY7WMrbLMdzQj1AqVPiZ4F00eVYWjKSQULWjRCXPAKsyjPNeNalp95b688+sPdkK+JDfDcsgPReM7R9PStDwXE0niG7sTc+YUPmWlyIg6QL1KAHqPegDsdd+NOopqFxp9lohtWXaUuZlyAp/iGOCB/WtyT406dpmlh9VliaR4sw3ESkxzvj7q46n6V5p4o8G6rrM+oalFe2cNhMBHKys3zEZyFP8ACTmsPUdLt9J0nT9Eks7eC2uXCzG4kyiD++uM4NAHS+JfiAfFmi2Ka34kvvD5n4kNgnQEcI3v7iuasfh9b3tvbXWiePTqdzJ+88j7cGlCDuVBJIB6g07XfDMEEnkaXq2manIkQWJLokF+OgIGPxrovAfgWz062t/7R1eyS2Z9roy4MJJ+6rAc0AdJ8LfAUOmXsuvHxEsl3OvkSReSBA5BOAvOQa9v027vJYyt1aMki8bwQFf3HpXl0fwua71WaMa7O+kbVeOFOAjeteqaLpq6XYJaieacL/HK2W/OgC+OQMjB9KKKKQwooooA/LrSII5ppGeaaExL5okiUNswR8x5H6c5rS8UXGs65jX9VaWe3kf7PDNKVzgZIXA9Oe1c/ggA4OD0NXljtrzUYEFwbeBwoaSZf9WAMdvvcAc4GT6UARabf3WmXiXdhM8Fwmdrr1GRg/pXdeOZNBvL3R5tL00R3LwgXFmSS0xYE+azp784HNcrefYl0l4oNS80pKfKg+y7SRnli3/1zxjp27nwTpOq+GbWx8QXsbyabexCKEQEtjdkguvpyeecZoA5/wAbaRc2Vxb/ANqwQ2MC2221aJhJ5wGMDGcgc9SOPeuU0+O4mvYI7Lf9pZwI9hwc/XtXU/ErVYL/AFOC2tkIFqrB2L7suxBIB9Bgcdua5/Sr+5sbyK+iZmktQPLy+NvXHHUjk8D1oA6q7tdaTxRDZ3JhW68kCdoSSJlPBJ45fH8q+yvgT4Qs9E8L2upmEtqF3F/rpV/eCPJIXPXHP+c18qfDe9uLjxF/aeoqx8iQRKuwOjsxw21uc9PwzxX3xFGsUSRxjCIoVR6AUAOooooAKKKKACiiigApGRWI3AHByKWigBssiRRs8rBEHUk4rzXxZ8R9O0+GeR8yWoO0PbnLA9t2OnNbfjbxXY6ZFNZyp5zMvzbWGAc9PrXg/j5G1+8tRosTyHyz5rWw+WI9hJnvTQjUsvimdUvb+C5iZ5HAVLRHbYy+rP647VY0/wAeWurx3Vy0dt9rsFI8hf8AWRr6479K8l0uwuk8RwRaj89hExWQhCGdsjqvpj0r1DUdEtrvRYLLQRp01+zb5DLbkPtHYHPH40wOA8TePJ9USe1tdKlke/zGLqIkDYeDu/uN9K6zwZo9nai70jUXbbcW4dLy6A3RN3Xjg/Wm6J4D1LW75LaWZtJinlMcs8KDMag9CDwc9s175D4D0mLS7TTGtI5YI0CyTkBXfH09aQHkvgD4WT6he+fdtEdMjIAkUECbHdRXsesa1oPgbToReSfZ42+VFVdzvgfrWZ498d6Z4JtIbOII14yhYYB92NRxlsdBXA6t4h0rU9OmXxC8kss8ZaO5SPKc9FB7c0AWPGfxYsFexkkVJNLuXCRxjIlD9mJHAFeS6neXyeJdbcavLEl7iQRlfnCdwD6/Wqut+GGt12jZJpmDKsdouVBHP7wD1ra09Uks9OvLuaGK2lXaC8QErt2A77aAMjw9Y2viue3M0y2tvHKFjWVT5rYPVl9feu/ksbSd76eGYaY9nH5Md/IuZmXuFboB7VxltBpdtc3OqWt1BZa9G+JLqR8R+Vn7oPTdik019Q8SG+sdLjuXsnUmVJXZ/tB/2cn5fqKAOw0SMXQsIdG1RTaXUu28EqljIe7EetdP4ljj0i+Nxp0he4jh8vI/dKo7MSetcb4SceB9Itr3xDYyLeSsdsCHe8a+jehHrXI+MfFeo/EKeSysvNtbKCYPi3O7zFAyULg5yeaYFLxN4xgWO50rX/s91qMStLGWYG1b0Ei/xN36VzHiGK68Q+G9LnnlgkvNwAggby1KZ+6c/d7dazW0u3SeS+0aV7PTC4jvI72NTJAR1ALA9c/X69vavg54FtNQ0a9vxa3UNrI3yfaQrC8/2weSB9MUgMLwBpfhtRHDq/2a1kwUgs3nWV489S2CcZPevWdE8LaH4Z/s20sNP1UXxO2F5VkmgIPU5OQK6qDw/pXh7RYDcWWn2iO6osboN8rnopbrzXoURLQqXQISoyuc49qAK+n2kdtbpGpBZTlivGTVumxqqr8gGDzx3qBryNbxLVlcSOCVOODj3pDJ5ceW27O3BzivLPAHjiaU6nDqCutrZXDW8aFcvjdwzH05r0y980WjrFhnb5Rn3r588VaBrWi/FTRotQ12R/DuoShRbW6KHVh8208Zxkd6YH0WpyoPqM0tYml61FqWt31lbvHssVQOufmLN/QYoutRunSSezjQxQOVbcch+2fpSA/OnyI9N0fT76fTLa5ju4Jo9xlcnfvIDsBwpAxgDrg9654n5sg5x0zXaeOb+PTtQn0Kxu57qwtIlghlDBQ4KgksNvPXHbpXFUAdP8P4kudeZBFayXJiPkR3EQdGfI4wc89f1r2T4qaR471Kytbww2Wn2NnEgit42CSEnqWX7uOc/hXB/AabSbXxOt3qc2xoDuZJMbWXsy+jA55PGDXs2s+JtP8AGk08NyI18LWFwFmvDL83mbfu5HDDB5xTEfNeoaffandyRafDDfG1j3SyWcZyxPVmz1b6cViQkQXQE9v5m0lWifK89McYINes+I/idYWmqXcHhrTEt4bcC2tby3kCO8YzndkEEHt0471ka22i3/8AaNxfXcbah9iEsKvbshYkZ+8WxnkcYpDOq/Zw0i11nXYLGQyx3IvFmZCfk8tMMQc/xHBH5V9RfFvxPrnhj/hFf7BfTV/tfWYNIl+22rzbPOztkXbKn3dpyp65HK45+d/2dNJc+NvD6FEtsRtO+3jzdq5H196+iPi34Y1zxP8A8Ir/AGCmmt/ZGswavL9tunh3+TnbGu2J/vbjlj0wOGzwAZ9/8Q7/AMFeKF0r4hrYnTrq1mu7HV9Mt5/3nlKhlie2HmupQF3Mm7btA6HdjpdO+IPhjUL82dvqeyUaYus7ri3lgj+xMFIn8x1C7fmGeeDkHBVscprnw91zxtq95qPi+802yWPTLzTdKsrAPcLaNcxLHJcvKwjMjEb18soFA24O7JPFH4LeKtcmWz8TXOiW2ljwzb+HEl0+5lkmj8h45kmKvEFfMsfKZT5GwGyMkA9q8I+MdC8Xw3Enh+++0/Z/LMsbwyQyIsiB42KSKrbWUgq2MMM4Jwa6CuA8I+FNcbxxceMfGEumpq50yPSIbXSmdoBEGEryM0gDFmkzhQAFUAEuTkd/QAUUUhYBgpI3HkDPJoAhv5pLezmmhhaeRFLCJTgt7V5APGviLV9QvvKBsViX9zaxoGZ/r33V7NXkfxQ8NRaXHqGuW9ssluy+bInnvEVkz1Uqf06U0B57F9vurm5s9WQxvMSyCeHaV9X9zzWxo+gLZXQs5NVuIbFl3lvMKG4b1OOtYMfi25utGlOrGSYRJm2bywSrdg7DnHvUuh65f6tqNlby39hdSJFvnkt4yyAY/wBXyOD7/rTEaup6NqF7r8N9sK2UB8uOdQFaVfdhzmt7wzpMQ1S9urKC6uJlASNZuHPc8Zx+NbGn6S2uyWKLG9g9qdxs5ySGUd/lP5c16TY6baWIxawJGT1IHP5mlcDmvCPheWxuLm91FiXuGLC3Ll1T654J+lHxG13VtM8OXY8H2sOoa6uFSBnAC56k9s+gNS65420exeaA34R4W2zOqFvL/QjNeX+J/sOpaRe67oWpSzpcMBN9jc5f69cH8qAPINZg8Rt4oCThZNRLCS4+3NnJPVeM4/lXYxWbC6iW/sri/t1j34tziON/RhkY+tdjp9vp6aSLmwtJmnMe0iT/AF6n+9k9fyqp5Lvax6e3nSXD/wCsRVMO4H+8xzn8KYHld5r19aw3GmeHLeJmuHY/aAdwRh/A2eMfr1rQ8M39rePDFIEFrpsh3+YG8xpv7qg8bee1b2veDbm7e103A05Yp1lje3TfFLyDt9S3HXNdZMng3TNRhOo3FqmtWyBmgZwu0f3iO9AHJP4GvtW1Zo74HStPvT5wkRVYdc7VBBAz71vWGmanog1aPQtKkmR1ESXbSAZIHXA/pUeofE3S31O4FjdC6sYEyTDH5hjPcFQa6vw94i0+cwXFpJbTQOu/c8gjEf8AwHn+dAHnWheAIl1a51TxNc61NG6bX8iXcise20gmsfUNNm0vxXaQwPcLpS7tk0YG/PG0Hjr1r6KsdSsbrzLm2Cyqn3vJk3Kx75Na8Wj2Evl3ENrbiMjeQUDEN65pAfJM3h2LU/FwU2b3E1zmL7OEO089SP4jX0r8OEh8P+F4tOa3K3tpiN4FjKrEO2M9sV1Vnp+nC/jmW0gF2illkVQCAeOPStZkVgQwBBGD70DM6602x1hEOo20N2F5UuuVB9QD/OotWvn0+5jklkS306GItI7LncegUe9a2NigRqMDjHTFMngiuY9lxGsiZBwwyM0gOA1XxNe6dd28DRGOS7lHlSLFncCfu7fWu5vrZp1iljDLPEdyYbHXqD60+WxtprqO5lhR5o/uORkr9KpamuoHVLA2LoIQH89XPUcYx79aANKQB1dMjpz7V5F4p0G31rxroeuWQUPbsY1KXDIWPqcfQ8V6Xr2oDQ9DuLzymuGjGducbiTjk9hXFtcalpsjastrAI3QSraJtyT32n8aaENufAunXniubUL/AO0i9aJd7W9zIhfGcBipGevQ8VqpFcW9tK1yr2cK8Rx/eRsdCfes7U9V1W/kttS0K7sobeQhLobldsf3evB/Wn6praNIbIz5tLdQzuV43emepoA/PrVL2XUtQnvJ8eZK24gdAOw/AYFVKsQram2laaaZbgY8tFiDK31bcCPwBr3z4O+Ffg/4psUsL6TxBN4g8sNIkw8tWbHPleXkAZ6bzn+iGfPn0q4dUvTpa6cbmX7CrbxBn5d3rivq26/ZZ0q91C4ns9VvNPsHUGC3kCvIhxyHPI/KuO8cfA++0OWC8utN+2WcJ2yyWRCrKvPzMoIIPfigDwO9mtDLA1jA0QRQHDvv3MD1/l2H0p9vdidRBqVzcfZVyw2KHbdjgckcfj+Fek6T8HtV1LWpGiT7Lph+eAyujufQFQTgfWuW8Z6VJocLWV7pcC3KzMv24SENLjnOzP5nGPSgD0z4E+JftXxS0e4SIwWay/Y4gzZJ3jAGOg4619sV+YnhvUJ7S/h+yq7XW8CJhLt2/T3r9Avhb45tPFmi28U08a61DEouYM85x94euevtQB3NFFFABRRSbhgkHI9uaAFJwMnpXm/xFuZNHjbxTc372U1n+5srcHKzgnkOP9r8Md69E80ASM+EROpY4/E+leTeKrzTvFGoz3GsaaNQ0bTSyQWzy7FnYjDSHj8h+NNAeg+C/EVv4q8O2uq2q7BLlXQnOx1OGH5ir+t6bBq+k3en3ShobiMxsCM9eh/A4NeY/CTXLKy1y/8ADdtY/YLKQi4sIl5REI+ZN3rnmvW6QHxr410zUvD99fabFOIYbd8TSxRkCZeoDgk5+oxUmk6i0lhCdDdYbiTaCsKbDMcgAZOQQc/pXsnx70e2jgt9altBPEoMU0cbESOT9046HHNZPwe0nw/qF1potdBgh1Gxj82e+MmZX6gBkxxnP6UxHq/gjRDouixLOxe9mAknYnOGx90ewo8S+JbPSI5UlZ94Q8opbB9PrWf8V/EM3hzwjPPZ7vtc7CCIqMlS3GfwrzDXrjVdO8JyahNdyS2ccX+rYAyBsdQe5+tAGl4psLbxHoy6vp8weDaVuIgTAV9fXc3scfWvJNVsIPCFumpW1+1pazcy26vtE3ozL2PTmus0bVre/so5k8+SS1hLNaScYbHBbGQT+dYN3oN14qsodY1i0srmzwVaSVthiI6Dae1MDU8M+LrnULGS+ty8kyOFAth5oEfYknGP1rR1TxfLrV3aQtYy/aPmigmBwr8cggc9q5L4PXB8L/EVtLntkuUv4HZZ4/lZfm4XnjGOlQ3Ux8KfEO71aC9lF5ZzmaK1uGLRPkcphQevPIHWkBS1f4heILWaaxk0+fSprRzFyfM2g5AkIbbgH1GelWpH03xFpUfiLXZLO5uNPiaJA+AkrH1PUnI9K9J+M+mWfjXwNp3im00MX2oLGPPSJgJY4++M4zg4P0FfP3hiHT9V8d+F7cpCNFnYkWjSKRuAOd+DgE8e9AGNBYXOj6VdpcW6afdXb7UmNw3yR9eQpOe45rPtdUNmPsVhqE8doWCPFDHueZum5c9iexI+ldh8WdZ07TNen0rR9GsI4IMrvLhyWPfAPH4155FdrYWEsMdun2uX71wWDFF9FHb60hnoNr4k1ZbPSbG31W9Nzby5ubeFliATPVsdTz05rvvAXxk1qXVb21uby1+zW+Y7ZACWlwe+M5/CvniG7uTJCElAZAVXcccHrk+/vVy1ulsbfzLW6FveRTGSMLGHfpgfvBxjk9qAPtrQviK8W25uNOaRWXa7QtuMfsw6ivVNL1Wy1S0iubK4SSOQZGDz9COoNfGHwVv5lsb651TWZLYzuZvLZdzTt6nn7vFd3+z54re6+KGtR6lfWz2syYtmjOE3/wB0ds4piPqKiikVlcZQgjpxSGLUE8aPIrjBuI1bZzyMj/8AVUzELjJAycc15b8X9fl0q6sIlvfs80cq3UYgx5jIDgq2T0NAHVeMtYtYdIubM+VPeSJs8gMGKsem4V5ZJev4R0sz+KWtby8jUsIUvABBH6HP8yKNR+LFne+MINOttJuF2xebcXkMSvtz078nivDNb0SaXWdcv71b/UY3uvtDowOJoxyBIR0xngDsBTEdNHq03jfXLrUvB2mNp1no+ZSqzlIbh+cliOD09O9d94budWvkW41bS50tIwHaLzM7n9d2Bke2PyrN+D/gnXtUguNRTT4dL0Gba0FtvwbhfdcDaB05r1m08Arb6hBfojLJHwsSzHCj0IPBoA/PFAGYAsFBOMnoK+iv2MtLsL7xlqd7Kr/a7G0Up83ysXYgnHsAK+eQYWEpdWRto8sJyN3Gc57YzXs37N1lqFt480fVYreW2tbmcQLLDKwRl6OrDPIOOh7/AIUhn3RSOqupVwGU8EEZBpaKAPAfjSt14E1ax1bSZobSwvZfLLND5uJcZ2BewIDHPbFfNPxf1e31rV4rqGd7h3BLOv8Aqi3Gdv8AhX2H+0qlqfhHq8t5Zx3axFHVHYrg7sZBHQ4Jr4Mi067Nk2ppa7rGNwGLHjr065I7ZFAFAEggjgiuk8M+JbjR5XnjmvYbhWEsd1byESJIOhyeP89DW74C8E6d4vsLs3GrRaVqLSFrZHGY5FHUAdep9fSp9J+E+saxrV9pllPatdW4yFDbQyjvz9PegD1Xwd8WPHuuJaWGh6zY3d9s3GGa3WZ8erNkGrN18ZPiFZ3s1petax3VvxJGNOwWOe2X9K9C+BXgKfTbKa78T6RawahbN5VjLEOUh2jOPcsD+led/FpLrwt4za/0eWGSbV/kkS8TMcATOWUHjOB0pgdtZa/rHim1xZJrU+osAd8DbUhYjpg4RfxIq/oPhPxh4RtPtVpPJe3Nw7GS1jnXapIJ8yRnIH1C/hmvGdJ+P2vaVa3Nrf6hI7wMRatb2UAhlUdjhQQTnqOKy/HPxt1jxV4f+xakkItZnWSOOJAGjKn+J+mCD0x3oEfR+l3Oo3IiXxfquhmdCZP3NyDLH7BF4IHqTTNG03SodRub1Lma9incmTIySOmR2FebfBLwtqOp2f8AamlXtujRrtMQm3k5/vMP5V6ho/8AbeiX14s2jmVY03lYWCKQf4vQ/hQBhr4LS31qXVPDGnytcCdbhJ55h+6HfC5zj2r2uJt8aPwdwB46V5Lq/jC4tf7GuLBoCL7d5yADeEAB5Xt1r0Twlqo1rQoLwJszlcDocHGRQwMr4owRy+ELp3RGeIho2bohz96vOfgDe6a+tal5fy3twvMrMMzkHnjtivYPE2ntqmhXtnGEMksZChxxmvnrwFA2iePNLeawmiD3TQJsTKK20g80AepfGXTJL+y0uRPMPlT4CxSBJCSOMZ615ne6HPLaTb7qZrlRsxdSZWU/3SOntXsfxT0u51Lwjcvp7bb61xcQt3yvJA+or5rfxAZory21K8m+2SKWE8nytA3ThOhGe5oQHXfDnUVnj1WK+sbZJrY+WUhxhD6yHscc81j64LLVUu7SezuZtNY7XnRmgJbPAHTK/TrR4J0/UW8MTafcRTxOWMr3snG9c/ebuRTfFOsT6N4Xlijmjv8AUb2QJDcxJhY4843AdDgc80wLmmeHLHfb6hpXmJqCjyXN1KeR2UMelef+KdDnsPiHcW9ybppZI1kCnc6rzyA/TB9K63w9fSadqEn2fUPsF5JEEt5psSRyOf4mXsc9qwviReyaHaQRaxP/AGjrTgszwZUze5Hbk9qQFLwH43uk+Islo2oXy21zmylsBGXEijOdvoev51wfit4rXxXr9toSrpthbyM8aTRgSKRjIDEZDE5wB+lU7ltHg0tJbG01GC8d/wB35rD74zyCOwz+P51latp8+leZDqcBa7n2ypKJNwA53cjqTxSGdX4n33enaZrmmxBLaVfs0oa3WSTPduepOPX+dc9JoUG1rh76OytN+1I7ri4I6FvLHbOe/ar2h+LJLXwjqeg3s0/2aTEluIjgiTPTPp3/ADpmt6FfQQ2k+s3Il1G6UgJPdLmJR0JJPP0oAyNOsDe6qthbB5EkP3hGodl6ggMeMjHeu/8AGnhsaf4MtZHsrpbK3cKlyUTepPBDcjOTj/IrzyTULuOaESspntXGyTgsCvQbu4Brr4fiJfXltJBq1kuox/eMLjMQA77CD0oAv/Cu9hkE1lqF55dvEpkjwp8xRz17Y6dM9fpXdWnge81R9M169j8jSZZSLNYspdbj0YrkH8K848F+H9W8Y6pd3qyDTrLZmS6C4CqowEj/ACxx6fWvpb4Xi/bUdG1PxFYWuo36q9tpzmZYpbaHjLFWPzEgDkc0xG94C1PxxY+LIdJ12EXOkzKfLlIG+IAZyxz7dK9N8QX1xpmj3V5aWT308KFlt0YKX9smm2k8GpuZhDPDPbSGPEqFDx1x6qfUVpfeBDD8KQzj57K/8R6WjX982mzvDuSCyYloye5PU14npHwQ1HWvEtzeavq1xcQ2rGPfO5L3IPUMO36dK+itL0pLG8vp1ZmNy4PzHO0AdB6CqN8l1Y2Tt56wiRiihFydzHhie5piPlDXtNTwFeTTfD8tch2aF4VfLJIODnPPp+VeifsxJrd5pGs33iKGSaJZiqwyoGL8ZJ9+c8Vrat8P7PwzdieKzeaO7m8y6mdyxZ2PLD0HsOldh4S8Nap4U1bUY9HeCXRpYhOIJS3meac5wfQjtQB3FlcRz21tJpohazIxhfl2/QdOPSroGGJ9aoafNF/Zy3a25hMo3vGoyd3fj1qSWWW4hdbQmGYYIMqcflSGfmlPaXNx4gcWln9qn3famiCFgwI3kEDt2x+FafgrXNQ0nxlYa1ZwCNNMnE5iG7yoFJw3BJwOTxWda6q+kN5um6jeG4lgKsUYx+WzAE4bJJx9B9avvdX9v4StZrPZJHNK8l3KIg7q4f5RIxz1znmgD9ILC7iv7KC6tnDwzIJFYHOQRmrFfn18NPjHrvgfXZbqHfdaZMMSaYZikIPHzKMHaevQc55rr/FH7QXjLxNbag2j3um+H7FYivkbw1w/H8DEZyenGKAPSP2iviVbSXa+GNCeyvZrUG5vPNYGEFQR5bZ4JwWbHYgZr5Aubl7iSVmwiPI0vlpwik+g7elMllaUlnJLscsxJJc5JyST15qU2lwlml55RNuzFRIMEBh2Pp+PWgCuCVIIJBHIIr2H4Na/FqXxF0WbVrxrCDTrVjJcRDa8qqB8jkclT/OvHjya7f4Z63babrOmwJoFvql/Jdjy2mlZB82FC/LjI6nB4oA/QbSddstS0eLVLeWMafKu5JC2OO3H9Ko+LfCGh+MrCKDW7FZ4wRIpIwR+Ncp410K/1Xw5p+htIbMzTxzuLNtpG1txQeo7fSvSLOJre1giyzbFAJdst+fegD5x8bfsxW2oXE03hzUls1+9HDKu5QfT6fjXDJ8CvFGlbLGXTJLi1kcO0sLpIRjqBxwD6H1r6i8caD4i1aS0uPC/imXQ7i2DZjNqlxDPkj76tz2wCDxk1zP9v/E/w9ga14W03xJaqcNc6JdeTLj1MMvU+ymgDhPCPw48V6HqVqfD0yaPbb1mML7vnK9VcA8g19CCN7mw8u8RVeRNsiqeMnrg15B4k/aF8O6DpySX2k63ban5qq+mXlo1vMF/iYEjYcem7mux8I/EXQfHMMb+FNRWdwnmSxNGQ8eDja6nkfXoexoAb4v8IQ3FvazWCRxtbRmPaQdoUjGRjnit/wAG6VLovhyzsbiRZZo1O51GM5JPT6YrUEjtbCRIyXIyEb5T+NTUAc/47utTtPDF3JocQlv2wkYJxjJwT+ArwHV9d8Q+E/FGlRXNtIIoGWYOBvWZjwQcd+a+gPF3iLTfD1mkuq7mWQkKirnJHr2A+tcroHj7RvEepTWa2NnJOoBC71csp49KYHZajfoPDM17PG6q1vvKDqCV6frXgOpxRaf4Vn15Ps0Wrf6t0TDTuM4Cg/j16V9JNGjRmNkUxkbSpHGPTFfGPjrUF0nVFa60dopmmkjMsi7GWIn5SD37d80IR33hS21GPTtMvLgWyw6gxjkma6U3K5GQp9R6+leYfE65vPDYFo1zcCza78xkt23BYyScK38JPGaxdB1S2hd9SNutnZW/zwSzRB5WboQXOWOemM103jDV0u/BljPJoyS6lcESTWscrhlXqCQOhoA4vw9q9uNZuppkEtlqLK0KAhnjdR1OPunjr7fjV/4hw6nHa2up3FxbXsl2yw28iDJReeN+c56d6xNFglm8Q3d5BYf8S6ZNk0S4R4AQBkrwRyO3v1rvviVY6pYeCtFu7RWuLa1cMzSQIsMYwcHgAntQM871SRZo2e5MNvLFt2XJ1Dz2QdwI+p7jOK5e6lM8gH2lJ4YT8gkBTdnrwP8AGuz8P2+oDTfEdtb6WkuoxAXXnxKrEox4wDxt78etcRqt1Ne3jXFysSyOBxGAAAOAMD6d6QHReB4rFLe5u7y406OZZY1iS5wWYA5bAPTjGGrvPjnZ+H20/T9R0sJ5zJ5RSJhlT1yx6kf57140k0vkNApzGx3lcA8gdR6cV0ngW9jt7u+tpN7G6tWRZEYfJhSejDnj+VAHNW4PnoUkWNgdwdjgAjmvUPBHw7uvEmk2EdtBIZdSlKSTTfL9nxnDkZyU5/HIrnfht4ch1zxZbRS3ZS0gxNJKi9wchRn6enY/Wvpnwt4W0y/sL2/tNSm/ty6iMENygw0EY6bQRgfjTA9J8E/DHw54a8Jw6DHELkhd00rtlnfqWx257Vu6VZRPdTWskMUsVm4CSMuHBxxyK5fwe2mzaN9mm1BZdQtkMZY5++O7eprs/DbTz6FCt7cRz3ABSR4crjnp1yDjFAjW4GScD3oU5UE45Haq6WsS27WsjPNGwOVlbcSPrWJf6tZaNdJY6hd21tbCIPAGfa7YPTrz0pDOjPC5bHHNZwZ/Ma5s4kull4Y+bjAHp+tcLr3jjUrTW7eGJLUaTIA0twxw0Yz+RrZ1bxRpWgJZTWMtvNFfSYMSyfM2R95R/OnYDq7q1hvFj85dwjcOvPcVKsSrM8gzuYAHnjisrw/Lbtb74b0SrISwjLD5MnOB3rV3qJdhOGIyB60gI7oyRQs8CpkAsQeM15rc6/8Aa7N9Qur57S6ttyGWNdoC/T+KuS+MXjfxD4JtFlu50m06eR4xsJEmSDhTjtx1r58tvipdQ+DNW0qRBJ/aErZiZmcqp65duQOT0P0x2YjzmK0Et0tqp8qQEh3l4VT3zjOAD3q1q1sNKDWcV9JK0qq0qx5ER7jnPzeoOKhGo30VlNGjNHFef61wvM2D3Y/Xt+NUpJXkVFZ3ZUGFDNnaPb0pDNXwzoUmuXjRfaYLKBFLPc3GRGuO2QOpqO90lILW4uLe9juY4ZRCzJGwBJzyDjBHH+eM+kX1oPD/AIEg0vUdU32OroJPtEURnRWGCqhh06DjuBx7Znh+2sbDRrqw1PWYryGXcTpkMe5g46NkHdkY6Y4NMDziSN4m2yIyPgHDDBwRkH8Qc1JHczxW0sCSusE2N6Z4bByDj6in317daldCa8naaYhUDO3QAYA9AKYpO+N7tZZIcbRhsZA7AkEcfSkBe0uJryzltzbRCBG82W8ETO8Ix/sn7vHp3q3oFzY6Pr9vd/ahcRwOWB8lhnjgj3zx+FQabDJDZXc6TXtvM8LBUWL5JYz97L56fh6VR+2zjTTYqw+ymTzSNgzvxjr1/DNAHsX/AAtTxnJrWneIb2Py4oGGPKbcpgPVWjzknH8WR+VfXvw/8b6L408NLq2h3Bkhj+SaMg74nAyVYeuDn6GvgXwNBepDcXml6hb292JFjEMygh16kseoHPYVof8ACXXfhW/1K28O6zqEKXTlrpoRsV37qBn7vXnr0oA/QhtTso1Rp7mKAuu9RM4QkeuDUlne2t7Hvs7mC4T+9FIHH6V+eniDxJrEOpaZf317eS21zCHVJJi7Ih6gc49/51PpPiqbw+u7wvqt9pqSOXiuXI2Bs8gIMgd+1AH238R/h1oXxCt7KDxGLp4bRmeJIJvLG5gASfXgfqa800r9nvw1p+sw3NhfeItEu7fLpcWmopk88cmOvO/D3x91CzhuZNfunS/lw0fBbK9sqMgfzrqtA8cwatGfE/iHxZZyLkJBabXjEf8AsgAck+ppge6WllfWum2xN/d6ldwHYLiVUDOvQllUBSeOoAp9nLq66jvvmQWIJGAoGPcmr/h+7i1DR7W8t4zHFOgkVT1welVPG07W/hDWJo03ulrIQPfHX8OtIDxz4z+ILIa1Mt/cSQxwoqxJI2I8Hq5wen1rK+Bvg6LVvEh123u0ewsJ9yyRKALhypGPoM/pXjmtahb3+kWV9dWj6ncm3CvKzkjnqxBNfXPwP8Nr4X+HOmWmwpLMv2iQE5OW9+/GPzpiOq8Sazb6Bo1zqN0HaOFSdqKSWPYCvIfEXiTw9qtuzX9vpeq2d8Nk1u2TLbk/0qb43+MJNO1qLS5JpoNJitHnvGTAEjHhFJI6Yye3SvD/ABdqPhLQvDNpH4OmOo61qH76+cHy5FXBIwSPXgDnrQAzxV8LtU0S7it7R7k6Dcy+fGY8OkR42g5yffPSl8OTeIdO1XULPWCXW4UrBO0sJXA6HAHHHOK7P4b+Nde1GNZL9bM6ILYw3Fq7kzqf7xOOB7YrgfFkenXVpO2natb2NijNG7eSJMKeMA5HPb1oA5x7S1v/ABrp/wBj1G91CYS+VcS+XwhHQAKoyM19H6JpsHjnw5Jpt9erJbW8n2aSGIbXkwBxjnb1rw/4e6roPgvUluYZDcalYIZGkZsIYzg7u47jgV9F/Dr4meF/Eskp0a3t7XVPLMpVkCtOO7AcZ9CetAHm958FJPB14Z9KExguHKhmly8aHsSBgjpxj8a8R+JGj2dj4vns5L6FMR+Zut7QqhJJzkbid3qfavrm88a3t95vnw/uImyCgBGc4x+VcN8SvAOg+NNXs2mcWF8YDL5sa4DD0btRYD5Y8P2l1cXu+xlt1mhwVEsgXf8A7IB6554r0HRPC6eIrKG7YQae9lKXuIY4hAyNkfdB3Bug6/8A1qt6j8HL6xuFu9G1FLjHzwRKAZNy9OpAIyKn1HRvFEE1prOqaVLNeyoLe5tIyArrk/PhTjdz9KBnR6Bqfhj+1wNKt5Yba3k/fxmLhn6EmXsfUc/0r1Hw94v0L7Lq+iaboF+moEbyScCZT3R8/oPWr3wt+HmgP4Vktlt2/smYCUwyH5opT1+Y88e+RTrv4cjQLa8v7SaW9ttwKqXxNsz1DdPwoEWPBvirRrzT9Utf7Eu7GW3j8spLCN+cf3u5989utavgvUZrDw80CaZLA8m4h7hgHbr8zYzzVWykgitpLi7kjs/LjxEbiRQWGOp96828Q/FrRNC0OWz8JGfWNU3OehbY2eSR1AB9sUAez399deXp1xaXcAaMFXJyVwe3ua8z8bWNld+JrzUtT0Nda1CG3zEZJG8uP6AnCt9BXlXgP40X+nazFNq2pC/iaJppbaZRDFBJ/dTjJPPqelcd49+MPiHxU9/HHJ9hs7uRZHSI/P8AL0G4YwPpQB9BaH4htLx7TRvEumWNtpcsBDG6nyFY/wAJwc81saTpXgfS/Ea3ryQzGwgZYIkl3pGpx0BPHQd6+LZNZuZ7G4trrZOZ3DtPKC8oKjAAYnpxj8TVEXM4MhE8oMi7XO8/MPQ+oouB9mHx/oPiTXryHQ7iFv7NTz0nV9gHfbno3TtmupX4u+GNX+Hk+tWmvCyliQoSwAdZcYAKkHqSPzr4EpaLjPRPH3xF1bVvEMsyXZkRY9g3Msibu7rjjp9a89kkeWRpJGLOxyWJySaZRSA6XxDq1vNoOmaXY3txcQ2w3uskIUb+eQ2c4AOAMdO57c4oOGIK8Dv37cVrTW91a6CDdwQLDPIJLd3I8wno2zHY8ZzxwMc1j0Aek2mqf2Tp+j6ZbXlvFYXS+a99u87ymIJZdpCgNnj2zWJ4rvoLi5t9N0CG1itLTMwe3bc7vjJYuQCSAOgz9T2wbBb29gOn2w8yEP55jwOoGM+p4PQUlzp7pbyXKSW7QrIYyFcqQeOArYY9ffpzQBX+1T+fLMJCJJc7yvG7PXpVi71e+vLGGzuJy9tCcxx7QAvGOMCqjwskMchKbZM4AdSwx6gHI/HGa6PULDSodBs5tNke4nKh7y4EygxE/KUERwxHuRz64NAC3ep+c2kX8Nmx1IcY3BklKnAOwHI57YH41gRg3l8TIrlpGLN5MYY5PovH5VtT+Hr+z0RLt49PHm5ZJU1OFpGTGCqxrJknnGME89KzNIF6t2raZK0d1tO0o4UgYIPOeP8A9VAGn4fmtNNuTe6hFBM0FxgpKW85vdVBwCCM/N6+tS+N9ch1y5jubSygtIX67WUySkDGXA6Y5xn1rGuLC+8+YPBcvJHhpmeNgULDPzEjj6n61bsbbR2e3uL27ljgaXEtvGm50XnndkcdO2eaAKlxf3rWMVlNOr2yDKJlW29+o5H+RVa5iMErRF9230BHOPQgH9K6zX7DS7t4r7w/ayS6dbgi7YfIBjHTOOcZ/SsrQtO/tO/hUW8t1biURmOJgJtp6E8c4H+GaAINEe30/UIZtTglCFd8eU4OeAxB+8Pp6Vtab9nv0vGDhVmk2JafdVj13o54Tvwc17/4K/Zv0+4s54dekuDMHEscg+6UI4XIPBGea6bU/wBmbw5JpTCwu7qLU0+aKfdwp6gYPGKAPRPhdqMFl8MtEk1C5SONIREskkmc46Anua1rbxJpWvrqWn2V0v2iNWjZHXk8dQp6ivmyK11Ozt108JJYXNpMYZTuYozg4JAP9K3otQ1Tw3ewX9jHZz3kqeXH5pZfMb0yAcduTTsI27vQzrFvLpUmnQWslrMpEqLtMoDZ6Y6fjXvNmnk2UCYA2RqMDoMCvPvDfh7xTqkum6t4o1VLN1Pmy6dZqGR+uAz9+x4rB/aC+Kh8G6bFpWi+XLrN98gLglIkI5JI7/57UMZ86/E7xPF4l8e6wy2onZpzGkdxcOu8IfuhACvbqag+HtouseIDfalpqWrW3yJJu4LDjGDxj3rmLO6uL3Wk1TUba6hV1aJlt51iLHrwGIIHX/Gui1LVbLwr4Is7GxRTd3EpadZlPmMmcna44U8jmgDf+J3ia2t/D11pdpby+ZcSYF24ESgjqqlTkjjvivJLmSykXYZZLSVowJsqHVumFUL0wfWrepeLbi88OpozQwtbeZ5hlkG6fhuBv+mOcVlWNol9E0FsA15JIBHGxAwoBOd3GSc4x7UgG2ktnEQkiGVZcJJLInMS55KAHrjufyr0vwpZ+FrDWIbrRdauLpgPLW3mBjlDE4+U4C4z2zzXmsdzJBZbWmjlOHh+zTIW8oH+Jc8A57jkfnVOAyoTJC4RkIIO8KQc8Ed/y6UAfQerWviHS/EJ1P7Q1hYGNVktnnVZZB1JwTj05qxq3xfi066W1v8AQ7iCwEewBlylx/tA/j615l451iCfw7FZJrH9rXCSKDJLgyRptzt3j74yBzXCXl9d3xQ3lzNPsGE8xy20egz0p3EfREfibQ9W1W3ubHUDbWelpvknjO0qTzt91969D0drTU7+GSxv0urm8XmPzQAIzzvA618c2EM2o3wt4pYoTNncWOyMADPOO3Fe4/B52g1Frf7XE2s2MYFpcXS+XD5ZAykbDJbgd6LgfS8Onr4fhtrY3Pn2incVXlzznGB1rb1G4e/+yJ5L2sRcNG0pxvPYba8vudIstT1SPX9Lu57u7ZVimtll/dq474zgc5rd1T4mSeG7m2s9X0uZmOFaUEbUJOBz0/rQByfxPs/EF1rF1GINPlhRP3ahCwDHoG6c14nqPhrxK+rXsU2m3r3JhKyPZ2oiYnHynfuOR2r6g8R6tZmbOpGG1u7qLdGEcfOoxzz9RXzz4h+Nlxpuvz6bb2ZjsYJPLeSF/ncDuM/40AeQ6r4O1/TvK+1aZPlvl/dqXOeeDjv+lZ2maVNe3jwO8dssR/fSTtsWLtz368dK9K8R/FCGfxEslvbR3WnCMBX2lJVbueeM/h+NcH4h8QLq8148ljbh5WBjmx+8UD1PfjikM6u5tPDKWOpf2Lbm6W2iV5w0uVfHo2cj6gVy/iLR7aLT7PVNLE/2W4XMkci/6k54Ge4Pr7deRXPE5OTya6iy8X3f2e3ttRX7XBAwZQW27gOz/wB/6H9aAOWors/iHpcCy2utaXHCum3yKQIiAFkxyNvbIH6GuMoAKKKKAL+u6a+katcWEsiSvCQC6AgNkA5Gee9UWxuO0EDsCc0+eaW4lMs8jyyHGXdixOBgcmo6AJrW6uLSXzbSeWCXGN8TlTj6imzTSzOXmkeRiclnYkk+v8qSYIJW8okx5+Unrj396cIJTAZhE5hU7TJtO0H0z60ATCeFdPMC26mZ2BaVuSuOgX0znmlWxb+zGvZHWNd4SNWBzJ67fp3p+h3VvZ6rbTXsLz2auDNCjAeYmeV5GP8APbrTNWuILnUbmSyiMFm0rtDDkny0J4HU9sUANF0GW0SeJHigJ4Hyl1LZIJ/Pn3rpLnxGk2kItm6aZcWz5SCOIMsg7Hdjgjn61zNhcT2t3HNaSmGdT8jg4wfr2rpdK8Rx2+vW13dQb5DFsuZLeQIZSecknj0z05HpigCvHBb+VDqGvadeCzuFK/aLeUZkk67sNwOO3T+mVZaZPqdxcLpcLSRx5bDsoITPGegzWnqd4/iDV0tLGa7VJ5cBLq6DRjOMewA59e2Kz9VW5snm024mQi3k2iONsoT3YH19zzzQBXSOKIg3Ubo6YJiII80Z9e3Fdj4T8Ux6TfWd6BbXltpx8yLTtRBYls8CNlX6den61jaX5OqxWUd7qUMAseFhuBhGXdng+vY+1WNEgENwt7b2s81zBdEhYIPNh2ZGPm9M5oA/Q/wffT6poFpf3WnPpr3MayfZXI3Jkd8VtV4x8F/HviHxJqE9prGkeSsDCEus4wBtyGC/Qdq9noA53xxBpsXhnU7/AFK2t5Leytpbpw6/3FLdfwrzjUvDcevaDazaAN4vIEvIGEm35GUMAv59a3f2ktVGk/BfxJIPv3ESWqjOM+Y6qf8Ax0sfwrG/ZO8Rf258JLS0lk33OkzPZtkc7Pvp+G1gP+A0wPCfiLrvj7wfp9vAfEmrQoXcmJo2CRjsgfGG+teW2kmveN9YFo81xeXEnzn5uEAI3OR3wK+wvj14ITxLo7wWUs5uMlsJhgD3HSvnOLwf4g8IeF5r2NFtlnl8m5vH+UwIfl4Gff8AWgDzzWrYNrRsbO6nvnjHk75eMuOoHtmp59Rme1toLyzhW3sWCtG7/vC30Y5I9ulX/iB4ZsNAlsjpN3NeW80eXnk27d3ouBn1qhcWMVxDDY217HPcQ7vKhihbLk8nJ9f5YpAYbuWklcAEMTk7ABz7DgfhU9tdXKTwyWnyTwxsA8a84wxJPvgnn0FTXlvdaSs9leWyRTSKpcuCWUZyAD05xVS2uXtxKEWMmRChLKCQD1wexoAS1EH2lBdtKIM/OYgC2PbPFXlvUlS3tGQLp8DGVo8gNIe5J65IwPak0/Q9Uv8AY1np1zOjfxJGSPxPQfjUer2D2F0YnhmiwBlZexxyMjg/WgCoSjzEsNiM2SFGdoz2FXDppaxNzbXME+0bpIlyJI19SCOnI6E1o3mkPZPp4gCx35j86VHkVlQZ4YnoQfTnAHOaW209NI161+3i3uoFTzXBk2I2QejH72CQeOtAHbfAjwLp3i291GbVNRt4Ftov3cRG5mY98dunX617zo/wa0O90iGKGzhttRZv9I+cFJI8/wB0d/evG/g/rkelJDCLbTFjnR2aKPa1zPySMv1wP7teofCPxDqF54nNxHrtnbr8yyWF6AJSM8DPYCmI1l8M6t4Q8babp1pIttos3/HsrXIVZMfeRs9T0xXJ/tR2mpW2q6Mmq38lj4ZuDzDbKSolXnLkdfb06/T1v41aZZ65oGmajbXdnLqek3QubOJ5h5UsmMbW74/wrxrx348sfGFtdaD8StNGkahGD9ivbd2a3dtoyVZhjvgnpQB5744l0/SdQh1WbUU1S4nhVUtUuvMwOPmyM7OBXnWvaquqSo6QRwAZJRVBOfUv1b8a3n1Twot4Um0Vri2ig8oSLM0bO4PDAKQPU5NcpbIFjeeWJZYVPlld+0hmU4PHpjPpxSGTRaVcXFzHBZbLpnQPmE5Cg/3icbfxqnGm8kZVcAn5jjoKaCcEZOD1FKhCupZQwByVPf2oAbRStjcducds1bs0smt7tryaZJVjBgWNAQ756Mew/wA+xALFrrd5b6XNp2Y5bKRSPKlQMEJ/iXuCPyrNdi5ycZwBwAP5U2igAopcYx70lAC96u2FzZ2wLXFj9rkwcCSUrGPQkLgn/vqqYZghQMdpIJGeCR0/mfzptAD5X8yV3CqgZidqjAHsPanW881vJ5lvLJE+MbkYqcfUVFTpHLuWO0E/3VAH5CgBOO9ao0mL+ylvm1OyA/jtw+Zh6YXv/Sso1LGHguU3R/vFIISQEc9s0ATrYTxRpPcRBIvvhZHCF174zW74c0W8vLqWe1+yWsLIz7blEm2R9QSrg4X/AGsVzasYbhvtEIkYEhkl3Dn3wQc1ueH7Sbz4NQ1KG6/saVjbzSIX+ZcYx8p3EDAHpxigCppVrdpqa/Y7Vb9YpQCUj3xtz/eI4HvxVjUtGzrCwpeaYr3MjbY4ZWZYmyMIcLx1x6cVq/ECOyt0tYtNlaO2UbY7ZQdoHJLlj1J49+/ermkaro9hr+n6hG9tZQzwbLhEjZzER1GM8Envj+H3oAteC/hnrGo6zarqCxaXaM4R5p4hMAMdcEEc+vavRvE3wxtdG1220fSr6+kjuI/Nd7AYMhxjJwNoH0Araf4s6L4M+HsmnaFeRaxqsqsxL9IgW6HHPAPAqx4A+Nnh+xvFnurTVIwlsC8j4dDwTxgDb+JpiPQ/gLoF7pMeoyXth9iSWQSRguzNJgbdzbuhx2HFevEgYyQM8V4hb/tFeCLq8hNvJOk5ysouFEaqvqGJwTXdeFPiJoXi2zmu9JvLQQQsUMk8q5Vv93PT8aQzY8beG9M8VeHrjTtas0u7bmVY3JA3gHaeCM4zXD/sz6Rpll8JtF1DTrSKC5v4A11Imf3ro7qCe2eteh2t79rtl8meKeTdy9uMp+PPT8a534OeF73wZ8PtP0HUTCZrWScr5Lll2PM7ryQOcMM+9AF/x1/a8PhW/wD+EdeBdVfP2fzThCx7H8K8q8UeEJvG3gh9EW5n1DU4iHuZJX2LFJ1wfXHpXu09vFPt81A205Ge1Q2NnFZRSiNEQuxd9o4J/r+NAHhngf4NeHtbhtL/AF2+bW57RfKkYx7Azjt1yMV03gL4PeHPCWs3VyLEXE90WeNpTuWBf7iZ6deor020trayjke1jSKNvnZUUKM9zXF6544ia0s9T0YSz2kFyYr1RERKiHjIU84Bpgea/Ff4ceFY/FmnNcXIghn3SC2ZmbEg5DEnJx/s5xXmviXw9pF/4hsb/Q1tDewyBbhB85mxwDsPC9uRX1fe6XBr8cJeBVAUMJ5owxdSOgrzm9+EWjaVrlqugXk1neSzG7HnOHEjZyy4x3oEeCjSPEEWqeJLiK+ltJoAJJPsTM8RTupUjG7jsP8A6/nniia11m0GqW8WoK4wsnmIPKAzjKnuSa+x/F97DoczG2sxb318ph8mRQIZW9zjr+NecRfCHXrjw7daxdPaJcDLRadApTyznkl8nPU9qAOcTwHdeG9AsdW0zSTeLeWAS4a4JZRgdRn7p9uBxXGeJdCsrfwsNXS3sbs7NimeWVSnOTtAYBu+P616n4s1y+g8OW3hzw1rMGpRMvl6nZzEGSBSOm4dPoQa5bx2ug+OPBy29hqiaVe+GoSPsDsGjlGBk5GMYxjPOMkUAec/DfUtTvNRtdFgncxKsjW8KQBsyH1IG7HJPXriu88ceDtR+H3gKwvdYkghv7i53FbUnLsRkiTcSW78jHA9q8p8FeILjwzqcmp2F/PZ30cZ8ny4wyyN/dY5GB07Grfivx7rfi/UBceJrj7dGMYh+4qf7uOQffnrSGe2+FPAvh7WPC63Fr4zlttbdM28ExLC3cjgHPb3PPvXB/ETVfGXh1LTwz4ytdI1N4VM0MkmJzs55G0jHGeSOlcH4h1hr6CMx3SKsoAe2iQgIB0DOcbjz06f1xLm5nupfMuZpJpMAb5GLHA4AyaAI5GDSMwVUBOdq9B7DNNoooAKKe6MqoWGA43D3GSP5g0ygAooooAKK7b4Y/DbXfiPe30GhG0hjsoxJcXF3IUjjznaDtVjk4boP4TXYXX7O/iuHTLi9i1Pw7dLHBNcxR2127tcxxY3NGfL2nlgOSOT2oA8ZoopQcHNACU8upiCeWoYHO/nJ9uuP0rW8aaTFoPjHXdHt5Hlg0+/ntEeTG5ljkZQTjjJArMs7d7u7gtodvmTOsa7jgZJwMntQBEQRjIxmprWZYJGZ4IpwVK7ZM4Ge4wRzXf6N4Ie71K9Otajb3VnpUINy8V2GEYVsmMP05UMBjoT0r2Wx+Enw1m+IqaVK9xFBfaJa6hp9nLelfNkkeUMN4GcYSPj/aOM8AAHz54F8Mar4i1RV0Wyh1G4hZS1q5GGB4yc8Y9ec8V2PiT4PeIvDPhu41/UEt4bi3k3yWqkFIk57nr24/nX0F4N8C+H/hzqUscFve2OsT6ZPq1zI9359tBDE6Aw7tq7sCTIYgdCSegr0+K50LxLoKBL/Tr622q8jCVHXBGecZFMD88tBvdCtdTtptT0y6urdBmSIXAwzY4ONo4z2J/E11eqeOYoNPtZvD0iQXA3RNbywcwoemGzg9P1r3nxH8LfB2qfFm+srvS57eGTThdRm2OyOaQnBKgHt1NfJmuWcen6ze2cLu6W8zxAyLtb5SRyMn0oA2td1/zp7WeweT90AXLsFV5ccv5XOCM4zkjio9E8Oah4oE89gRJNFlrnfx16EY65/DmvdPD/AMPPAeo/DzTdS0jXSl7uWV1uhGVlmC4KMpyQOT0rw2e11Wz8WXumaTI1vcvKQY7GcqhwN2ASRkAZ64pAdNpvhaLUbC3j1SxbS5bZArzF9/mjqSy/Xtmu91XQW08aelyhhivojDbyxpugdcdZR/CMZ6A151Nqd9pbRXWmxajLBbEi6kupVkZmx3wWwAaavj7XVuhba1ffadKdi6oqfu+n8BxnFMDmdWFlb6c9nFaQyXdvcFGv4JmKSDngA9R747VnadqF3ptwJ7Gd4ZR3U9fYjoR7GrN9BFJYyagkcsHm3LCOLyz5YQgnhsY4IxisukB9P/CP9oFSuneHddtY9PR2CNqUBzk/7SY+UfTNfUV7qkMGnRXFvIs/m7REVIO/PevzBhkeGVJI2ZHUgqynBBr2jwD421fw14Ga9WW5uD5p+zm6kKopBwEQkfP07fTtTA+5zIgkVC6h25Ck8n8KHdFxvZRuOBk9a+b/AIL/ABO1TxRLq+o+IYVa5tiUTYcCMAdAPxr1G41uC78KaVrsl/Ja20NwslyZwM7MkYPI2jODn0oA66y0x0nM17cNcSDIQfdVF9Md6gt9BtYvE15q+S09xCkTIR8oAPX8cU/xJrkOi+HLvV9puI4oTLGsZz5hxkAH39a4b4GeOdR8ZeH7nUdeks0lM7BEh4EagnCnPU470gPTiVUovA7KPwrI1jS9Pn1fTNRu2K3ds5SDDY3Fu2O9Ra9f21tqNjHcGYTBt8ITADnoVPNc/wDEHxCmia74fbUlWPS5i6ySkEmKQgbdxHAB6Zz1oAm+KmrWml6EyanaR30VydsMRwrLIOhBPf34rifhj4xvPFmvXVnZ2TRJaRBLk3Em1omwMDbg7sjnOfSvGv2kfHMeu63p+n3ZufJspBMix8LIpOM5yDnjj8aoW/joXjxy+FNWbTtaiTYiynbCyd88ZY+g5P4UxHnHiyS3sfGniX7Pe3fmC6lEUsA2Bm3ksG5Bxnjj61zCSBYZEMaMXxhznK49Oe/vmpNQuZr2/ubq7l864mkaSSTGNzE5Jxxj8qr0hhRRUkUMswcxRPII1LvtUnavqfQe9AEdFFFABRRRQAUUUo4I4z7UAJRRRQB6p+zvql7pvjOYaPpeu6jqUsI8tNKuUi2qrqzeaHRlZTgLliANx7lSO8+OvxE8dXPhT7AfDV14O0f7VNp2oJHcJIty7KkixhggKjbuJ2/K4Zs55Fcd+zb4vsvCPifUJ9Y8QwaRpc9uFnimspLgXeDwoMfKEAkhufTBru/iB4t+GPjD4e3WgWHiS60SO11WTULaOeyuLp58ROoAP8Kuzkjc2QMAgdAAfMtFFFAG5428Q3HivxTqGt3qwi5vHDv5MIiUkKFztBOCcZPJyST3rKjnxEIZQWgDF9q4U5xjrg+3FQVv+C/CGueNdXfTPDNib69SFp2jEiRgICASWcgDlgOvegD1v4b6dodz4Ytr2GBJLlFRpQGwweMggmPo2GGcnrWPqX7QXj06693Bqlp+6jktoylnGFKMwO7HPPyqepA/E529D+HHxH0HQ9TuPEVvLYaRpkDOyfaIm+VV3EjYSWUA9j1yOoIrxTUtUm1RQ14WkuV+7IXACoM/KFx+ue1MD0nXfH/ifxNpC+EtJ8QXl7Yzp5tytwI1MzffYeZ97bn+HgZzXnF3cTW4ksbG7vvsoH72FmwoYfe4ViCPeqthBDLdRJdziCGTP7wfNtODjI+uK6wzaZP4Q8hkFnqtuzRC8gTy4rmPOCCQPnOB0PP60gNvw/8AFu/8KeGoLXwx9oh1eYML67u384Y/h8rPK8cn+vWsvQ/iGthZawL/AMO6Rqepairhr64jw4LfeJAGDk88Yrg6SgAqWCaS3lWWCSSKVfuujFSPxFRgZ4q1MJNOvXWG4id0BXzYW3KQRzg/QkUAaPh/V722W8sbfY6X6lJBIhc9DyAO9XLZ/PsLaOHWBCtqWZo7gBCgPUBefM78fhjnFcvRQBpza1ey6bLpzzGSzaXzVVlxsPP3R0Uc9BxWZRRQAV6Lazg/Ca7tNQu3tDb3GYIQmWlcndg5xgd8j0z6151V+S/uDYpa3GyaNUxCXO4wjdk7cHgk9c0AQRXlzDNJNDcSxSyZ3NG5UnPXpXcaJ8XPFmieC5PDOm3kUVg7FjI0QeUAnJUM2Rj8K8/ooA7u9+Juu6xrWlXuvXD3UGnx+UlvGxRGGCMkeucZ+lekfs3+JNEGo6ha65qseni5uzdR2ZDBJGwOd2MZHPBPbpXz5RQB9d/En4qW118UdD0KGO01HSpdscgSULtdyAh35ABB6jPp7Zz/AIyDXfB/w81y11nVl1NNTudttE65NvESPkP0GcH1r5WVijBkJVgcgg4INaWr+INX1mKCPVdRurxIRiMTSFsdu/U+5p3A9p+MngC7j0vwnr9/fWi6NcQxQ3F2ihpIt3IYgHLrzxjofrXkniLSk8MeIIjp9/BqtmjrLb3kSkRzbSCR1PIPBGTWRc6lfXVrDbXN7czW0AAiiklZkjHT5QTgfhVSkBf1vUP7V1a5vvs8Vv57bvKiGFX/AD1PvVCiigAp7EKf3TMQVGSRjtyOvSmUUALSUUUAFPWMtG7gphMZywB59B1P4UyigAooooAkeGRIo5GQiOTOxj0OODUdFFAHtH7KmrabonjrXL7V7uC0hi0O4aOWV0U7xJEfk38F8BsD69s17L4b1f4catY2/jXVdQg1O4tt91c3ut3EUepW8sLKYYo4IwFIOHIC9fl+8Tx8ZV7h8HfC+keI/hT4ll1bw3cXL2Wq2BXUrWGSSdoXmjE8UYUHJSMMxAyf3oJA4yAaf7Ves6Atxpuh+FzZyxXFxNrd9LAVYtPMcDJHQ4BJB55XPQV1fhHWHsvhP4a04+I/DmrXUt/Zzw29zfW0LaJAsqsnQb2l6ZJX5ctwQPm7e++GPhK08WaNPpnhXRpjPFLHdWcwLLHZJg/aBCw3mbOyPIBOZMn1Hylbf8I5pvxg26laXcHheHVWSa3vEbzooPMIIkX7wZR1H3hjuaAP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    MRCP image shows two small stones in the distal common bile duct (arrows) immediately adjacent to the duodenal bulb (Duo). Note the normal appearing, nondistended pancreatic duct (small white arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_47_28403=[""].join("\n");
var outline_f27_47_28403=null;
var title_f27_47_28404="Pinna embryology";
var content_f27_47_28404=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80743&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80743&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 528px\">",
"   <div class=\"ttl\">",
"    Pinna embryology",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 508px; height: 608px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The auricle or pinna is formed from the fusion of six raised soft tissue swellings (hillocks) on the surface of the embryo. Three of these hillocks are derived from the first branchial arch (FBA)&nbsp;and three from the second branchial arch (SBA) during the fifth and sixth weeks of intrauterine life. The hillocks of the FBA and SBA flank the first branchial cleft (FBC). The FBA and SBA contribute almost equally to the immature pinna, whereas the mature pinna predominantly originates from the SBA.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Original figure redrawn for this publication. Anson BJ, McVay CB. Surgical anatomy, 6th Edition, Philadelphia: WB Saunders, 1984. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_47_28404=[""].join("\n");
var outline_f27_47_28404=null;
var title_f27_47_28405="Amlodipine and benazepril: Patient drug information";
var content_f27_47_28405=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Amlodipine and benazepril: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/54/41831?source=see_link\">",
"     see \"Amlodipine and benazepril: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F134078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lotrel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10029596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700281",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you are pregnant. Use during pregnancy may cause birth defects or loss of the unborn baby. If you get pregnant or plan on getting pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701505",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to amlodipine, benazepril, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3915366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes) and are taking aliskiren.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697100",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a salt substitute that has potassium, potassium-sparing diuretics, or potassium, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698395",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Kidney function that gets worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you have too much sweat, fluid loss, throwing up, or loose stools. This may lead to low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling or pain of hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10029601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696480",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take more often than every 24 hours unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10029606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10865 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-221.179.173.170-189A616C48-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_47_28405=[""].join("\n");
var outline_f27_47_28405=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134078\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029596\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029598\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029597\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029602\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029603\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029605\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029600\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029601\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029606\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029607\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/54/41831?source=related_link\">",
"      Amlodipine and benazepril: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_47_28406="Malaria western hemisphere";
var content_f27_47_28406=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F80738&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F80738&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 472px\">",
"   <div class=\"ttl\">",
"    Malaria western hemisphere",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 452px; height: 674px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this map, countries with areas endemic for malaria are shaded completely even if transmission occurs only in a small part of the country. For more specific within-country malaria transmission information, please see the Yellow Fever and Malaria Information, by Country section in Chapter 3 (",
"    <a href=\"file://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/yellow-fever-and-malaria-information-by-country.htm\" target=\"_blank\">",
"     file://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/yellow-fever-and-malaria-information-by-country.htm",
"    </a>",
"    ) and the CDC Malaria Map Application (www.cdc.gov/malaria/map).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Arguin PM, Mali S. Infectious diseases related to travel. Yellow Book 2012. Centers for Disease Control and Prevention. Available at:",
"     <a href=\"file://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/malaria.htm#2528\" target=\"_blank\">",
"      file://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/malaria.htm#2528",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_47_28406=[""].join("\n");
var outline_f27_47_28406=null;
var title_f27_47_28407="Oxygen toxicity";
var content_f27_47_28407=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Oxygen toxicity",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/47/28407/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/47/28407/contributors\">",
"     Atul Malhotra, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/47/28407/contributors\">",
"     David R Schwartz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/47/28407/contributors\">",
"     Richard M Schwartzstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/47/28407/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/47/28407/contributors\">",
"     Scott Manaker, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/47/28407/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/47/28407/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/47/28407/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although supplemental oxygen is valuable in many clinical situations, excessive or inappropriate supplemental oxygen can be deleterious [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28407/abstract/1\">",
"     1",
"    </a>",
"    ]. According to human and animal studies, high concentrations of inspired oxygen can cause a spectrum of lung injury, ranging from mild tracheobronchitis to diffuse alveolar damage (DAD) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28407/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. The latter is histologically indistinguishable from that observed in the acute respiratory distress syndrome (ARDS). The mechanisms and clinical consequences of oxygen toxicity are reviewed here. Specific issues related to the administration of oxygen are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3064?source=see_link\">",
"     \"Use of oxygen in patients with hypercapnia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42215?source=see_link\">",
"     \"Long-term supplemental oxygen therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CELLULAR INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperoxia is poorly defined, but probably exists whenever oxygen tension exceeds 21 percent of atmospheric pressure. It appears to produce cellular injury through increased production of reactive oxygen species, such as the superoxide anion, the hydroxyl radical, and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28407/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. When the production of these reactive species increases",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the cell's antioxidant defenses are depleted, oxygen radicals can react with and impair the function of essential intracellular macromolecules, resulting in cell death [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28407/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oxygen free radicals may also promote a deleterious inflammatory response, leading to secondary tissue damage",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28407/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Support for the role of reactive oxygen species in producing cellular injury has come from studies in transgenic mice with altered superoxide dismutase activity. Mice with augmented antioxidant mechanisms have a relative tolerance to hyperoxia, while manganese superoxide dismutase knockout mice die shortly after birth with extensive mitochondrial injury within degenerating neurons and cardiac myocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28407/abstract/13-15\">",
"     13-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lung tissue is exposed to the highest concentrations of oxygen in the body, placing cells that line the tracheobronchial tree and alveoli at the greatest risk for hyperoxic cytotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28407/abstract/16\">",
"     16",
"    </a>",
"    ]. Hyperoxia may also increase susceptibility to mucous plugging, atelectasis, and secondary infection by impairing both mucociliary clearance and the bactericidal capacity of immune cells [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28407/abstract/17-22\">",
"     17-22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL CONSEQUENCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;High fractions of inspired oxygen (FiO",
"    <sub>",
"     2",
"    </sub>",
"    ) have been associated with several pulmonary consequences: increased intrapulmonary right-to-left shunt fraction and diminished lung volumes due to absorptive atelectasis; accentuation of hypercapnia; and damage to airways and pulmonary parenchyma. The term \"oxygen toxicity\" is usually reserved for the last of these consequences, ie, tracheobronchial and pulmonary parenchymal damage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Absorptive atelectasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;High concentrations of supplemental oxygen cause washout of alveolar nitrogen (ie, oxygen replaces nitrogen in the alveolus). This may cause absorptive atelectasis if oxygen diffuses from the alveoli to the capillaries faster than it is replenished by inhaled oxygen. Absorptive atelectasis is theoretically more likely in the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A low regional ventilation-perfusion ratio, which limits replenishment of alveolar oxygen (in general, airway closure is required for this mechanism to be important)",
"     </li>",
"     <li>",
"      Qualitative or quantitative surfactant abnormalities that promote alveolar collapse and further reduce the ventilation-perfusion ratio",
"     </li>",
"     <li>",
"      A high rate of oxygen uptake, due to an increase in metabolic demand",
"     </li>",
"     <li>",
"      An impaired pattern of respiration that fails to correct atelectasis (eg, ventilation at low tidal volumes",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      without intermittent sighs)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Shunting resulting from absorptive atelectasis is minor in younger patients, but can rise to as high as 11 percent in older, otherwise healthy volunteers breathing 100 percent oxygen for 30 minutes (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?1/6/1123?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28407/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once well established, absorptive atelectasis is not rapidly reversed by a reduction of FiO",
"    <sub>",
"     2",
"    </sub>",
"    to maintenance levels, emphasizing the desirability of rapid titration of FiO",
"    <sub>",
"     2",
"    </sub>",
"    to the lowest fraction necessary to maintain an SaO",
"    <sub>",
"     2",
"    </sub>",
"    &gt;90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28407/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Decrements in vital capacity of up to 20 percent have been noted after hyperoxic exposure in a number of experiments [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28407/abstract/2,17\">",
"     2,17",
"    </a>",
"    ]. This is presumably due to a combination of absorptive atelectasis and shallow breaths secondary to pleuritic pain from tracheobronchitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Accentuation of hypercapnia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperoxic hypercarbia describes the phenomenon of increased PaCO",
"    <sub>",
"     2",
"    </sub>",
"    associated with increases in FiO",
"    <sub>",
"     2",
"    </sub>",
"    in individuals with chronic compensated respiratory acidosis. In general, the increased hypercapnia does not lead to CO",
"    <sub>",
"     2",
"    </sub>",
"    narcosis and respiratory failure, because the relative rise in PaCO",
"    <sub>",
"     2",
"    </sub>",
"    is small and these patients are acclimatized to their higher baseline level of PaCO",
"    <sub>",
"     2",
"    </sub>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3064?source=see_link\">",
"     \"Use of oxygen in patients with hypercapnia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several mechanisms act in concert to produce hyperoxic hypercapnia, including [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28407/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Haldane effect. The rightward displacement of the CO",
"      <sub>",
"       2",
"      </sub>",
"      -hemoglobin dissociation curve in the presence of increased oxygen saturation. This occurs because oxyhemoglobin binds CO",
"      <sub>",
"       2",
"      </sub>",
"      less avidly than deoxyhemoglobin, thereby increasing the amount of CO",
"      <sub>",
"       2",
"      </sub>",
"      dissolved in blood, which in turn determines PaCO",
"      <sub>",
"       2",
"      </sub>",
"      .",
"     </li>",
"     <li>",
"      An increase in dead space (ie, \"wasted\") ventilation. This probably reflects worsening ventilation-perfusion matching and redistribution of blood flow from well-ventilated to poorly ventilated alveoli due to a loss of hypoxic pulmonary vasoconstriction. Carbon dioxide-induced bronchodilation may also be important in mediating the increase in dead space [",
"      <a class=\"abstract\" href=\"UTD.htm?27/47/28407/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A modest decrease in minute ventilation due to decreased stimuli from peripheral chemoreceptors to the central respiratory center. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40008?source=see_link\">",
"       \"Control of ventilation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The anxiolytic and anti-dyspneic effects of supplemental oxygen can promote sleep, particularly in patients who arrive in the emergency department sleep-deprived. The onset of sleep is associated with loss of the voluntary drive to breath. When the behavioral influences on breathing present during wakefulness are absent, respiration is sustained solely by metabolic control mechanisms. This can result in progressive hypercarbia [",
"      <a class=\"abstract\" href=\"UTD.htm?27/47/28407/abstract/29,30\">",
"       29,30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hypoventilation decreases inspiratory flow demand, which reduces the amount of room air entrained around a face mask or nasal cannula. This may increase the FIO",
"      <sub>",
"       2",
"      </sub>",
"      delivered to the patient, even if the flow rate from the oxygen source is unchanged [",
"      <a class=\"abstract\" href=\"UTD.htm?27/47/28407/abstract/29\">",
"       29",
"      </a>",
"      ]. The net effect is supplementation of the causes of hypercapnia, which were discussed above.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Airway injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many healthy volunteers experience substernal heaviness, pleuritic chest pain, cough, and dyspnea within 24 hours of breathing pure oxygen; these symptoms are probably due to a combination of tracheobronchitis and absorptive atelectasis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28407/abstract/31\">",
"     31",
"    </a>",
"    ]. Erythema and edema of large airways can be observed bronchoscopically in most patients treated with a FiO",
"    <sub>",
"     2",
"    </sub>",
"    of 0.9 for six hours and are thought to reflect hyperoxic bronchitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28407/abstract/32\">",
"     32",
"    </a>",
"    ]. In addition, the concentration of reactive oxygen species in exhaled gas increases after only one hour of breathing 28 percent oxygen, regardless of the presence of underlying lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28407/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bronchopulmonary dysplasia (BPD), a disease seen in neonates following recovery from neonatal respiratory distress syndrome, has been attributed to the effects of mechanical ventilation and oxygen toxicity in the immature lung. BPD is characterized by epithelial hyperplasia and squamous metaplasia in the large airways, thickened alveolar walls, and peribronchial and interstitial fibrosis. Infants with BPD generally suffer respiratory distress and require supplemental oxygen for up to six months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18793?source=see_link\">",
"     \"Pathogenesis and clinical features of bronchopulmonary dysplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Parenchymal injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progressive worsening of airspace disease can be observed in patients with ARDS who are sustained on mechanical ventilation, and may be due to progression of the underlying process that produced ARDS, development of ventilator-associated pneumonia, ventilator-induced lung injury secondary to mechanical forces, or DAD from the toxic effects of oxygen. Determining the magnitude of parenchymal injury due solely to oxygen therapy in humans is problematic because confounders are usually present. Many of the limited human data on hyperoxic pulmonary injury are from healthy volunteers, and their relevance to actual clinical settings is debatable.",
"   </p>",
"   <p>",
"    Several studies involving patients in critical care units have attempted to assess the clinical significance of pulmonary oxygen toxicity but have yielded conflicting results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One prospective study randomized 40 patients undergoing cardiac surgery to postoperative treatment with either 100 percent oxygen via an endotracheal tube for a mean of 24 hours, or to the minimum FiO",
"      <sub>",
"       2",
"      </sub>",
"      required to maintain an arterial oxygen tension of 80 to 120 mmHg [",
"      <a class=\"abstract\" href=\"UTD.htm?27/47/28407/abstract/34\">",
"       34",
"      </a>",
"      ]. Despite the differences in FiO",
"      <sub>",
"       2",
"      </sub>",
"      exposure, there was no difference in right-to-left shunt fraction, effective compliance, or dead space to tidal volume ratio between the two groups.",
"     </li>",
"     <li>",
"      A second report randomized 10 patients with irreversible brain damage to either 21 percent or 100 percent oxygen for a mean of 52 hours and noted substantial deterioration in the hyperoxic group in terms of decreased PaO",
"      <sub>",
"       2",
"      </sub>",
"      , increased right-to-left shunt fraction, and increased dead space to tidal volume ratio [",
"      <a class=\"abstract\" href=\"UTD.htm?27/47/28407/abstract/35\">",
"       35",
"      </a>",
"      ]. However, postmortem examination of the lungs revealed no major histopathologic differences (including no hyaline membranes characteristic of early DAD) among the two treatment groups.",
"      <br/>",
"      <br/>",
"      The physiologic deterioration in the hyperoxic patients in the second study may have reflected progressive absorptive atelectasis, which was less prominent in the first series because patients were exposed to hyperoxia for shorter periods of time and had spontaneous respiratory efforts. Alternatively, physiologic changes associated with brain injury or cardiac surgery may explain the apparent differences in behavior of these two populations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25271?source=see_link\">",
"       \"Neurogenic pulmonary edema\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A retrospective study of 16 previously healthy, nonsmoking survivors of ARDS found that treatment with an FiO",
"      <sub>",
"       2",
"      </sub>",
"      &gt;0.6 for more than 24 hours was both a sensitive and specific predictor of a reduced diffusing capacity (DLCO) at one year [",
"      <a class=\"abstract\" href=\"UTD.htm?27/47/28407/abstract/36\">",
"       36",
"      </a>",
"      ]. Although there were potential biases in this study based on severity of illness (patients with more biologically severe ARDS presumably received higher concentrations of oxygen), the duration of FiO",
"      <sub>",
"       2",
"      </sub>",
"      &gt;0.6 was the only variable which predicted the degree of diffusing abnormality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Potentiation by bleomycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    appear to be more susceptible to diffuse alveolar damage following oxygen exposure, based upon in vitro data and uncontrolled clinical experience [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28407/abstract/37\">",
"     37",
"    </a>",
"    ]. The typical presentation of combined",
"    <span class=\"nowrap\">",
"     bleomycin/oxygen",
"    </span>",
"    toxicity involves a patient with testicular cancer or Hodgkin lymphoma who, after receiving bleomycin, requires supplemental oxygen due to aspiration, pneumonia, or general anesthesia. Following oxygen administration, the patient develops subacute worsening of bilateral alveolar infiltrates with increasing dyspnea, nonproductive cough, and decreasing lung compliance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12794?source=see_link\">",
"     \"Bleomycin-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of this syndrome is established by the exclusion of other processes such as heart failure, worsening pneumonia, ongoing aspiration, or alveolar hemorrhage. Lung injury associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    or external beam radiation may involve oxygen radicals in its pathogenesis, and also may predispose individuals to hyperoxic complications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29767?source=see_link\">",
"     \"Amiodarone pulmonary toxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24090?source=see_link\">",
"     \"Radiation-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Extrapulmonary toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The retinopathy of prematurity (previously called retrolental fibroplasia) has been attributed to the toxic effects of oxygen. One cohort study of 101 infants demonstrated a significant association between the duration of transcutaneously measured PaO",
"    <sub>",
"     2",
"    </sub>",
"    &gt;80 mmHg and the incidence and severity of retinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28407/abstract/38\">",
"     38",
"    </a>",
"    ]. Central nervous system symptoms, including generalized tonic-clonic seizures, have been reported secondary to hyperoxia but are unusual in the absence of hyperbaric therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10762?source=see_link\">",
"     \"Retinopathy of prematurity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hyperoxia may also alter cardiovascular function [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28407/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Increased oxygen tension can lead to local coronary vasoconstriction, and microscopic foci of myocardial necrosis have been observed in animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28407/abstract/41\">",
"     41",
"    </a>",
"    ]. Reductions in stroke volume and cardiac output, relative bradycardia, and an increase in systemic vascular resistance may ensue, but the clinical relevance of hyperoxia-related hemodynamic effects remains unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28407/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no single threshold of FiO",
"    <sub>",
"     2",
"    </sub>",
"    defining a safe upper limit for prevention of oxygen toxicity. The relative importance of the duration and magnitude of hyperoxic exposure also has not been clearly defined, although it is most likely that the area under the FiO",
"    <sub>",
"     2",
"    </sub>",
"    versus time curve is the best predictive variable. Factors that are difficult to quantify, such as the adequacy of a given patient's antioxidant defenses, probably also play a role in determining individual susceptibility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Reduction of FiO2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reducing the FiO",
"    <sub>",
"     2",
"    </sub>",
"    to the lowest tolerable limit is a good principle for all patients, in particular those likely to be at risk of hyperoxia-induced lung injury because of a prolonged duration of oxygen therapy or prior therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    . In practical terms, oxygen should be administered to achieve a PaO",
"    <sub>",
"     2",
"    </sub>",
"    of 60 to 65 mmHg (SaO",
"    <sub>",
"     2",
"    </sub>",
"    approximately 90 percent).",
"   </p>",
"   <p>",
"    A number of therapeutic strategies can be employed in patients with ARDS to minimize the need for a high FiO",
"    <sub>",
"     2",
"    </sub>",
"    and thereby reduce the risk of oxygen toxicity. However, despite their dramatic effect on FiO",
"    <sub>",
"     2",
"    </sub>",
"    in some cases, none of these therapies has been unequivocally demonstrated to improve overall mortality in ARDS. Interventions of this type include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Administration of PEEP to prevent alveolar derecruitment and lower the right-to-left shunt fraction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30663?source=see_link\">",
"       \"Positive end-expiratory pressure (PEEP)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Titration of an \"ideal PEEP\" in conjunction with a protective ventilation strategy, which has reduced mortality in one study, but has been somewhat controversial [",
"      <a class=\"abstract\" href=\"UTD.htm?27/47/28407/abstract/43\">",
"       43",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=see_link\">",
"       \"Mechanical ventilation in acute respiratory distress syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Performance of additional alveolar recruitment maneuvers (eg, a sustained delivery of continuous positive airway pressure of 40 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O for 60 seconds) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/47/28407/abstract/43,44\">",
"       43,44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Prone positioning [",
"      <a class=\"abstract\" href=\"UTD.htm?27/47/28407/abstract/45\">",
"       45",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9065?source=see_link\">",
"       \"Supportive care and oxygenation in acute respiratory distress syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inverse-ratio or other alternative modes of ventilation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=see_link\">",
"       \"Modes of mechanical ventilation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inhaled nitric oxide [",
"      <a class=\"abstract\" href=\"UTD.htm?27/47/28407/abstract/46,47\">",
"       46,47",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9033?source=see_link\">",
"       \"Novel therapies for the acute respiratory distress syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Extracorporeal membrane oxygenation [",
"      <a class=\"abstract\" href=\"UTD.htm?27/47/28407/abstract/48\">",
"       48",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37863?source=see_link\">",
"       \"Extracorporeal membrane oxygenation (ECMO) in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Liquid ventilation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/61/984?source=see_link\">",
"       \"Liquid ventilation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diuresis if pulmonary edema is possible.",
"     </li>",
"     <li>",
"      Bronchopulmonary hygiene if secretions are prominent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In our practice, we begin to implement these measures as soon as it is evident that the patient will require greater than 60 percent inspired oxygen for longer than six hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Augmentation of antioxidants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because oxygen radicals lead to pulmonary toxicity, enhanced defenses against these molecules theoretically should minimize or prevent lung damage [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28407/abstract/49\">",
"     49",
"    </a>",
"    ]. The potential importance of augmented antioxidant mechanisms is illustrated by the relative tolerance to hyperoxia of transgenic mice with increased superoxide dismutase activity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28407/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Animal data suggest potentially beneficial roles for strategies that either inhibit oxidant generation (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    , tungsten) or provide supplemental antioxidants (eg, alpha tocopherol,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    , N-acetylcysteine, dimethylthiourea) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28407/abstract/16,50-54\">",
"     16,50-54",
"    </a>",
"    ]. As an example, one prospective randomized baboon study demonstrated decreased hyperoxic pulmonary injury in animals randomized to aerosolized manganese superoxide dismutase [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28407/abstract/55\">",
"     55",
"    </a>",
"    ]. A different study induced protection against hyperoxic lung injury in rats by transferring the heme oxygenase-1 gene via a recombinant adenovirus vector [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28407/abstract/56\">",
"     56",
"    </a>",
"    ]. Data on the efficacy of these potential therapies in humans are lacking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Immune modulators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Manipulation of the cytokine milieu may permit modification of the deleterious inflammatory response provoked by hyperoxia. As an example, one study of transgenic mice with increased lung expression of interleukin (IL)-11 found reduced hyperoxic lung injury, possibly mediated through diminished hyperoxia-induced expression of IL-1 and tumor necrosis factor [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28407/abstract/10\">",
"     10",
"    </a>",
"    ]. The improved tolerance to hyperoxia occurred despite only small changes in lung antioxidant concentrations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Potential adverse clinical consequences of supplemental oxygen therapy include absorptive atelectasis, accentuation of preexisting hypercapnia, airway injury, parenchymal lung injury, and extrapulmonary toxicity. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical consequences'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The term, \"oxygen toxicity\", generally refers to parenchymal lung injury due to supplemental oxygen. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical consequences'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oxygen toxicity is mediated by reactive oxygen species, which can promote inflammation and induce cell death. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Cellular injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no well-defined threshold FiO",
"      <sub>",
"       2",
"      </sub>",
"      or duration of supplemental oxygen therapy below which oxygen toxicity cannot occur. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with any previous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      exposure who are hypoxemic should receive the lowest possible FiO",
"      <sub>",
"       2",
"      </sub>",
"      compatible with oxygenation goals (ie, avoidance of tissue hypoxia). The potential for oxygen toxicity must be communicated to the anesthesiologist if a patient with bleomycin exposure needs a surgical or endoscopic procedure. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Reduction of FiO2'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The FiO",
"      <sub>",
"       2",
"      </sub>",
"      should be titrated to the lowest concentration required to meet oxygenation goals. In our practice, we typically aim for a PaO",
"      <sub>",
"       2",
"      </sub>",
"      between 60 and 70 mmHg and oxygen saturation between 90 and 93 percent; further increases in PaO",
"      <sub>",
"       2",
"      </sub>",
"      add relatively little to the oxygen content of the blood. But, clinical judgment should be used in selecting a target oxygen saturation for an individual patient (eg, patients with coronary artery disease or pulmonary hypertension may tolerate hypoxemia poorly).(See",
"      <a class=\"local\" href=\"#H11\">",
"       'Reduction of FiO2'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional strategies to maximize oxygenation and reduce FiO",
"      <sub>",
"       2",
"      </sub>",
"      (eg, diuresis, bronchopulmonary hygiene, prone positioning, inhaled nitric oxide, recruitment maneuvers",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      optimal PEEP) should be considered when FiO",
"      <sub>",
"       2",
"      </sub>",
"      exceeds 60 percent for more than six hours. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Reduction of FiO2'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of antioxidants to prevent oxygen toxicity remains experimental. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Augmentation of antioxidants'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Gilbert DL. Oxygen: An overall biological view. In: Oxygen and Living Processes, Gilbert DL (Ed), Springer-Verlag, New York 1981. p.376.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/2\">",
"      Jenkinson SG. Oxygen toxicity. New Horiz 1993; 1:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/3\">",
"      Deneke SM, Fanburg BL. Normobaric oxygen toxicity of the lung. N Engl J Med 1980; 303:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/4\">",
"      Hedley-Whyte J. Causes of pulmonary oxygen toxicity. N Engl J Med 1970; 283:1518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/5\">",
"      Jackson RM. Pulmonary oxygen toxicity. Chest 1985; 88:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/6\">",
"      Davis WB, Rennard SI, Bitterman PB, Crystal RG. Pulmonary oxygen toxicity. Early reversible changes in human alveolar structures induced by hyperoxia. N Engl J Med 1983; 309:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/7\">",
"      Freeman BA, Crapo JD. Hyperoxia increases oxygen radical production in rat lungs and lung mitochondria. J Biol Chem 1981; 256:10986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/8\">",
"      Winslow RM. Oxygen: the poison is in the dose. Transfusion 2013; 53:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/9\">",
"      Fridovich I. Oxygen toxicity: a radical explanation. J Exp Biol 1998; 201:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/10\">",
"      Waxman AB, Einarsson O, Seres T, et al. Targeted lung expression of interleukin-11 enhances murine tolerance of 100% oxygen and diminishes hyperoxia-induced DNA fragmentation. J Clin Invest 1998; 101:1970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/11\">",
"      Barazzone C, Horowitz S, Donati YR, et al. Oxygen toxicity in mouse lung: pathways to cell death. Am J Respir Cell Mol Biol 1998; 19:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/12\">",
"      Mantell LL, Lee PJ. Signal transduction pathways in hyperoxia-induced lung cell death. Mol Genet Metab 2000; 71:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/13\">",
"      White CW, Avraham KB, Shanley PF, Groner Y. Transgenic mice with expression of elevated levels of copper-zinc superoxide dismutase in the lungs are resistant to pulmonary oxygen toxicity. J Clin Invest 1991; 87:2162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/14\">",
"      Lebovitz RM, Zhang H, Vogel H, et al. Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice. Proc Natl Acad Sci U S A 1996; 93:9782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/15\">",
"      Folz RJ, Abushamaa AM, Suliman HB. Extracellular superoxide dismutase in the airways of transgenic mice reduces inflammation and attenuates lung toxicity following hyperoxia. J Clin Invest 1999; 103:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/16\">",
"      Heffner JE, Repine JE. Pulmonary strategies of antioxidant defense. Am Rev Respir Dis 1989; 140:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/17\">",
"      Carvalho CR, de Paula Pinto Schettino G, Maranh&atilde;o B, Bethlem EP. Hyperoxia and lung disease. Curr Opin Pulm Med 1998; 4:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/18\">",
"      Huber GL, Porter SL, Burley SW, et al. The effect of oxygen toxicity on the inactivation of bacteria by the lung. Chest 1972; 61:Suppl:66S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/19\">",
"      Suttorp N, Simon LM. Decreased bactericidal function and impaired respiratory burst in lung macrophages after sustained in vitro hyperoxia. Am Rev Respir Dis 1983; 128:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/20\">",
"      Sackner MA, Hirsch JA, Epstein S, Rywlin AM. Effect of oxygen in graded concentrations upon tracheal mucous velocity. A study in anesthetized dogs. Chest 1976; 69:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/21\">",
"      Vlessis AA, Bartos D, Muller P, Trunkey DD. Role of reactive O2 in phagocyte-induced hypermetabolism and pulmonary injury. J Appl Physiol 1995; 78:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/22\">",
"      Griffith DE, Garcia JG, James HL, et al. Hyperoxic exposure in humans. Effects of 50 percent oxygen on alveolar macrophage leukotriene B4 synthesis. Chest 1992; 101:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/23\">",
"      Wagner PD, Laravuso RB, Uhl RR, West JB. Continuous distributions of ventilation-perfusion ratios in normal subjects breathing air and 100 per cent O2. J Clin Invest 1974; 54:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/24\">",
"      Santos C, Ferrer M, Roca J, et al. Pulmonary gas exchange response to oxygen breathing in acute lung injury. Am J Respir Crit Care Med 2000; 161:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/25\">",
"      Dunn WF, Nelson SB, Hubmayr RD. Oxygen-induced hypercarbia in obstructive pulmonary disease. Am Rev Respir Dis 1991; 144:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/26\">",
"      Aubier M, Murciano D, Milic-Emili J, et al. Effects of the administration of O2 on ventilation and blood gases in patients with chronic obstructive pulmonary disease during acute respiratory failure. Am Rev Respir Dis 1980; 122:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/27\">",
"      Sassoon CS, Hassell KT, Mahutte CK. Hyperoxic-induced hypercapnia in stable chronic obstructive pulmonary disease. Am Rev Respir Dis 1987; 135:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/28\">",
"      Robinson TD, Freiberg DB, Regnis JA, Young IH. The role of hypoventilation and ventilation-perfusion redistribution in oxygen-induced hypercapnia during acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161:1524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/29\">",
"      Malhotra A, Schwartz DR, Ayas N, et al. Treatment of oxygen-induced hypercapnia. Lancet 2001; 357:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/30\">",
"      Orem J. The nature of the wakefulness stimulus for breathing. Prog Clin Biol Res 1990; 345:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/31\">",
"      Comroe, JH, Dripps, RD, Dumke, PR, Deming, M. The effect of inhalation of high concentrations of oxygen for 24 hours on normal men at sea level and at a simulated altitude of 18,000. JAMA 1945; 128:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/32\">",
"      Sackner MA, Landa J, Hirsch J, Zapata A. Pulmonary effects of oxygen breathing. A 6-hour study in normal men. Ann Intern Med 1975; 82:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/33\">",
"      Carpagnano GE, Kharitonov SA, Foschino-Barbaro MP, et al. Supplementary oxygen in healthy subjects and those with COPD increases oxidative stress and airway inflammation. Thorax 2004; 59:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/34\">",
"      Singer MM, Wright F, Stanley LK, et al. Oxygen toxicity in man. A prospective study in patients after open-heart surgery. N Engl J Med 1970; 283:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/35\">",
"      Barber RE, Hamilton WK. Oxygen toxicity in man. A A/Barber RE, Lee J, Hamilton WK: Oxygen toxicity in man. A prospective study in patients with irreversible brain damage. N Engl J Med 1970; 283:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/36\">",
"      Elliott CG, Rasmusson BY, Crapo RO, et al. Prediction of pulmonary function abnormalities after adult respiratory distress syndrome (ARDS). Am Rev Respir Dis 1987; 135:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/37\">",
"      Berend N. Protective effect of hypoxia on bleomycin lung toxicity in the rat. Am Rev Respir Dis 1984; 130:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/38\">",
"      Flynn JT, Bancalari E, Snyder ES, et al. A cohort study of transcutaneous oxygen tension and the incidence and severity of retinopathy of prematurity. N Engl J Med 1992; 326:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/39\">",
"      Lodato RF. Effects of normobaric hyperoxia on hemodynamics and O2 utilization in conscious dogs. Adv Exp Med Biol 1990; 277:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/40\">",
"      Ganz W, Donoso R, Marcus H, Swan HJ. Coronary hemodynamics and myocardial oxygen metabolism during oxygen breathing in patients with and without coronary artery disease. Circulation 1972; 45:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/41\">",
"      B&uuml;sing CM, Kreinsen U, B&uuml;hler F, Bleyl U. Light and electron microscopic examinations of experimentally produced heart muscle necroses following normobaric hyperoxia. Virchows Arch A Pathol Anat Histol 1975; 366:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/42\">",
"      Lodato RF. Decreased O2 consumption and cardiac output during normobaric hyperoxia in conscious dogs. J Appl Physiol 1989; 67:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/43\">",
"      Amato MB, Barbas CS, Medeiros DM, et al. Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med 1998; 338:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/44\">",
"      Rothen HU, Sporre B, Engberg G, et al. Re-expansion of atelectasis during general anaesthesia: a computed tomography study. Br J Anaesth 1993; 71:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/45\">",
"      Albert RK. The prone position in acute respiratory distress syndrome: where we are, and where do we go from here. Crit Care Med 1997; 25:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/46\">",
"      Dellinger RP, Zimmerman JL, Taylor RW, Straube RC. Placebo and inhaled nitric oxide mortality the same in ARDS clinical trial. Crit Care Med 1998; 26:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/47\">",
"      Dellinger RP, Zimmerman JL, Taylor RW, et al. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Inhaled Nitric Oxide in ARDS Study Group. Crit Care Med 1998; 26:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/48\">",
"      Lewandowski K, Rossaint R, Pappert D, et al. High survival rate in 122 ARDS patients managed according to a clinical algorithm including extracorporeal membrane oxygenation. Intensive Care Med 1997; 23:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/49\">",
"      Comhair SA, Erzurum SC. Antioxidant responses to oxidant-mediated lung diseases. Am J Physiol Lung Cell Mol Physiol 2002; 283:L246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/50\">",
"      Kolleck I, Sinha P, R&uuml;stow B. Vitamin E as an antioxidant of the lung: mechanisms of vitamin E delivery to alveolar type II cells. Am J Respir Crit Care Med 2002; 166:S62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/51\">",
"      Bitterman N, Melamed Y, Ben-Amotz A. Beta-carotene and CNS oxygen toxicity in rats. J Appl Physiol 1994; 76:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/52\">",
"      Tang G, White JE, Gordon RJ, et al. Polyethylene glycol-conjugated superoxide dismutase protects rats against oxygen toxicity. J Appl Physiol 1993; 74:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/53\">",
"      Turrens JF, Crapo JD, Freeman BA. Protection against oxygen toxicity by intravenous injection of liposome-entrapped catalase and superoxide dismutase. J Clin Invest 1984; 73:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/54\">",
"      Dennery PA, Spitz DR, Yang G, et al. Oxygen toxicity and iron accumulation in the lungs of mice lacking heme oxygenase-2. J Clin Invest 1998; 101:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/55\">",
"      Welty-Wolf, KE, Simonson, SG, Huang, YCT, et al. Aerosolized manganese SOD decreases hyperoxic pulmonary injury in primates. II. Morphometric analysis. J Appl Physiol 1997; 83:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28407/abstract/56\">",
"      Otterbein LE, Kolls JK, Mantell LL, et al. Exogenous administration of heme oxygenase-1 by gene transfer provides protection against hyperoxia-induced lung injury. J Clin Invest 1999; 103:1047.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1622 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-A93D27A9D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_47_28407=[""].join("\n");
var outline_f27_47_28407=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CELLULAR INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL CONSEQUENCES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Absorptive atelectasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Accentuation of hypercapnia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Airway injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Parenchymal injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Potentiation by bleomycin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Extrapulmonary toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Reduction of FiO2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Augmentation of antioxidants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Immune modulators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?1/6/1123?source=related_link\" title=\"calculator 1\">",
"      Calculator: Right to Left Shunt Fraction Qs/Qt",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29767?source=related_link\">",
"      Amiodarone pulmonary toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12794?source=related_link\">",
"      Bleomycin-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40008?source=related_link\">",
"      Control of ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37863?source=related_link\">",
"      Extracorporeal membrane oxygenation (ECMO) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/61/984?source=related_link\">",
"      Liquid ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42215?source=related_link\">",
"      Long-term supplemental oxygen therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=related_link\">",
"      Mechanical ventilation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=related_link\">",
"      Modes of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25271?source=related_link\">",
"      Neurogenic pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9033?source=related_link\">",
"      Novel therapies for the acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18793?source=related_link\">",
"      Pathogenesis and clinical features of bronchopulmonary dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30663?source=related_link\">",
"      Positive end-expiratory pressure (PEEP)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24090?source=related_link\">",
"      Radiation-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10762?source=related_link\">",
"      Retinopathy of prematurity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9065?source=related_link\">",
"      Supportive care and oxygenation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3064?source=related_link\">",
"      Use of oxygen in patients with hypercapnia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_47_28408="Pityriasis lichenoides et varioliformis acuta";
var content_f27_47_28408=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F57911%7EDERM%2F83096&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F57911%7EDERM%2F83096&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pityriasis lichenoides et varioliformis acuta",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple inflammatory papules are present. Some lesions demonstrate necrosis and crusting.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pityriasis lichenoides et varioliformis acuta (PLEVA)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_47_28408=[""].join("\n");
var outline_f27_47_28408=null;
var title_f27_47_28409="Termination of pregnancy: Second trimester";
var content_f27_47_28409=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Termination of pregnancy: Second trimester",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/47/28409/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/47/28409/contributors\">",
"     Lee P Shulman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/47/28409/contributors\">",
"     Frank W Ling, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/47/28409/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/47/28409/contributors\">",
"     Mimi Zieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/47/28409/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/47/28409/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/47/28409/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methods for second trimester pregnancy termination will be discussed here. An overview of general issues of pregnancy termination (preoperative evaluation, use of antibiotics and anesthesia, complications, follow-up, etc) and issues pertaining to first trimester surgical termination of pregnancy are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19498?source=see_link\">",
"     \"Overview of pregnancy termination\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4453?source=see_link\">",
"     \"Surgical termination of pregnancy: First trimester\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three general methods of second trimester pregnancy termination:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dilation and evacuation (D&amp;E)",
"     </li>",
"     <li>",
"      Administration of systemic abortifacients",
"     </li>",
"     <li>",
"      Intrauterine instillation of abortifacients",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hysterotomy or hysterectomy are rarely performed for pregnancy termination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DILATION AND EXTRACTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     General issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dilation and extraction (D&amp;E) is the most common technique used for second-trimester pregnancy termination in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/1\">",
"     1",
"    </a>",
"    ]. It has the lowest maternal mortality rate of all second trimester pregnancy termination procedures and comparable morbidity to other second trimester techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/2\">",
"     2",
"    </a>",
"    ]. As an example:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 9572 extraction procedures were compared to 2805 instillation procedures using an instillate composed of PGF2 alpha and urea [",
"      <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/3\">",
"       3",
"      </a>",
"      ]. All procedures were performed between 13 and 24 weeks of gestation. Serious complications (fever of 38&ordm;C or more, hemorrhage requiring blood transfusion, or performance of unintended surgery as result of an abortion-related incident) were lower in women undergoing an extraction procedure (0.49 versus 1.03 percent). Only uterine perforation occurred more frequently in the extraction group.",
"     </li>",
"     <li>",
"      These findings were confirmed in another series of women undergoing abortions through the 15th menstrual week that showed surgical extraction had a lower frequency of blood loss requiring transfusion, cervical laceration, retained products of conception, fever, vomiting, and diarrhea than labor induction abortion by intravaginal prostaglandin (PG) suppositories [",
"      <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similar results were reported in a study comparing dilation and extraction to intraamniotic saline infusion [",
"      <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/5\">",
"       5",
"      </a>",
"      ]. The major complication rate for extraction was less than one-half that of saline instillation (0.69 and 1.78 percent, respectively) and there were lower rates of treatment complications, such as antibiotic administration (2 versus 6 percent) and blood transfusion (0.2 versus 1 percent).",
"     </li>",
"     <li>",
"      Other studies comparing D&amp;E to labor induction for cases of fetal anomalies or demise in the second trimester demonstrated D&amp;E to be significantly safer and more effective than labor induction in second trimester cases undertaken for fetal indications [",
"      <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/6\">",
"       6",
"      </a>",
"      ]. One study found that D&amp;E was less morbid than labor induction for uterine evacuation in cases of second trimester fetal demise as result of an increased risk of presumed infection [",
"      <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There are also psychological benefits of a rapid procedure that does not involve labor [",
"      <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/8\">",
"       8",
"      </a>",
"      ]. This was illustrated in a study that reported that women undergoing second trimester extraction experienced less postoperative pain, anger, and depression than those undergoing labor induction methods [",
"      <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a mathematical model, surgical termination was less expensive than medical termination using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    &nbsp;(see",
"    <a class=\"local\" href=\"#H12\">",
"     'Misoprostol'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In many centers, feticidal agents are given before any second trimester procedure prior to inserting laminaria so the surgical extraction will be performed on a dead fetus, thus avoiding uncertainties in abortion law (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Intact dilation and extraction'",
"    </a>",
"    below). Options include intracardiac injection of about 5 mEq",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    or injection of 0.5 to 1.5 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    into the fetus or amniotic sac [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/11\">",
"     11",
"    </a>",
"    ]. A large case series reported that failure rates for intraamniotic digoxin administration were higher than for intrafetal administration (8.3 versus 3.6 percent); there were no adverse maternal events [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    is the safest approach. Maternal cardiac arrest after attempted fetal intracardiac injection of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cervical preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Second-trimester extraction requires dilation of the cervix. Careful manual dilation can achieve sufficient cervical dilation to allow uterine evacuation in many cases. However, this technique carries a significantly increased risk of cervical laceration, hemorrhage, and unsuccessful uterine evacuation due to the need for extensive dilation of the cervix to allow removal of the larger volume of intrauterine contents [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/14\">",
"     14",
"    </a>",
"    ]. The preferred technique of cervical dilation is to use multiple osmotic dilators (eg, synthetic or natural seaweed-based laminaria). Prostaglandins are alternative agents for cervical ripening. Therefore, progressive cervical dilation, which may take several days, is performed for patient safety. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19498?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of pregnancy termination\", section on 'Cervical preparation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Evacuation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending on the patient and gestational age, a variety of anesthetic approaches may be used, including conscious sedation, regional block, and general anesthesia. Sometimes a vasoconstrictive agent such as vasopressin is added to the paracervical block to reduce intra- and postoperative bleeding.",
"   </p>",
"   <p>",
"    The cervix is prepped with antiseptic solution and, after spot injection of a local anesthetic (eg, 3 mL of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/17/3350?source=see_link\">",
"     chloroprocaine",
"    </a>",
"    hydrochloride), the anterior lip is grasped with a tenaculum. A paracervical block is then placed (",
"    <a class=\"graphic graphic_figure graphicRef64237 \" href=\"UTD.htm?16/0/16385\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19498?source=see_link&amp;anchor=H15#H15\">",
"     \"Overview of pregnancy termination\", section on 'Anesthesia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A vacuum cannula of 12 to 14 mm is adequate for evacuation at 13 to 15 weeks of gestation. Instruments specifically designed to extract intrauterine contents are required after 16 to 17 weeks because the products of conception are too large to aspirate through even 16-mm cannulas. However, large bore cannulas are useful in procedures after 16 weeks to aspirate amniotic fluid and placenta and to pull the large fetal parts down to the lower uterine segment for extraction with forceps. Cannulas should not be inserted deeply into the uterus due to the risk of perforation. They are rotated 360 degrees around their long axis under vacuum pressures of 50 to 60 cm Hg.",
"   </p>",
"   <p>",
"    The authors prefer either the Sopher (",
"    <a class=\"graphic graphic_picture graphicRef56683 \" href=\"UTD.htm?25/26/26030\">",
"     picture 1",
"    </a>",
"    ) or Bierer ovum forceps, although several other ovum forceps (Hern, Clemetson, Peterson, Barrett, Sanger, Moore, Forester, Van Lith, Kelly placental forceps) are available for uterine evacuation in the second trimester. The Sopher forceps are inserted such that the hinge is at the level of the cervical canal. Although concomitant ultrasound guidance is not essential for a safe and successful uterine evacuation, it often facilitates the evacuation procedure, particularly in problematic cases such as severe uterine anteflexion or fibroids [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Ultrasound guidance has been shown to increase safety [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/16\">",
"     16",
"    </a>",
"    ]. Placing a hand on the fundus of the uterus during the procedure may help to decrease the risk of perforation when the uterus is large and assists with assessment of the changing uterine size and position. For the same reason, it is preferable to explore the uterus with a large curette instead of narrower instruments, such as forceps or suction cannula.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Curettage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suction curettage is performed to extract any remaining tissue after the products of conception have been evacuated. The physician must examine the specimen to verify that all products of conception have been removed. The fetal foot length should be recorded to corroborate the estimated gestational age (",
"    <a class=\"graphic graphic_table graphicRef64496 \" href=\"UTD.htm?5/54/5995\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Complications of extraction procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications are similar to those after first trimester suction curettage (eg, hemorrhage, uterine perforation, infection, retained products of conception) and are addressed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19498?source=see_link&amp;anchor=H24#H24\">",
"     \"Overview of pregnancy termination\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Complications are more frequent at later gestational ages in most [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/17\">",
"     17",
"    </a>",
"    ], but not all, studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/5\">",
"     5",
"    </a>",
"    ]. This was demonstrated in a report showing the rate of unplanned hospitalizations resulting from extraction at 13 weeks was 0.6 percent, but was 1.4 percent at 20 to 21 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The morbidity associated with extraction procedures is lower than that with labor induction methods [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/18\">",
"     18",
"    </a>",
"    ]. However, other factors need to be considered when choosing the best technique for late second-trimester uterine evacuation. As an example, the indication for uterine evacuation may be an important consideration (ie, is an intact fetal specimen important for diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]) as well as the availability of personnel skilled in performing D &amp; E procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Intact dilation and extraction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intact dilation and extraction (D&amp;X) refers to a procedure in which an assisted breech delivery of the fetus is accomplished, often under ultrasound guidance, and then the calvarium is decompressed so that the fetus can be delivered intact [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/11\">",
"     11",
"    </a>",
"    ]. Multistage laminaria insertion beginning two days before the procedure is used to obtain wide cervical dilation.",
"   </p>",
"   <p>",
"    An observational study comparing 120 intact D&amp;Xs at a median gestational age of 23 weeks to 263 D&amp;Es at a median gestational age of 21 weeks found similar complication rates and outcomes for both procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/21\">",
"     21",
"    </a>",
"    ]. The authors tended to choose D&amp;X when the cervix was well dilated (mean preoperative dilation 5 cm, range 2 to 10 cm) at more advanced gestational ages because they believed this approach minimized the need to use forceps for disarticulation and evacuation and thus potentially reduced the risk of uterine trauma. The procedures were performed between June 1996 and June 2003. Women who underwent either procedure for reasons other than advanced cervical dilation or PPROM had a 4 percent risk of spontaneous preterm birth in the subsequent pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In November 2003, the United States Congress passed a bill banning partial birth abortion (S. 3-8, 108th Congress, First Session). The bill makes it illegal to intentionally perform an act that will kill a partially delivered, living fetus. A partially delivered fetus is defined as one whose entire head is outside the mother's body (in vertex presentation) or in whom any part of the fetal trunk past the navel is outside the mother's body (in breech presentation). The ban on intact D&amp;X was not being enforced because the constitutionality of the law was challenged in federal courts in New York, Nebraska, and San Francisco and was ruled unconstitutional in all three courts. However, in April 2007 the Supreme Court upheld the law, which does not contain an exception to permit the procedure when the mother's life is threatened; the broader repercussions of this ruling are currently unknown.",
"   </p>",
"   <p>",
"    The ban does not apply to fetuses that expire before the evacuation begins, thus some physicians choose to effect fetal demise before the procedure to avoid criminal and civil liability. It also does not apply to standard D&amp;Es in which the fetus is removed in pieces. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'General issues'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SYSTEMIC ABORTIFACIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic abortifacients (eg, prostaglandin E2,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    ) are usually given intravaginally; occasionally, they are given intramuscularly (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/29/20948?source=see_link\">",
"     carboprost tromethamine",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Fetacidal agents are recommended in conjunction with these procedures to avoid the possibility of transient fetal survival. Options include intraamniotic instillation of saline (60 mL of a 23 percent solution), intracardiac injection of about 5 mEq",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    , or injection of 1 to 1.5 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    into the fetus or amniotic sac [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Prostaglandin E2",
"    </span>",
"    &nbsp;&mdash;&nbsp;PGE2 suppositories (20 mg) can be used for second trimester pregnancy termination. A suppository is placed in the posterior fornix at three to five hour intervals until abortion occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/1\">",
"     1",
"    </a>",
"    ]. The dose may be adjusted downward to 5 mg based upon a more advanced gestational age (more sensitive to prostaglandins), a pronounced uterotonic response, or undesirable side effects. Patients are often premedicated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , compazine, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/56/9094?source=see_link\">",
"     diphenoxylate",
"    </a>",
"    to minimize fever, nausea, vomiting, and diarrhea, which invariably occur.",
"   </p>",
"   <p>",
"    The mean time to abortion is 13.4 hours and 90 percent of women abort by 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/23\">",
"     23",
"    </a>",
"    ]. Postoperative care is the same as that for women undergoing other pregnancy termination procedures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19498?source=see_link&amp;anchor=H23#H23\">",
"     \"Overview of pregnancy termination\", section on 'Postoperative care'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19498?source=see_link&amp;anchor=H36#H36\">",
"     \"Overview of pregnancy termination\", section on 'Follow up'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Instead of vaginal administration, a lower dose of PGE2 suppositories (1 to 3 mg) may be inserted between the fetal membranes and endometrium (extra-amniotic) by passing the viscous gel through a catheter placed in this location [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/24\">",
"     24",
"    </a>",
"    ]. This approach may result in fewer systemic side effects. Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    may be used concomitantly with PGE2 to hasten delivery, but poses additional risks of hyperstimulation and uterine rupture. Therefore, we recommend oxytocin",
"    <strong>",
"     NOT",
"    </strong>",
"    be administered until at least two hours after the last dose of PG.",
"   </p>",
"   <p>",
"    A placebo controlled randomized European trial compared outcomes of second trimester abortion with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/24/19846?source=see_link\">",
"     isosorbide mononitrate",
"    </a>",
"    (IMN, 40 mg per vagina) plus gemeprost (1 mg up to three times daily) versus gemeprost alone [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/25\">",
"     25",
"    </a>",
"    ]. The addition of IMN significantly increased the proportion of expulsions within 24 hours (68 versus 38 percent); however, the mean induction to abortion interval was not significantly different for the two groups (23.2 and 29.9 hours, respectively). In addition, IMN was associated with a high frequency of headache (18 versus 0 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Misoprostol",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the second trimester, the PGE1 analog",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    is safe and effective for pregnancy termination. Higher doses of misoprostol are associated with increased rates of side effects and complications (eg, fever, nausea, vomiting, diarrhea, uterine rupture). A full discussion of misoprostol-alone regimens can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28330?source=see_link\">",
"     \"Misoprostol as a single agent for medical termination of pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Misoprostol with mifepristone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combining",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    appears to shorten the induction to delivery time [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/26-31\">",
"     26-31",
"    </a>",
"    ]. The addition of mifepristone may also decrease procedure-related pain [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. These points are illustrated by the following randomized trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, women undergoing abortion at 18 to 23 weeks of gestation were treated with feticidal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      , and then randomized to receive 200 mg of oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"       mifepristone",
"      </a>",
"      or placebo; all women then underwent an oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      regimen the following day [",
"      <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/30\">",
"       30",
"      </a>",
"      ]. Time from induction to fetal expulsion was significantly shorter for women who had been pre-treated with mifepristone compared with those who were not (10 versus 18 hours).",
"     </li>",
"     <li>",
"      A second trial assigned women at 15 to 22 weeks of gestation to receive 200 mg of oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"       mifepristone",
"      </a>",
"      or laminaria; all women then underwent an oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      regimen the following day [",
"      <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/31\">",
"       31",
"      </a>",
"      ]. Mean induction-to-delivery time was significantly shorter for women who had received mifepristone (10 versus 16 hours). Pain with cervical ripening was also significantly less in the mifepristone group. Fetal demise prior to induction, need for postpartum curettage, blood loss, pain during induction, delivery, and at the time of discharge were not significantly different between the two groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     Mifepristone",
"    </a>",
"    can be administered orally or vaginally [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/33\">",
"     33",
"    </a>",
"    ]. An example of an effective regimen is mifepristone (200 mg) administered 36 to 48 hours before",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    (800 mcg per vagina followed by 400 mcg orally or intravaginally every three hours up to four doses) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     Mifepristone",
"    </a>",
"    was licensed for the termination of pregnancy of greater than 13 weeks in France and Sweden in 1992, in the United Kingdom in 1995, and in nine other European countries in 1999 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Carboprost tromethamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/29/20948?source=see_link\">",
"     Carboprost tromethamine",
"    </a>",
"    is a prostaglandin similar to PGF2 alpha except for the addition of a methyl group at the C-15 position. This substitution produces a longer duration of activity. The dose for inducing second trimester abortion is 250 mcg intramuscularly to start, 250 mcg at 1.5 to 3.5 hour intervals depending on uterine response; a 500 mcg dose may be given if uterine response is not adequate after several 250 mcg doses; the maximum total dose administered should not exceed 12 mg. The mean time to abortion is 15 to 17 hours and 80 percent of women abort within 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     High-dose oxytocin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     Oxytocin",
"    </a>",
"    at high doses can also be used as an abortifacient and is associated with less fever and fewer gastrointestinal side effects than prostaglandins. The initial dose is 50 units in 500 mL of 5 percent",
"    <span class=\"nowrap\">",
"     dextrose/normal",
"    </span>",
"    saline over three hours [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/36\">",
"     36",
"    </a>",
"    ]. After an hour of rest, the infusion is repeated using 60 units of oxytocin. This regimen is continued up to a maximum of 300 units oxytocin in 500 mL solution (ie, 1667",
"    <span class=\"nowrap\">",
"     mU/min).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Termination",
"    of pregnancy using systemic abortifacients is associated with the same complications as for extraction procedures (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19498?source=see_link&amp;anchor=H24#H24\">",
"     \"Overview of pregnancy termination\", section on 'Complications'",
"    </a>",
"    ). The risk of complications increases with the length of the \"third stage\". As an example, one series reported the complication rate (hemorrhage or infection) at 30, 60, and 120 minutes after fetal expulsion was 4.2, 5.2, and 9.3 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/37\">",
"     37",
"    </a>",
"    ]. Use of systemic abortifacients may also be associated with complications such as retained placenta and uterine rupture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Retained placenta",
"    </span>",
"    &nbsp;&mdash;&nbsp;A common guideline is that the placenta should be expelled within 30 to 120 minutes of expulsion of the fetus. A longer period of expectant management is not necessarily harmful, but the main benefit appears to be avoiding instrumentation. In a retrospective study of second trimester",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    induction terminations, no increased morbidity was observed with expectant management of a retained placenta up to four hours after fetal expulsion [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/31\">",
"     31",
"    </a>",
"    ]. If placental expulsion is delayed, then the placenta can be removed by suction curettage [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Uterine rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine rupture from second trimester induction for pregnancy termination has been described in case reports. Women with a scarred uterus (eg, previous cesarean delivery) are at highest risk [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/39\">",
"     39",
"    </a>",
"    ]; other purported risk factors include grand multiparity and nulliparity with insufficiently ripened cervix. However, most women with a previous hysterotomy can safely undergo midtrimester pregnancy termination [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     INTRAUTERINE INSTILLATION OF ABORTIFACIENT AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Instillation of abortifacient agents was, at one time, a common method for second trimester pregnancy termination. These techniques have been largely abandoned due to development of safe and effective systemic agents and operative techniques (discussed above). Surgical extraction, provided the surgeon is experienced with second trimester abortion techniques, has a lower rate of complications before 16 to 20 weeks of gestation than intraamniotic instillation methods and time to abortion is much faster [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/3,5,17\">",
"     3,5,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypertonic agents infused into the intraamniotic cavity or extraovular space (ie, between the amniotic membranes and uterine wall) induce contractions leading to evacuation of uterine contents. The two major agents employed are PGF2 alpha and hypertonic saline. PGF2 alpha has the advantage of speed, but the fetus may be born alive and maternal side effects (eg, vomiting, diarrhea, incomplete abortion) are common [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/1\">",
"     1",
"    </a>",
"    ]; hypertonic saline has the advantage of causing fetal death, but the duration of the procedure can be long and it can cause hypernatremia, coagulopathy, and volume overload. PGF2 alpha is available as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/29/20948?source=see_link\">",
"     carboprost tromethamine",
"    </a>",
"    (Hemabate) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/11\">",
"     11",
"    </a>",
"    ]. Hypertonic urea (80 to 90 g) is an alternative agent, but it has a very long infusion to delivery interval and therefore is rarely used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Saline infusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osmotic dilators should be placed at least 12 hours prior to the procedure to facilitate cervical dilation and shorten the infusion to abortion time. In addition, use of laminaria or other materials to dilate the cervix prior to instillation of abortifacients facilitates expulsion, and may prevent delivery through the lower uterine segment in primiparous females. After the woman empties her bladder, an 18 gauge spinal needle is inserted into the amniotic cavity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/1\">",
"     1",
"    </a>",
"    ]. The location is confirmed by withdrawing a small amount of amniotic fluid. This is important to avoid intravascular or intramyometrial infusion of the hypertonic saline, which can result in life-threatening hypernatremia, myometrial necrosis, or disseminated intravascular coagulation. Two hundred milliliters of 20 percent saline solution (40 grams) are infused by gravity and the needle removed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Prostaglandin F2 alpha infusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The procedure is the same as that described above for hypertonic saline, except 2.5 to 5 mg PGF2 alpha is infused as a test dose, followed by 17.5 to 35 mg if the test dose is tolerated. One-quarter of women will require a second injection to maintain labor and complete the procedure. Alternatively,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/29/20948?source=see_link\">",
"     carboprost tromethamine",
"    </a>",
"    (2 mg) can be instilled.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Combined prostaglandin F2 alpha and hypertonic saline infusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of these two drugs serves to hasten the induction to delivery interval, ensure death of the fetus, and has few side effects. The optimal dose is 1.5 mg of 15-methyl-PGF2 alpha and 64 to 100 mL of 23.4 percent saline. The average time to abortion is eight hours.",
"   </p>",
"   <p>",
"    Parenteral administration must be avoided because these agents can cause cardiac arrhythmias, bronchospasm, pulmonary hypertension, and hypoxemia. Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    may be used concomitantly with either drug to hasten delivery, but poses additional risks, such as hyperstimulation and uterine rupture. Therefore, oxytocin should not be administered until at least two hours after the last dose of prostaglandin.",
"   </p>",
"   <p>",
"    The placenta often fails to be expelled along with the second trimester fetus.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     Oxytocin",
"    </a>",
"    can be used safely after fetal delivery to help with placental expulsion, but removal with forceps and suction curettage is recommended as well [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/41\">",
"     41",
"    </a>",
"    ]. Gentle exploration of the uterus with a large curette is also recommended to make sure placental fragments have not been retained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostaglandin F2 alpha should not be used in women with asthma, epilepsy, glaucoma, pulmonary hypertension, or hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/41\">",
"     41",
"    </a>",
"    ]. Hypertonic saline should be avoided in women who cannot tolerate a saline load and those with an intrauterine fetal demise, because of the increased potential for coagulopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Postoperative issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative care and monitoring is the same as that for women undergoing other pregnancy termination procedures. The risk of perforation is less with instillation procedures, although overall complication rates from fever, endometritis, retained products of conception, hemorrhage, and cervical injury requiring repair are the same or higher than those for extraction procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19498?source=see_link&amp;anchor=H24#H24\">",
"     \"Overview of pregnancy termination\", section on 'Complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19498?source=see_link&amp;anchor=H23#H23\">",
"     \"Overview of pregnancy termination\", section on 'Postoperative care'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19498?source=see_link&amp;anchor=H36#H36\">",
"     \"Overview of pregnancy termination\", section on 'Follow up'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9277352\">",
"    <span class=\"h1\">",
"     CHOICE OF TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary factors in choosing a particular technique for pregnancy termination are the volume and content of intrauterine tissue, the experience of the surgeon, and patient preference. Some studies suggest benefit for D&amp;E compared to induction techniques when pregnancy termination or uterine evacuation is performed for fetal indications or fetal death [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. However, both studies were undertaken in centers with surgeons experienced in performing second trimester D&amp;E. Likewise, an earlier study found D&amp;E to be safer than, and preferable to, labor induction techniques. A randomized trial of 122 women undergoing termination at 13 to 20 weeks of gestation compared medical (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    ) and surgical evacuation procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/43\">",
"     43",
"    </a>",
"    ]. Women who underwent surgical termination had significantly less bleeding (4 versus 37 percent had bleeding greater than menses). Fewer women in the surgical group had moderate or severe pain (23 versus 43 percent had moderate or severe pain), but this did not reach statistical significance due to insufficient statistical power. Women in the surgical group found the procedure more acceptable; more reported that they would choose the same procedure again (100 versus 53 percent) and fewer found the experience to be worse than expected (0 versus 53 percent). Further comparative data are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Surgical",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dilation and evacuation (D&amp;E) procedures require the least amount of time and can be performed in a uterus of almost any size for removal of most types of intrauterine contents (eg, placenta, molar tissue, fetal tissue). The patient does not experience labor, which most women consider a benefit of D&amp;E, and the fetus will not be born alive, which is important medicolegally.",
"   </p>",
"   <p>",
"    There are fewer drug-related side-effects with D&amp;E than with nonsurgical abortion; however, there is a small risk of operative complications, such as uterine perforation, and the fetus is not delivered intact, which can be important if the termination was done because of a fetal abnormality. In two small randomized trials, dilation and evacuation resulted in significantly fewer complications than either systemic use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    with vaginal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    or intrauterine usage of prostaglandin F2 alpha [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For these reasons, D&amp;E is the preferred method of second trimester termination when highly experienced personnel are available and autopsy of an intact fetus is not important for counseling [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Nonsurgical",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsurgical techniques for uterine evacuation involve labor induction using systemic (eg, intravaginal or oral prostaglandins) or intraamniotic (eg, saline, prostaglandin F2 alpha, urea) abortifacients. Although use of abortifacients does not require a skilled operator, physicians who use nonsurgical methods must be prepared to employ surgical techniques of uterine evacuation when there are retained products of conception, a common occurrence following labor induction methods.",
"   </p>",
"   <p>",
"    There are no data from large randomized trials comparing a variety of medical approaches on which to make a recommendation for one regimen over another. The few randomized studies which are available are difficult to compare because of differences in the drug regimens employed. Based upon the preceding discussion, vaginal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    (400 mcg every four hours up to six doses) appears to be the preferred approach because:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       Misoprostol",
"      </a>",
"      is significantly less expensive than vaginal prostaglandins and is as or more effective than these agents. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28330?source=see_link&amp;anchor=H35#H35\">",
"       \"Misoprostol as a single agent for medical termination of pregnancy\", section on 'Misoprostol versus other prostaglandins'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       Misoprostol",
"      </a>",
"      is more acceptable to women and is as or more effective than intrauterine instillation of prostaglandin F2 alpha [",
"      <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/45-48\">",
"       45-48",
"      </a>",
"      ]. In some trials, misoprostol had a shorter induction to delivery interval and fewer side effects than prostaglandin F2 alpha. However, misoprostol results in more live births (20 versus 5 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Saline infusion and urea infusion act much more slowly than other techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]; these modalities are no longer used alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     HYSTEROTOMY AND HYSTERECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hysterotomy and hysterectomy have essentially been abandoned as techniques for uterine evacuation because of high rates of associated maternal morbidity and mortality and the ready availability of less invasive techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/51\">",
"     51",
"    </a>",
"    ]. Hysterotomy is now justified only in rare cases in which systemic abortifacients have failed to terminate the pregnancy and no physician skilled in performing second-trimester extraction procedures is available. Hysterectomy may be justified in very rare instances when the need for termination is accompanied by cervical, uterine, or ovarian pathology (eg, cancer) requiring uterine excision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SPECIAL CASES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Fetal demise",
"    </span>",
"    &nbsp;&mdash;&nbsp;The uterine evacuation procedure and postoperative care provided to women carrying a nonviable embryo or fetus is similar to that for women undergoing first or second trimester pregnancy termination. The type of procedure is determined by the estimated gestational size as determined by menstrual history, bimanual pelvic examination, and ultrasonographic measurements.",
"   </p>",
"   <p>",
"    The patient's fibrinogen concentration should be determined to detect a potential coagulopathic state developing from retention of a nonviable fetus, which is most common after 20 weeks of gestation and at more than six weeks from the actual fetal death. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/56/8073?source=see_link&amp;anchor=H11#H11\">",
"     \"Pathogenesis and etiology of disseminated intravascular coagulation\", section on 'Obstetrical complications'",
"    </a>",
"    .) Management of late fetal demise (over 24 to 28 weeks) is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31306?source=see_link\">",
"     \"Incidence, etiology, and prevention of stillbirth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Fetal abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Termination of pregnancies after detection of congenital abnormalities has the added concern of confirming the prenatal diagnoses and obtaining any additional information about fetal maldevelopment. Successful and consistent confirmation of prenatal diagnostic results by evaluation of products of conception obtained by second-trimester dilation and evacuation is possible [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/52-54\">",
"     52-54",
"    </a>",
"    ], although recovery of an intact fetus may occasionally be required to confirm a specific prenatal diagnosis. In one study, the additional information provided by autopsy changed the estimated risk of recurrence in 27 percent of cases characterized by structural anomalies and possible syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/55\">",
"     55",
"    </a>",
"    ]. Maternal",
"    <span class=\"nowrap\">",
"     grief/depression",
"    </span>",
"    measured by standard instruments appears to be the same regardless of the method of pregnancy termination (induction versus extraction) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/56\">",
"     56",
"    </a>",
"    ], although most women undergoing these procedures do so in a situation of a desired, or even highly sought after, pregnancy, in which the detection of a fetal abnormality resulted in the decision to not continue the pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Hydatidiform mole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine evacuation following detection of hydatidiform mole (ie, gestational trophoblastic disease) should be performed within a hospital. Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    should be started before induction of anesthesia to prevent excessive hemorrhage during and immediately following the procedure. Bleeding may be heavy as the cervix is manually dilated, but usually subsides within a few minutes of suction curettage. These patients are also at risk for hyperthyroidism, thyroid storm, and trophoblastic embolization, which can lead to full blown acute respiratory distress syndrome. They are best managed by physicians familiar with the multiple uncommon, but significant, problems that can arise. Post-evacuation follow-up of beta-hCG titers is critical in these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42234?source=see_link\">",
"     \"Gestational trophoblastic neoplasia: Staging and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Placenta previa and previous cesarean delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placenta previa is not a contraindication to pregnancy termination through the cervix, although data are scanty. Previous cesarean delivery is also not associated with increased risk from use of laminaria or D&amp;E [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28409/abstract/57\">",
"     57",
"    </a>",
"    ]. However, in women with advanced gestational age, multiple prior cesareans and anterior placentation, the diagnosis of accreta should be considered and special precautions taken in case of hemorrhage.",
"   </p>",
"   <p>",
"    There are few data regarding the safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    (or other prostaglandins) for second trimester pregnancy termination in women with previous cesarean deliveries. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28330?source=see_link&amp;anchor=H6#H6\">",
"     \"Misoprostol as a single agent for medical termination of pregnancy\", section on 'Risk factors for uterine rupture'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/47/42739?source=see_link\">",
"       \"Patient information: Abortion (pregnancy termination) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Extraction",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extraction is the most common technique used for second-trimester pregnancy termination in the United States. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Dilation and extraction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Extraction procedures require the least amount of time and can be performed in a uterus of almost any size for removal of most types of intrauterine contents (eg, placenta, molar tissue, fetal tissue). The patient does not experience labor, which most women consider a benefit of D&amp;E, and the fetus will not be born alive, which is important medicolegally. There are fewer drug-related side-effects with D&amp;E than with nonsurgical abortion; however, there is a small risk of operative complications, such as uterine perforation, and the fetus is not delivered intact, which can be important if the termination was done because of a fetal abnormality. For these reasons, D&amp;E is the preferred method of second trimester termination when highly experienced personnel are available and autopsy of an intact fetus is not important for counseling. (See",
"      <a class=\"local\" href=\"#H9277352\">",
"       'Choice of technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cervical dilation with multiple osmotic dilators is recommended prior to second trimester pregnancy termination to prevent cervical laceration. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Cervical preparation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A vacuum cannula of 12 to 14 mm is adequate for evacuation at 13 to 15 weeks of gestation. Instruments specifically designed to extract intrauterine contents are required after 16 to 17 weeks because the products of conception are too large to aspirate through even 16-mm cannulas. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Evacuation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Systemic abortifacients",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although use of abortifacients does not require a skilled operator, physicians who use nonsurgical methods must be prepared to employ surgical techniques of uterine evacuation when there are retained products of conception, a common occurrence following labor induction methods. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Systemic abortifacients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intraamniotic instillation of saline (60 mL of a 23 percent solution), fetal intracardiac injection of about 5 mEq",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"       potassium chloride",
"      </a>",
"      , or injection of 1 to 1.5 mg",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      into the fetus or amniotic sac is suggested to insure feticide. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Systemic abortifacients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In women undergoing pregnancy termination, we recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      over gemeprost (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28330?source=see_link\">",
"       \"Misoprostol as a single agent for medical termination of pregnancy\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H12\">",
"       'Misoprostol'",
"      </a>",
"      above.)\" and (see",
"      <a class=\"local\" href=\"#H9277352\">",
"       'Choice of technique'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Prostaglandin E2 suppositories (20 mg per vaginam every three to five hours) are an alternative. The dose should be adjusted down to 5 mg based upon a more advanced gestational age (more sensitive to prostaglandins), a pronounced uterotonic response, or undesirable side effects. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Prostaglandin E2'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/29/20948?source=see_link\">",
"       Carboprost tromethamine",
"      </a>",
"      and high dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      are also acceptable systemic abortifacients for second trimester procedures. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Carboprost tromethamine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'High-dose oxytocin'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Intrauterine instillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Instillation of abortifacient agents has largely been abandoned due to development of safe and effective systemic agents and operative techniques. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Intrauterine instillation of abortifacient agents'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American College of Obstetricians and Gynecologists. Methods of midtrimester abortion. ACOG technical bulletin #109. American College of Obstetricians and Gynecologists, Washington, DC 1987.",
"    </li>",
"    <li>",
"     Stubblefield, PG. Pregnancy termination. p. 1303. In: Obstetrics: Normal and Problem Pregnancies, 2nd ed, Gabbe, SG, Niebyl, JR, Simpson, JL (eds), Churchill Livingstone, New York 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/3\">",
"      Kafrissen ME, Schulz KF, Grimes DA, Cates W Jr. Midtrimester abortion. Intra-amniotic instillation of hyperosmolar urea and prostaglandin F2 alpha v dilatation and evacuation. JAMA 1984; 251:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/4\">",
"      Robins J, Surrago EJ. Early midtrimester pregnancy termination. A comparison of dilatation and evacuation and intravaginal prostaglandin E2. J Reprod Med 1982; 27:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/5\">",
"      Grimes DA, Schulz KF, Cates W Jr, Tyler CW Jr. Mid-trimester abortion by dilatation and evacuation: a safe and practical alternative. N Engl J Med 1977; 296:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/6\">",
"      Bryant AG, Grimes DA, Garrett JM, Stuart GS. Second-trimester abortion for fetal anomalies or fetal death: labor induction compared with dilation and evacuation. Obstet Gynecol 2011; 117:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/7\">",
"      Edlow AG, Hou MY, Maurer R, et al. Uterine evacuation for second-trimester fetal death and maternal morbidity. Obstet Gynecol 2011; 117:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/8\">",
"      Grimes DA, Hulka JF, McCutchen ME. Midtrimester abortion by dilatation and evacuation versus intra-amniotic instillation of prostaglandin F2 alpha: a randomized clinical trial. Am J Obstet Gynecol 1980; 137:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/9\">",
"      Kaltreider NB, Goldsmith S, Margolis AJ. The impact of midtrimester abortion techniques on patients and staff. Am J Obstet Gynecol 1979; 135:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/10\">",
"      Cowett AA, Golub RM, Grobman WA. Cost-effectiveness of dilation and evacuation versus the induction of labor for second-trimester pregnancy termination. Am J Obstet Gynecol 2006; 194:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/11\">",
"      Stubblefield PG, Carr-Ellis S, Borgatta L. Methods for induced abortion. Obstet Gynecol 2004; 104:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/12\">",
"      Molaei M, Jones HE, Weiselberg T, et al. Effectiveness and safety of digoxin to induce fetal demise prior to second-trimester abortion. Contraception 2008; 77:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/13\">",
"      Coke GA, Baschat AA, Mighty HE, Malinow AM. Maternal cardiac arrest associated with attempted fetal injection of potassium chloride. Int J Obstet Anesth 2004; 13:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/14\">",
"      Schulz KF, Grimes DA, Cates W Jr. Measures to prevent cervical injury during suction curettage abortion. Lancet 1983; 1:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/15\">",
"      Hornstein MD, Osathanondh R, Birnholz JC, et al. Ultrasound guidance for selected dilatation and evacuation procedures. J Reprod Med 1986; 31:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/16\">",
"      Darney PD, Sweet RL. Routine intraoperative ultrasonography for second trimester abortion reduces incidence of uterine perforation. J Ultrasound Med 1989; 8:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/17\">",
"      Peterson WF, Berry FN, Grace MR, Gulbranson CL. Second-trimester abortion by dilatation and evacuation: an analysis of 11,747 cases. Obstet Gynecol 1983; 62:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/18\">",
"      Autry AM, Hayes EC, Jacobson GF, Kirby RS. A comparison of medical induction and dilation and evacuation for second-trimester abortion. Am J Obstet Gynecol 2002; 187:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/19\">",
"      Rayburn WF, Laferla JJ. Mid-gestational abortion for medical or genetic indications. Clin Obstet Gynaecol 1986; 13:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/20\">",
"      Jackson LG, Zachary JM, Fowler SE, et al. A randomized comparison of transcervical and transabdominal chorionic-villus sampling. The U.S. National Institute of Child Health and Human Development Chorionic-Villus Sampling and Amniocentesis Study Group. N Engl J Med 1992; 327:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/21\">",
"      Chasen ST, Kalish RB, Gupta M, et al. Dilation and evacuation at &gt;or=20 weeks: comparison of operative techniques. Am J Obstet Gynecol 2004; 190:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/22\">",
"      Chasen ST, Kalish RB, Gupta M, et al. Obstetric outcomes after surgical abortion at &gt; or = 20 weeks' gestation. Am J Obstet Gynecol 2005; 193:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/23\">",
"      Surrago EJ, Robins J. Midtrimester pregnancy termination by intravaginal administration of prostaglandin E2. Contraception 1982; 26:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/24\">",
"      Mackenzie IZ, Embrey MP. Single extra-amniotic injection of prostaglandins in viscous gel to induce abortion. Br J Obstet Gynaecol 1976; 83:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/25\">",
"      Eppel W, Facchinetti F, Schleussner E, et al. Second trimester abortion using isosorbide mononitrate in addition to gemeprost compared with gemeprost alone: a double-blind randomized, placebo-controlled multicenter trial. Am J Obstet Gynecol 2005; 192:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/26\">",
"      Goldberg AB, Greenberg MB, Darney PD. Misoprostol and pregnancy. N Engl J Med 2001; 344:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/27\">",
"      Tang OS, Thong KJ, Baird DT. Second trimester medical abortion with mifepristone and gemeprost: a review of 956 cases. Contraception 2001; 64:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/28\">",
"      Ashok PW, Templeton A, Wagaarachchi PT, Flett GM. Midtrimester medical termination of pregnancy: a review of 1002 consecutive cases. Contraception 2004; 69:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/29\">",
"      Bartley J, Baird DT. A randomised study of misoprostol and gemeprost in combination with mifepristone for induction of abortion in the second trimester of pregnancy. BJOG 2002; 109:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/30\">",
"      Kapp N, Borgatta L, Stubblefield P, et al. Mifepristone in second-trimester medical abortion: a randomized controlled trial. Obstet Gynecol 2007; 110:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/31\">",
"      Green J, Borgatta L, Sia M, et al. Intervention rates for placental removal following induction abortion with misoprostol. Contraception 2007; 76:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/32\">",
"      Spitz IM, Bardin CW. Clinical pharmacology of RU 486--an antiprogestin and antiglucocorticoid. Contraception 1993; 48:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/33\">",
"      Ngai SW, Tang OS, Ho PC. Randomized comparison of vaginal (200 microg every 3 h) and oral (400 microg every 3 h) misoprostol when combined with mifepristone in termination of second trimester pregnancy. Hum Reprod 2000; 15:2205.",
"     </a>",
"    </li>",
"    <li>",
"     Sitruk-Ware, R, personal communication.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/35\">",
"      Robins J, Mann LI. Midtrimester pregnancy termination by intramuscular injection of a 15-methyl analogue of prostaglandin F2 alpha. Am J Obstet Gynecol 1975; 123:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/36\">",
"      Winkler CL, Gray SE, Hauth JC, et al. Mid-second-trimester labor induction: concentrated oxytocin compared with prostaglandin E2 vaginal suppositories. Obstet Gynecol 1991; 77:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/37\">",
"      Castadot RG. Pregnancy termination: techniques, risks, and complications and their management. Fertil Steril 1986; 45:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/38\">",
"      Kirz DS, Haag MK. Management of the third stage of labor in pregnancies terminated by prostaglandin E2. Am J Obstet Gynecol 1989; 160:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/39\">",
"      Chapman SJ, Crispens M, Owen J, Savage K. Complications of midtrimester pregnancy termination: the effect of prior cesarean delivery. Am J Obstet Gynecol 1996; 175:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/40\">",
"      Dickinson JE. Misoprostol for second-trimester pregnancy termination in women with a prior cesarean delivery. Obstet Gynecol 2005; 105:352.",
"     </a>",
"    </li>",
"    <li>",
"     Hern, WM. Abortion practice. JB Lippincott, Philadelphia, PA 1984.",
"    </li>",
"    <li>",
"     Centers for Disease Control. Abortion surveillance 1981. Atlanta, GA 1985.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/43\">",
"      Kelly T, Suddes J, Howel D, et al. Comparing medical versus surgical termination of pregnancy at 13-20 weeks of gestation: a randomised controlled trial. BJOG 2010; 117:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/44\">",
"      Lohr PA, Hayes JL, Gemzell-Danielsson K. Surgical versus medical methods for second trimester induced abortion. Cochrane Database Syst Rev 2008; :CD006714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/45\">",
"      Akoury HA, Hannah ME, Chitayat D, et al. Randomized controlled trial of misoprostol for second-trimester pregnancy termination associated with fetal malformation. Am J Obstet Gynecol 2004; 190:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/46\">",
"      Paz B, Ohel G, Tal T, et al. Second trimester abortion by laminaria followed by vaginal misoprostol or intrauterine prostaglandin F2alpha: a randomized trial. Contraception 2002; 65:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/47\">",
"      Munthali J, Moodley J. The use of misoprostol for mid-trimester therapeutic termination of pregnancy. Trop Doct 2001; 31:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/48\">",
"      Su LL, Biswas A, Choolani M, et al. A prospective, randomized comparison of vaginal misoprostol versus intra-amniotic prostaglandins for midtrimester termination of pregnancy. Am J Obstet Gynecol 2005; 193:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/49\">",
"      Comparison of intra-amniotic prostaglandin F2 alpha and hypertonic saline for induction of second-trimester abortion. Br Med J 1976; 1:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/50\">",
"      Ragab MI, Edelman DA. Midtrimester abortion: a comparison of intraamniotic prostaglandin F2alpha and hypertonic saline. Int J Gynaecol Obstet 1976; 14:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/51\">",
"      DeCherney AH, Schwarz RH, Drobney H. Infection as a complication of therapeutic abortion. Pa Med 1972; 75:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/52\">",
"      Shulman LP, Ling FW, Meyers CM, et al. Dilatation and evacuation is a preferable method for mid-trimester genetic termination of pregnancy. Prenat Diagn 1989; 9:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/53\">",
"      Shulman LP, Ling FW, Meyers CM, et al. Dilation and evacuation for second-trimester genetic pregnancy termination. Obstet Gynecol 1990; 75:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/54\">",
"      Shulman, LP, Ling, FW, Meyers, CM, et al. Dilation and evacuation for second-trimester genetic pregnancy termination: update on a reliable and preferable method. Am J Gyn Health 1991; 5:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/55\">",
"      Boyd PA, Tondi F, Hicks NR, Chamberlain PF. Autopsy after termination of pregnancy for fetal anomaly: retrospective cohort study. BMJ 2004; 328:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/56\">",
"      Burgoine GA, Van Kirk SD, Romm J, et al. Comparison of perinatal grief after dilation and evacuation or labor induction in second trimester terminations for fetal anomalies. Am J Obstet Gynecol 2005; 192:1928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28409/abstract/57\">",
"      Schneider D, Bukovsky I, Caspi E. Safety of midtrimester pregnancy termination by laminaria and evacuation in patients with previous cesarean section. Am J Obstet Gynecol 1994; 171:554.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3315 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-2143548A13-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_47_28409=[""].join("\n");
var outline_f27_47_28409=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H35\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DILATION AND EXTRACTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      General issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cervical preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Evacuation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Curettage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Complications of extraction procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Intact dilation and extraction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SYSTEMIC ABORTIFACIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Prostaglandin E2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Misoprostol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Misoprostol with mifepristone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Carboprost tromethamine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      High-dose oxytocin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Retained placenta",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Uterine rupture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      INTRAUTERINE INSTILLATION OF ABORTIFACIENT AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Saline infusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Prostaglandin F2 alpha infusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Combined prostaglandin F2 alpha and hypertonic saline infusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Contraindications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Postoperative issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9277352\">",
"      CHOICE OF TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Surgical",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Nonsurgical",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      HYSTEROTOMY AND HYSTERECTOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SPECIAL CASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Fetal demise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Fetal abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Hydatidiform mole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Placenta previa and previous cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Extraction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Systemic abortifacients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Intrauterine instillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3315\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3315|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/0/16385\" title=\"figure 1\">",
"      Paracervical block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3315|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/26/26030\" title=\"picture 1\">",
"      Sopher ovum forceps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3315|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/54/5995\" title=\"table 1\">",
"      Fetal age by foot length",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42234?source=related_link\">",
"      Gestational trophoblastic neoplasia: Staging and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31306?source=related_link\">",
"      Incidence, etiology, and prevention of stillbirth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28330?source=related_link\">",
"      Misoprostol as a single agent for medical termination of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19498?source=related_link\">",
"      Overview of pregnancy termination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/56/8073?source=related_link\">",
"      Pathogenesis and etiology of disseminated intravascular coagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/47/42739?source=related_link\">",
"      Patient information: Abortion (pregnancy termination) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4453?source=related_link\">",
"      Surgical termination of pregnancy: First trimester",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_47_28410="Overview of the evaluation of stroke";
var content_f27_47_28410=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the evaluation of stroke",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/47/28410/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/47/28410/contributors\">",
"     Louis R Caplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/47/28410/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/47/28410/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/47/28410/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/47/28410/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/47/28410/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms of brain ischemia may be transient, lasting seconds to minutes, or may persist for longer periods of time. Symptoms and signs remain indefinitely if the brain becomes irreversibly damaged and infarction occurs. Unfortunately, neurologic symptoms do not accurately reflect the presence or absence of infarction, and the tempo of the symptoms does not indicate the cause of the ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. This is a critical issue because treatment depends upon accurately identifying the cause of symptoms.",
"   </p>",
"   <p>",
"    An overview of the evaluation of patients who present with neurologic symptoms that may be consistent with stroke is discussed here. This evaluation includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Understanding the classification of stroke",
"     </li>",
"     <li>",
"      An initial quick evaluation to stabilize vital signs, determine if intracranial hemorrhage is present, and, in patients with ischemic stroke, decide if thrombolytic therapy is warranted (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=see_link\">",
"       \"Initial assessment and management of acute stroke\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Forming a hypothesis of the stroke etiology based upon the history, physical examination, and initial brain imaging study (usually a noncontrast head CT scan)",
"     </li>",
"     <li>",
"      Confirming the precise pathophysiologic process with more directed diagnostic testing",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The approach to patients with transient brain ischemia is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10426?source=see_link\">",
"     \"Initial evaluation and management of transient ischemic attack and minor stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebrovascular disease is caused by one of several pathophysiologic processes (",
"    <a class=\"graphic graphic_table graphicRef69907 \" href=\"UTD.htm?42/25/43419\">",
"     table 1",
"    </a>",
"    ) involving the blood vessels of the brain:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The process may be intrinsic to the vessel, as in atherosclerosis, lipohyalinosis, inflammation, amyloid deposition, arterial dissection, developmental malformation, aneurysmal dilation, or venous thrombosis.",
"     </li>",
"     <li>",
"      The process may originate remotely, as occurs when an embolus from the heart or extracranial circulation lodges in an intracranial vessel.",
"     </li>",
"     <li>",
"      The process may result from inadequate cerebral blood flow due to decreased perfusion pressure or increased blood viscosity.",
"     </li>",
"     <li>",
"      The process may result from rupture of a vessel in the subarachnoid space or intracerebral tissue",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The first three processes can lead to transient brain ischemia (transient ischemic attack or TIA) or permanent brain infarction (ischemic stroke), while the fourth results in either subarachnoid hemorrhage or an intracerebral hemorrhage (primary hemorrhagic stroke). Approximately 80 percent of strokes are due to ischemic cerebral infarction and 20 percent to brain hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Transient brain ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient ischemic attack (TIA) is now defined as a transient episode of neurologic dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute infarction. This tissue-based definition of TIA relies on the absence of end-organ injury as assessed by imaging or other techniques. The proposed advantages of the tissue-based definition are that the defined end point is biological (tissue injury) rather than arbitrary (24 hours). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18773?source=see_link\">",
"     \"Definition of transient ischemic attack\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The approach to patients with TIA is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10426?source=see_link\">",
"     \"Initial evaluation and management of transient ischemic attack and minor stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Intracerebral hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding in intracerebral hemorrhage (ICH) is usually derived from arterioles or small arteries. The bleeding is directly into the brain, forming a localized hematoma which spreads along white matter pathways. Accumulation of blood occurs over minutes or hours; the hematoma gradually enlarges by adding blood at its periphery like a snowball rolling downhill. The most common causes of ICH are hypertension, trauma, bleeding diatheses, amyloid angiopathy, illicit drug use (mostly amphetamines and cocaine), and vascular malformations. Less frequent causes include bleeding into tumors, aneurysmal rupture, and vasculitis. Neurologic symptoms usually increase gradually over minutes or a few hours. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29130?source=see_link\">",
"     \"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40216?source=see_link\">",
"     \"Clinical diagnosis of stroke subtypes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Subarachnoid hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rupture of arterial aneurysms is the major cause of subarachnoid hemorrhage (SAH). Aneurysm rupture releases blood directly into the cerebrospinal fluid (CSF) under arterial pressure. The blood spreads quickly within the CSF, rapidly increasing intracranial pressure. Death or deep coma ensues if the bleeding continues. The bleeding usually lasts only a few seconds but rebleeding is common. With causes of SAH other than aneurysm rupture (eg, vascular malformations, bleeding diatheses, trauma, amyloid angiopathy, and illicit drug use), the bleeding is less abrupt and may continue over a longer period of time.",
"   </p>",
"   <p>",
"    Symptoms of SAH begin abruptly, occurring at night in 30 percent of cases. The primary symptom is a sudden, severe headache (97 percent of cases) classically described as the \"worst headache of my life.\" The headache is lateralized in 30 percent of patients, predominantly to the side of the aneurysm. The onset of the headache may or may not be associated with a brief loss of consciousness, seizure, nausea, vomiting, focal neurologic deficit, or stiff neck (",
"    <a class=\"graphic graphic_figure graphicRef60831 \" href=\"UTD.htm?0/5/88\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/3\">",
"     3",
"    </a>",
"    ]. There are usually no important focal neurologic signs at presentation unless bleeding occurs into the brain and CSF at the same time (meningocerebral hemorrhage). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three main subtypes of brain ischemia:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Thrombosis",
"     </li>",
"     <li>",
"      Embolism",
"     </li>",
"     <li>",
"      Systemic hypoperfusion",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Thrombotic stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombotic strokes are those in which the pathologic process giving rise to thrombus formation in an artery produces a stroke either by reduced blood flow distally (low flow) or by an embolic fragment that breaks off and travels to a more distant vessel (artery-to-artery embolism). All thrombotic strokes can be divided into either large or small vessel disease (",
"    <a class=\"graphic graphic_table graphicRef55099 \" href=\"UTD.htm?20/39/21117\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Large vessel disease includes both the extracranial and intracranial arterial system; atherothrombosis is by far the most common pathologic process. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/24/9608?source=see_link\">",
"       \"Pathophysiology of symptoms from carotid atherosclerosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/61/2010?source=see_link\">",
"       \"Intracranial large artery atherosclerosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Small vessel disease refers specifically to penetrating arteries that arise from the distal vertebral artery, the basilar artery, the middle cerebral artery stem, and the arteries of the circle of Willis. These arteries thrombose due to atheroma formation at their origin or in the parent large artery, or due to lipohyalinosis (a lipid hyaline build-up distally secondary to hypertension). Penetrating artery (small vessel) disease can result in small deep infarcts usually referred to as lacunes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4026?source=see_link\">",
"       \"Lacunar infarcts\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Embolic stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Embolism refers to particles of debris originating elsewhere that block arterial access to a particular brain region. Since the process is not local (as with thrombosis), local therapy only temporarily solves the problem; further events may occur if the source of embolism is not identified and treated.",
"   </p>",
"   <p>",
"    Embolic strokes are divided into four categories (",
"    <a class=\"graphic graphic_table graphicRef55099 \" href=\"UTD.htm?20/39/21117\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9208?source=see_link\">",
"     \"Etiology and classification of stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Those with a known source that is cardiac",
"     </li>",
"     <li>",
"      Those with a possible cardiac or aortic source based upon transthoracic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      transesophageal echocardiographic findings",
"     </li>",
"     <li>",
"      Those with an arterial source",
"     </li>",
"     <li>",
"      Those with a truly unknown source in which these tests are negative or inconclusive",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Systemic hypoperfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic hypoperfusion is a more general circulatory problem, manifesting itself in the brain and perhaps other organs. Reduced perfusion can be due to cardiac pump failure caused by cardiac arrest or arrhythmia, or to reduced cardiac output related to acute myocardial ischemia, pulmonary embolism, pericardial effusion, or bleeding. Hypoxemia may further reduce the amount of oxygen carried to the brain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40216?source=see_link\">",
"     \"Clinical diagnosis of stroke subtypes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     INITIAL GENERAL ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sudden loss of focal brain function is the core feature of the onset of ischemic stroke. However, patients with conditions other than brain ischemia can present in a similar fashion (",
"    <a class=\"graphic graphic_table graphicRef69869 \" href=\"UTD.htm?26/51/27451\">",
"     table 3",
"    </a>",
"    ). In addition, patients who have an ischemic stroke may present with other serious medical conditions. Thus, the initial evaluation requires a rapid but broad assessment. The goals in this initial phase include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Insuring medical stability",
"     </li>",
"     <li>",
"      Quickly reversing any conditions that are contributing to the patient's problem",
"     </li>",
"     <li>",
"      Moving toward uncovering the pathophysiologic basis of the patient's neurologic symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Diagnosing an intracerebral or subarachnoid hemorrhage as soon as possible can be lifesaving and prevent or minimize permanent neurologic damage. The history may provide clues to these diagnoses, but early triage of the patient to CT scan or MRI is critical. However, it is important to assess and optimize vital physiologic function",
"    <strong>",
"     before",
"    </strong>",
"    sending the patient for an imaging study. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=see_link\">",
"     \"Initial assessment and management of acute stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Vital signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parameters of particular concern in patients with stroke include blood pressure, breathing, and temperature.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Blood pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mean arterial blood pressure (MAP) is usually elevated in patients with an acute stroke. This may be due to chronic hypertension, which is a major risk factor for ischemic stroke. However, an acute elevation in blood pressure often represents an appropriate response to maintain brain perfusion. The decision to treat requires a balance between the potential danger of severe increases in blood pressure, and a possible decline in neurologic functioning when blood pressure is lowered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=see_link&amp;anchor=H14#H14\">",
"     \"Initial assessment and management of acute stroke\", section on 'Blood pressure management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Breathing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with increased intracranial pressure (ICP) due to hemorrhage, vertebrobasilar ischemia, or bihemispheric ischemia can present with a decreased respiratory drive or muscular airway obstruction. Hypoventilation, with a resulting increase in the partial pressure of carbon dioxide, may lead to cerebral vasodilation which further elevates ICP.",
"   </p>",
"   <p>",
"    Intubation may be necessary to restore adequate ventilation and to protect the airway. This is especially important in the presence of vomiting, which occurs commonly with increased ICP, vertebrobasilar ischemia, and intracranial hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever may occur in patients with an acute stroke and can worsen brain ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/4\">",
"     4",
"    </a>",
"    ]. Normothermia should be maintained for at least the first several days after an acute stroke. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=see_link&amp;anchor=H12#H12\">",
"     \"Initial assessment and management of acute stroke\", section on 'Fever'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     History and physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history and physical examination should be used to distinguish between other disorders in the differential diagnosis of stroke (",
"    <a class=\"graphic graphic_table graphicRef69869 \" href=\"UTD.htm?26/51/27451\">",
"     table 3",
"    </a>",
"    ). As examples, seizures, syncope, migraine, and hypoglycemia can mimic acute ischemia. The most difficult cases involve patients with focal signs and altered level of consciousness. It is important to ask the patient or a relative whether the patient takes insulin or oral hypoglycemic agents, has a history of a seizure disorder or drug overdose or abuse, medications on admission, recent trauma, or hysteria (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/37/36439?source=see_link\">",
"     \"Differential diagnosis of transient ischemic attack and stroke\"",
"    </a>",
"    ). The history is also important in separating ischemia from hemorrhage and distinguishing between subtypes of ischemia and hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Ischemia versus hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noncontrast computed tomography (CT) is typically the first diagnostic study in patients with suspected stroke. The main advantages of CT are widespread access and speed of acquisition. CT is highly sensitive for the diagnosis of hemorrhage in the acute setting [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/5\">",
"     5",
"    </a>",
"    ]. Intracerebral hemorrhages are evident almost instantly after onset as focal white hyperdense lesions within the brain parenchyma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29130?source=see_link&amp;anchor=H18#H18\">",
"     \"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis\", section on 'Head CT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intracerebral hemorrhages can also be defined by MRI; the use of susceptibility sequences improves the sensitivity of MRI for early detection of hemorrhage. Gradient-echo images can also show the presence of old hemorrhages since this technique is very sensitive to hemosiderin, which can remain in old hemorrhages indefinitely. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29130?source=see_link&amp;anchor=H19#H19\">",
"     \"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis\", section on 'Brain MRI'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Small subarachnoid hemorrhages can be missed by either CT or MRI. Lumbar puncture may be needed to make the diagnosis in such patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=see_link&amp;anchor=H28#H28\">",
"     \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\", section on 'Lumbar puncture'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MRI is more sensitive than CT for the early diagnosis of brain infarction, although CT may identify subtle indicators of infarction within six hours of stroke onset in a significant number of patients (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17290?source=see_link&amp;anchor=H3#H3\">",
"     \"Neuroimaging of acute ischemic stroke\", section on 'Early signs of infarction on noncontrast CT'",
"    </a>",
"    ). Fluid-attenuated inversion recovery (FLAIR) MRI sequences and diffusion-weighted images (DWI-MRI) are especially useful in showing infarcts early after the onset of symptoms. In patients with ischemia who do not yet have brain infarction, both CT and MRI may be normal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17290?source=see_link&amp;anchor=H10#H10\">",
"     \"Neuroimaging of acute ischemic stroke\", section on 'Magnetic resonance imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Is the patient a candidate for thrombolysis?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once it has been determined that the patient has an acute ischemic stroke, consideration should be given to the use of thrombolysis.",
"   </p>",
"   <p>",
"    Thrombolytic therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    (recombinant tissue-type plasminogen activator or rt-PA) improves outcomes in patients with acute ischemic stroke who meet eligibility criteria (",
"    <a class=\"graphic graphic_table graphicRef71462 \" href=\"UTD.htm?31/40/32397\">",
"     table 4",
"    </a>",
"    ). This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6570?source=see_link\">",
"     \"Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41098?source=see_link&amp;anchor=H2#H2\">",
"     \"Reperfusion therapy for acute ischemic stroke\", section on 'Intravenous thrombolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Wherever possible, vascular imaging studies (extracranial and intracranial ultrasound, CTA, MRA) should show an occlusive thromboembolus. In patients without large vessel thromboembolism, there is no apparent target for recanalization. In addition, small studies suggest that 40 to 75 percent of these patients have good outcomes, although they often have evidence of infarction on imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients seen too late to be eligible for intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    according to the conventional treatment time window might still be candidates for either intravenous or intra-arterial thrombolysis if imaging studies show a significant \"at-risk\" brain that is underperfused but not yet infarcted, and if there is an occlusive thromboembolus shown by vascular imaging tests.",
"   </p>",
"   <p>",
"    In my opinion, potentially hazardous thrombolytic therapy is not clearly indicated if vascular imaging fails to confirm a clinically relevant large vessel thromboembolus. Nonetheless, it is reasonable to treat eligible patients with intravenous thrombolysis if neurovascular imaging is not readily available or if obtaining such imaging would significantly delay therapy.",
"   </p>",
"   <p>",
"    There is no clear consensus among experts regarding the use of neurovascular studies to guide decisions about thrombolysis. Many favor the use of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    for all patients who meet the inclusion and exclusion criteria (",
"    <a class=\"graphic graphic_table graphicRef71462 \" href=\"UTD.htm?31/40/32397\">",
"     table 4",
"    </a>",
"    ) regardless of the presence or absence of a relevant large vessel occlusive lesion, including cases of suspected small vessel stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intracranial hemorrhage is the most severe complication of thrombolytic therapy, occurring in approximately 6 percent of patients (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6570?source=see_link&amp;anchor=H33561301#H33561301\">",
"     \"Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use\", section on 'Intracerebral hemorrhage'",
"    </a>",
"    ). No patient characteristics can be identified at presentation that reliably predict whether a patient will or will not develop a hemorrhage as a result of treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    . However, patients with very severe strokes and those with evidence of major infarction on CT may be at an increased risk for intracerebral hemorrhage following treatment. Other predisposing factors for ICH in the setting of thrombolytic therapy include older age, hyperglycemia and a history of diabetes mellitus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41098?source=see_link&amp;anchor=H31#H31\">",
"     \"Reperfusion therapy for acute ischemic stroke\", section on 'Variables associated with intracerebral hemorrhage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients need to be advised of the potential risks prior to administering thrombolytic therapy. Not uncommonly, neurologic deficits caused by acute stroke preclude obtaining informed consent from the patient.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     Alteplase",
"    </a>",
"    is an approved therapy for acute stroke; consent is not required to administer alteplase as an emergent therapy if surrogate consent is not possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6570?source=see_link&amp;anchor=H17846222#H17846222\">",
"     \"Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use\", section on 'Informed consent'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DETERMINING A PRESUMPTIVE DIAGNOSIS OF STROKE SUBTYPE",
"    </span>",
"    &nbsp;&mdash;&nbsp;After completing the initial assessment, the goal of the subsequent evaluation is to determine the underlying pathophysiology of the stroke in order to guide therapy (",
"    <a class=\"graphic graphic_table graphicRef69907 \" href=\"UTD.htm?42/25/43419\">",
"     table 1",
"    </a>",
"    ). This part of the discussion assumes that patients with subarachnoid hemorrhage have already been identified by the initial history and physical examination and noncontrast head CT (with or without lumbar puncture). A review of the clinical features and diagnosis of subarachnoid hemorrhage is found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, the presence of intracerebral hemorrhage should already be evident by this phase of the evaluation; the diagnostic evaluation in these patients is reviewed elsewhere. (See",
"    <a class=\"local\" href=\"#H43\">",
"     'Evaluation of patients with intracerebral hemorrhage'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In practice, then, this second stage of evaluation is focused upon distinguishing between embolic and thrombotic strokes; in patients with the latter, it is worth differentiating between large vessel and small vessel (penetrating artery or lacunar) infarcts since the causes, outcomes, and treatments are different. Some patients will have more than one potential etiology for stroke, although the majority will have only one predominant cause [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9208?source=see_link\">",
"     \"Etiology and classification of stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40216?source=see_link\">",
"     \"Clinical diagnosis of stroke subtypes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A presumptive diagnosis of the stroke subtype can be made following a thorough history, physical examination, and imaging study such as CT or MRI. However, confirmation of the diagnosis requires more extensive testing.",
"   </p>",
"   <p>",
"    A history of carotid stenosis is a significant risk factor for large artery thrombotic stroke, but these patients need to have other stroke subtypes considered in the differential diagnosis. In the North American Symptomatic Carotid Endarterectomy Trial (NASCET), of patients with 70 to 99 percent stenosis who subsequently had an ischemic stroke, 20 and 45 percent of strokes that occurred in the territory of symptomatic and asymptomatic carotid arteries, respectively, were unrelated to carotid stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of features in the clinical history may be useful in determining the type of stroke:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Clinical course",
"     </li>",
"     <li>",
"      Ecology",
"     </li>",
"     <li>",
"      Previous transient ischemic attack (TIA)",
"     </li>",
"     <li>",
"      Activity at the onset or just before the stroke",
"     </li>",
"     <li>",
"      Associated symptoms",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important historical item for differentiating stroke subtypes is the pace and course of the symptoms and signs and their clearing [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/12\">",
"     12",
"    </a>",
"    ]. Each subtype has a characteristic course.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Embolic strokes most often occur suddenly (",
"      <a class=\"graphic graphic_figure graphicRef73261 \" href=\"UTD.htm?13/3/13373\">",
"       figure 2",
"      </a>",
"      ). The deficits indicate focal loss of brain function that is usually maximal at onset. Rapid recovery also favors embolism.",
"     </li>",
"     <li>",
"      Thrombosis-related symptoms often fluctuate, varying between normal and abnormal or progressing in a stepwise or stuttering fashion with some periods of improvement (",
"      <a class=\"graphic graphic_figure graphicRef64107 \" href=\"UTD.htm?8/62/9197\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Penetrating artery occlusions usually cause symptoms that develop during a period of hours or at most a few days (",
"      <a class=\"graphic graphic_figure graphicRef52246 \" href=\"UTD.htm?24/54/25453\">",
"       figure 4",
"      </a>",
"      ), compared with large artery-related brain ischemia, which can evolve over a longer period.",
"     </li>",
"     <li>",
"      Intracerebral hemorrhage (ICH) does not improve during the early period; it progresses gradually during minutes or a few hours (",
"      <a class=\"graphic graphic_figure graphicRef61491 \" href=\"UTD.htm?6/23/6526\">",
"       figure 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Aneurysmal SAH develops in an instant. Focal brain dysfunction is less common.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients often do not give a specific history regarding the course of neurologic symptoms. I may ask if the patient could walk, talk, use the phone, use the hand, etc, as the events developed after the first symptoms occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Ecology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ecology refers to known demographic and historical features that provide probabilities of the patient having one or more of the stroke subtypes. Age, sex, and race are important demographic variables known to the clinician before taking the history [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most thrombotic and embolic strokes related to atherosclerosis occur in older patients. Individuals under age 40 rarely have severe atherosclerosis unless they also have major risk factors such as diabetes, hypertension, hyperlipidemia, smoking, or a strong family history. In contrast, cardiac-origin embolism is common in young people who are known to have heart disease.",
"     </li>",
"     <li>",
"      Hypertensive ICH is more common among blacks and individuals of Asian descent than among whites.",
"     </li>",
"     <li>",
"      Premenopausal women have a lower frequency of atherosclerosis than men of similar age unless they have major stroke risk factors. Even after adjusting for age, the incidence of atherosclerotic stroke is four-times higher in men [",
"      <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Blacks, Asians, and women have a lower incidence of occlusive disease of the extracranial carotid and vertebral arteries than white men.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hypertension is the most common and most important stroke risk factor, including isolated systolic hypertension (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/61/30682?source=see_link&amp;anchor=H3#H3\">",
"     \"Secondary prevention of stroke: Risk factor reduction\", section on 'Hypertension'",
"    </a>",
"    ). Epidemiologic studies show that there is a gradually increasing incidence of both coronary disease and stroke as the blood pressure rises above",
"    <span class=\"nowrap\">",
"     110/75",
"    </span>",
"    mmHg (",
"    <a class=\"graphic graphic_figure graphicRef66793 \" href=\"UTD.htm?12/18/12591\">",
"     figure 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. However, these observations do not prove a causal relationship, since increasing blood pressure could be a marker for other risk factors such as increasing body weight, which is associated with dyslipidemia, glucose intolerance, and the metabolic syndrome. The best evidence for a causal role of increasing blood pressure in cardiovascular complications is an improvement in outcome with antihypertensive therapy. This evidence is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17305?source=see_link&amp;anchor=H3#H3\">",
"     \"Antihypertensive therapy to prevent recurrent stroke or transient ischemic attack\", section on 'Trials of long-term antihypertensive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic hypertension is a risk factor for both thrombotic extracranial and intracranial large artery disease and penetrating artery disease. Conversely, the absence of a history of hypertension or of present hypertension reduces the likelihood of penetrating artery disease.",
"   </p>",
"   <p>",
"    Smoking increases the likelihood of extracranial occlusive vascular disease, more than doubling the risk of stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/17\">",
"     17",
"    </a>",
"    ]. The risk of ischemic stroke decreases over time after smoking cessation. In one series of middle-aged women, for example, the excess risk among former smokers largely disappeared two to four years after cessation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1482?source=see_link\">",
"     \"Cardiovascular risk of smoking and benefits of smoking cessation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several other risk factors for stroke have been identified:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diabetes increases the likelihood of large and small artery occlusive disease.",
"     </li>",
"     <li>",
"      The use of amphetamines increases the likelihood of both ICH and SAH but not brain ischemia.",
"     </li>",
"     <li>",
"      Cocaine-related strokes are often hemorrhagic (ICH and SAH), due to aneurysms and vascular malformations [",
"      <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/18\">",
"       18",
"      </a>",
"      ]. Cocaine is also associated with brain ischemia, especially involving the posterior circulation intracranial arteries; this is probably due to vasoconstriction.",
"     </li>",
"     <li>",
"      Heart disease, including cardiac valvular disease, prior myocardial infarction, atrial fibrillation, and endocarditis, increases the probability of a stroke due to embolism.",
"     </li>",
"     <li>",
"      Stroke during the puerperium has an increased likelihood of being related to venous or arterial thrombosis.",
"     </li>",
"     <li>",
"      The presence of a known bleeding disorder or prescription of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      or other anticoagulants predisposes to hemorrhage, into either the brain or the CSF.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The link between stroke and oral contraceptive use has been a controversial issue. Initial studies suggesting this association were performed with oral contraceptives containing higher doses of estrogen; the risk may not be as great with current low dose oral contraceptives. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=see_link&amp;anchor=H10#H10\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\", section on 'Stroke'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of these risk factors increases the odds that a stroke is due to a particular mechanism, but the clinician cannot make a firm diagnosis simply on the basis of probability. As examples: some conditions such as hypertension predispose to more than one subtype (thrombosis, intracranial hemorrhage); the presence of a prior myocardial infarction increases the likelihood of cardiac origin embolism, but also increases the likelihood of carotid and vertebral artery neck occlusive disease (thrombosis); and an older patient with severe atherosclerosis may also harbor an unexpected cerebral aneurysm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Previous transient ischemic attack",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history of TIA (especially more than one) in the same territory as the stroke strongly favors the presence of a local vascular lesion (thrombosis). Attacks in more than one vascular territory suggest brain embolism from the heart or aorta. TIAs are not a feature of brain hemorrhage.",
"   </p>",
"   <p>",
"    Patients often will not volunteer a prior history of symptoms consistent with a TIA. Many patients, for example, do not relate prior hand or eye problems to subsequent leg problems. Thus, the physician must ask directly about specific symptoms. \"Did your arm, hand, or leg ever transiently go numb?\" \"Did you ever having difficulty speaking?\" \"Did you ever lose vision? If so, in which part of your vision? Was it in one eye and, if so, which one?\"",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Activity at the onset or just before the stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemorrhages (ICH and SAH) can be precipitated by sex or other physical activity, while thrombotic strokes are unusual under these circumstances. Trauma before the stroke suggests traumatic dissection or occlusion of arteries or traumatic brain hemorrhage. Sudden coughing and sneezing sometimes precipitates brain embolism. Similarly, getting up during the night to urinate seems to promote brain embolism (a matutinal embolus).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Associated symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of certain associated symptoms is suggestive of specific stroke subtypes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fever raises the suspicion of endocarditis and resulting embolic stroke.",
"     </li>",
"     <li>",
"      Infections activate acute phase blood reactants, thereby predisposing to thrombosis.",
"     </li>",
"     <li>",
"      Headache is typically a feature of hemorrhagic strokes, but some patients have headaches in the prodromal period before thrombotic strokes.",
"     </li>",
"     <li>",
"      Vomiting is common in patients with ICH, SAH, and posterior circulation large artery ischemia (",
"      <a class=\"graphic graphic_figure graphicRef60831 \" href=\"UTD.htm?0/5/88\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Seizures are most often seen in patients with lobar ICH or brain embolism; they are rare in patients with acute thrombosis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reduced alertness favors the presence of hemorrhage. Accompanying neurologic signs are suggestive of ICH, while the absence of focal signs suggests SAH. Loss of consciousness is also common in patients with thrombotic and embolic strokes that are large or involve the posterior circulation large arteries.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important clues in the general physical examination include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Absent pulses (inferior extremity, radial, or carotid) favors a diagnosis of atherosclerosis with thrombosis, although the sudden onset of a cold, blue limb favors embolism.",
"     </li>",
"     <li>",
"      The internal carotid arteries in the neck cannot be reliably palpated but, in some patients, occlusion of the common carotid artery in the neck can be diagnosed by the absence of a carotid pulse.",
"     </li>",
"     <li>",
"      The presence of a neck bruit suggests the presence of occlusive extracranial disease, especially if the bruit is long, focal, and high pitched.",
"     </li>",
"     <li>",
"      Palpating the facial pulses is helpful in diagnosing common carotid and internal carotid artery occlusions and temporal arteritis. The facial pulses on the side of the occlusion are often lost with common carotid artery occlusions. In contrast, some patients with internal carotid artery occlusion will have increased facial pulses on the side of the occlusion because collateral channels develop between the external carotid artery facial branches and the carotid arteries intracranially. In patients with temporal arteritis, the temporal arteries are often irregular and have sausage-shaped areas of dilatation, may be tender, and are often pulseless.",
"     </li>",
"     <li>",
"      Cardiac findings, especially atrial fibrillation, murmurs and cardiac enlargement, favor cardiac-origin embolism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=see_link\">",
"       \"Auscultation of cardiac murmurs\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Careful examination of the optic fundus may reveal a cholesterol crystal, white platelet-fibrin, or red clot emboli. Subhyaloid hemorrhages in the eye suggest a suddenly developing brain or subarachnoid hemorrhage. When the carotid artery is occluded, the iris may appear speckled and the ipsilateral pupil can become dilated and poorly reactive. The retina in that circumstance may also show evidence of chronic ischemia (venous stasis retinopathy).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Neurologic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient's account of his or her neurologic symptoms and the neurologic signs found on examination tell more about the location of the process in the brain than the particular stroke subtype. The blood supply to various parts of the brain and associated neurologic findings are shown in the Figures (",
"    <a class=\"graphic graphic_figure graphicRef65199 graphicRef60945 graphicRef81813 graphicRef60416 graphicRef71587 graphicRef73073 graphicRef68785 \" href=\"UTD.htm?0/11/186\">",
"     figure 7A-G",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Nevertheless, some constellations of symptoms and signs occasionally suggest a specific process (",
"    <a class=\"graphic graphic_table graphicRef75487 \" href=\"UTD.htm?27/15/27900\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Weakness of the face, arm, and leg on one side of the body unaccompanied by sensory, visual, or cognitive abnormalities (pure motor stroke) favors the presence of a thrombotic stroke involving penetrating arteries or a small ICH.",
"     </li>",
"     <li>",
"      Large focal neurologic deficits that begin abruptly or progress quickly are characteristic of embolism or ICH.",
"     </li>",
"     <li>",
"      Abnormalities of language suggest anterior circulation disease, as does the presence of motor and sensory signs on the same side of the body (",
"      <a class=\"graphic graphic_figure graphicRef69630 \" href=\"UTD.htm?31/10/31914\">",
"       figure 8",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Vertigo, staggering, diplopia, deafness, crossed symptoms (one side of the face and other side of the body), bilateral motor",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      sensory signs, and hemianopia or bilateral visual field loss suggest involvement of the posterior circulation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39273?source=see_link\">",
"       \"Posterior circulation cerebrovascular syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The sudden onset of impaired consciousness in the absence of focal neurologic signs is characteristic of SAH.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain imaging and a comprehensive neurovascular evaluation should be obtained for most patients suspected of having acute ischemic stroke or transient ischemic attack. Neurovascular imaging is important to determine the potential sources of embolism or low flow in ischemic stroke and to detect possible aneurysms or vessel malformations in hemorrhagic stroke. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17290?source=see_link\">",
"     \"Neuroimaging of acute ischemic stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The location and size of a brain infarct on CT or MRI may further aid in distinguishing between stroke subtypes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Small subcortical (deep) infarcts are most commonly located in the basal ganglia, internal capsule, thalamus, and pons. They are potentially within the blood supply of a single penetrating artery. The most common cause of a small deep infarct is lacunar infarction due to degenerative changes in the penetrating arteries.",
"     </li>",
"     <li>",
"      Rostral brainstem (midbrain and thalamus), occipital lobe, and cerebellar infarcts are most commonly caused by brain embolism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39273?source=see_link\">",
"       \"Posterior circulation cerebrovascular syndromes\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On the other hand, large subcortical infarcts, infarcts that are limited to the cerebral cortex, and infarcts that are both cortical and subcortical are commonly caused by thrombosis or embolism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     CONFIRMING THE DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The previous assessment should allow the formation of a presumptive diagnosis of the underlying stroke pathophysiology. The next phase of the evaluation is to confirm this hypothesis with diagnostic tests.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Embolic stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Embolism is especially likely in the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The onset is sudden and the neurologic deficit is maximal from the beginning",
"     </li>",
"     <li>",
"      The infarct and deficit are large",
"     </li>",
"     <li>",
"      There is a known cardiac or large artery lesion present",
"     </li>",
"     <li>",
"      The infarct is or becomes hemorrhagic on CT or MRI",
"     </li>",
"     <li>",
"      There are multiple cortical or",
"      <span class=\"nowrap\">",
"       cortical/subcortical",
"      </span>",
"      infarcts in different vascular territories",
"     </li>",
"     <li>",
"      Clinical findings improve quickly (so-called \"spectacular shrinking deficit\") [",
"      <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, embolic stroke is common in patients who have had a posterior circulation stroke; in a registry of 361 patients who had vertebrobasilar strokes or TIAs and were admitted to a University hospital, 41 percent had an embolic event [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A possible cardiac source should be considered in all patients with suspected embolic stroke, particularly in patients under age 45, whether or not they have clinical evidence of heart disease. This issue is discussed below. (See",
"    <a class=\"local\" href=\"#H35\">",
"     'Cardiac evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Vascular studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extracranial and intracranial arteries are also common sources of brain embolism and should be studied. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9208?source=see_link\">",
"     \"Etiology and classification of stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the infarct and brain symptoms are within the anterior circulation (carotid artery supply), then the extracranial and intracranial carotid arteries, and the middle and anterior cerebral artery branches should be the focus of the examinations.",
"     </li>",
"     <li>",
"      When the infarct is within the posterior circulation (vertebrobasilar system), the extracranial and intracranial vertebral arteries, the basilar artery, and the posterior cerebral arteries should be the focus of the vascular investigations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The anterior circulation can be studied using duplex ultrasound of the neck and transcranial Doppler (TCD) of the intracranial arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. B-mode images of the carotid artery also demonstrate the degree of stenosis and irregularities or ulcerations within plaques. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/24/9608?source=see_link&amp;anchor=H6#H6\">",
"     \"Pathophysiology of symptoms from carotid atherosclerosis\", section on 'Plaque morphology and pathology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alternatively, CT angiography or MR angiography of the neck and head arteries may be sufficient. Conventional angiography is performed when the screening tests do not fully define the lesion and more characterization is warranted, and when surgery or interventional treatment through an arterial catheter (angioplasty or intraarterial thrombolysis) may be indicated.",
"   </p>",
"   <p>",
"    Within the posterior circulation, duplex and color-flow Doppler investigation of the origins of the vertebral arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/24\">",
"     24",
"    </a>",
"    ] and ultrasound of the subclavian arteries (especially when the radial pulse or blood pressure on one side is lower than the other) can detect lesions of the proximal portion of the vertebral arteries. Atherosclerosis most often affects this proximal region. The ultrasonographer can then insonate over the rest of the vertebral artery in the neck using a continuous-wave Doppler to detect the direction of flow within the artery (craniad as would be normal, or reversed or to-and-fro flow suggesting proximal obstruction).",
"   </p>",
"   <p>",
"    CTA and MRA of the neck vertebral arteries are also helpful, but these tests may not adequately show the origins of the vertebral arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/25\">",
"     25",
"    </a>",
"    ]. The clinician must be certain that the films are adequate to see the complete extracranial and intracranial vertebrobasilar system.",
"   </p>",
"   <p>",
"    An important advance in the detection of brain embolism is monitoring by TCD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/26\">",
"     26",
"    </a>",
"    ]. Emboli that pass under ultrasound probes make a high-pitched chirp and are recorded as high-intensity transient signals (HITS). The location and pattern of these emboli can help define the presence of embolism and give clues as to the source. TCD monitoring can also help to assess the effectiveness of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Artery-to-artery versus cardiac sources of embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The distinction between artery-to-artery and non-artery-to-artery sources of embolism can be difficult. Suspicion of the former typically arises once vascular pathology in a large vessel has been identified (eg, with noninvasive testing). Repetitive spells within a single vascular territory are also suggestive of an artery-to-artery source, as is a normal echocardiogram. However, caution must be used in interpreting the results of a transthoracic echocardiogram. As previously mentioned, this study can exclude a cardiomyopathy and most atrial and mitral valve pathology, but may miss other potential embolic sources such as clot in the atrial appendage, a patent foramen ovale, mitral valve lesions, and aortic atherosclerosis. Transesophageal echocardiography is better for identifying these lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Small vessel (lacunar) stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with lacunar infarcts have risk factors for penetrating artery disease (eg, hypertension, diabetes mellitus, or polycythemia). The clinical findings typically conform to one of the well recognized lacunar syndromes: pure motor hemiparesis, pure sensory stroke, dysarthria-clumsy hand, or ataxic hemiparesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4026?source=see_link\">",
"     \"Lacunar infarcts\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Further testing is of low yield in patients suspected of having a lacunar infarction who have the typical risk factors, clinical neurologic findings, and characteristic brain imaging (eg, small subcortical infarct). On the other hand, some patients seen within the first few hours after symptom onset with clinical findings suggestive of lacunar infarction are found to have large artery disease; this has been particularly true for patients of Asian origin [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/27\">",
"     27",
"    </a>",
"    ]. Vascular imaging (CTA or MRA) can be performed at the same time as brain imaging (CT or MRI) to exclude occlusion of the parent feeding artery, a condition that can mimic a lacunar infarct. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4026?source=see_link&amp;anchor=H17#H17\">",
"     \"Lacunar infarcts\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is particularly important to perform intracranial vascular imaging in blacks and persons of Asian descent, since intracranial large artery occlusive disease is common in these patients. An alternative diagnostic test to exclude intracranial occlusive disease is TCD, a technique that measures the blood flow velocities in the large intracranial arteries using an ultrasound probe placed over the orbit, temporal bone, and foramen magnum [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17290?source=see_link&amp;anchor=H20#H20\">",
"     \"Neuroimaging of acute ischemic stroke\", section on 'Transcranial Doppler'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Large vessel atherothrombotic stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large vessel atherothrombotic strokes are often preceded by TIAs, and the onset may or may not be abrupt. The course of neurologic symptoms and signs fluctuates or is progressive in development. Infarcts that are large and subcortical are usually caused by occlusion of intracranial arteries.",
"   </p>",
"   <p>",
"    Patients with suspected large vessel atherothrombotic strokes need to have both intracranial and extracranial vascular testing. Extracranial vascular testing can be performed with MRA, CTA, or duplex carotid ultrasound. All are reliable and specific for detecting important severe occlusive lesions in the extracranial carotid arteries. Ultrasound devices such as color-flow Doppler imaging and power Doppler improve the resolution and quantification of carotid artery lesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31033?source=see_link\">",
"     \"Evaluation of carotid artery stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One approach to patients with suspected carotid artery stenosis is to first perform carotid duplex ultrasound. Patients with stenoses less than 50 percent are followed with serial examinations, usually on an annual basis to determine if there is progression. Transcranial Doppler and either MRA or CTA should be performed if the carotid stenosis is greater than 50 percent on the duplex ultrasound. Both MRA and CTA accurately define abnormalities within the carotid and vertebral arteries in the neck and their intracranial branches. MRI can be performed at the same time as MRA; the presence or absence of a brain infarct can help determine treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31033?source=see_link\">",
"     \"Evaluation of carotid artery stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Head CT and CTA are acceptable alternatives to MRI and MRA and may be more available than MR in some centers. Head CT and CTA should be done if MRI and MRA are contraindicated or impractical.",
"   </p>",
"   <p>",
"    Conventional angiography is rarely performed; indications include patients who cannot tolerate an MRA or CTA, patients with discrepant",
"    <span class=\"nowrap\">",
"     CTA/MRA",
"    </span>",
"    and ultrasound findings, and patients with suspected nonatherosclerotic disease (eg, dissection, fibromuscular dysplasia).",
"   </p>",
"   <p>",
"    Patients with carotid artery stenosis who have had nondisabling strokes may be candidates for carotid endarterectomy or carotid artery stenting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21530?source=see_link\">",
"     \"Management of symptomatic carotid atherosclerotic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     CARDIAC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cardiac evaluation is important in most patients with brain ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/28\">",
"     28",
"    </a>",
"    ]. Not only are cardiac and aortic origin emboli common, but many patients with cerebrovascular occlusive disease have concurrent coronary heart disease that can lead to significant morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/29-32\">",
"     29-32",
"    </a>",
"    ]. The basic evaluation includes a thorough history focusing on the presence of cardiac ischemia and arrhythmias, a careful cardiac examination, and an electrocardiogram.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Cardiac monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;An electrocardiogram and continuous electrocardiographic monitoring can identify patients who have atrial fibrillation as a possible source of emboli, and national guidelines recommend cardiac monitoring for at least the first 24 hours after the onset of ischemic stroke to look for arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/33\">",
"     33",
"    </a>",
"    ]. However, the demonstration of normal sinus rhythm does not exclude intermittent atrial fibrillation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40105?source=see_link&amp;anchor=H19246582#H19246582\">",
"     \"Cryptogenic stroke\", section on 'Subclinical atrial fibrillation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with suspected embolic stroke should have a transthoracic echocardiogram. A 2003 task force of the American College of Cardiology, the American Heart Association, and the American Society of Echocardiography recommended the use of echocardiography in this setting, especially in any patient younger than 45 years and in older patients without evidence of cerebrovascular disease or other obvious cause [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     TEE versus TTE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transesophageal echocardiography (TEE) is performed to examine the atria, atrial septal region, and the aorta if the transthoracic echocardiography (TTE) and preliminary cardiac and vascular imaging tests do not clarify the cause of brain ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10426?source=see_link\">",
"     \"Initial evaluation and management of transient ischemic attack and minor stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One analysis suggested that performing TEE alone in all patients with new onset stroke was more cost-effective that performing TTE and TEE in sequence [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/37\">",
"     37",
"    </a>",
"    ]. However, TEE is an uncomfortable invasive procedure that may not be tolerated by very ill patients.",
"   </p>",
"   <p>",
"    A TEE is the best test to exclude significant ascending aortic atheromatous disease. It is also the best test to look for evidence of patent foramen ovale (PFO) or atrial septal aneurysm, conditions that can cause otherwise cryptogenic stroke. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10809?source=see_link\">",
"     \"Embolism from aortic plaque: Thromboembolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31994?source=see_link\">",
"     \"Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39689?source=see_link\">",
"     \"Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TEE is also the best way to identify clot in the left atrial appendage. These emboli are 3 mm or less in diameter and are usually beyond the resolution of the transthoracic echocardiographic ultrasound probe. In contrast, left ventricular thrombi in patients with congestive heart failure or a previous myocardial infarction are best seen with transthoracic echocardiography (TTE) since the true left ventricular apex is not well seen on TEE. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12361?source=see_link\">",
"     \"Echocardiography in detection of intracardiac sources of embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical factors may be useful for selecting patients for echocardiography, particularly for the more invasive TEE. In a case series of 151 patients who had TEE within seven days of ischemic stroke or TIA, intracardiac thrombus was found in 26 percent of patients, and 70 percent of the thrombi were in the left atrial appendage [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/38\">",
"     38",
"    </a>",
"    ]. Thrombus detection was associated with large stroke, symptomatic coronary artery disease, and evidence of ischemia on ECG. The use of a more accurate multiplanar TEE technique may have increased the sensitivity of thrombus detection in this series, as older reports have generally detected intracardiac thrombus in a much lower percentage of patients with acute cerebral ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/39-41\">",
"     39-41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     BLOOD TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of blood tests are indicated in patients with brain ischemia or hemorrhage, including [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/33,42\">",
"     33,42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count, including hemoglobin, hematocrit, white blood cell count, and platelet count",
"     </li>",
"     <li>",
"      Prothrombin time, international normalized ratio (INR), and activated partial thromboplastin time",
"     </li>",
"     <li>",
"      Thrombin time",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ecarin clotting time if patient is known or suspected to be taking a direct thrombin inhibitor or a direct factor Xa inhibitor",
"     </li>",
"     <li>",
"      Blood lipids, including total, HDL, and LDL cholesterol, and triglycerides.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Hypercoagulable studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;While hypercoagulable states are sometimes found in patients who have had an ischemic stroke, widespread testing for these disorders is limited by a number of factors including a relatively low prevalence of coagulopathies and alteration of the sensitivity and specificity of the tests involved in the setting of an acute ischemic event and in patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/43\">",
"     43",
"    </a>",
"    ]. Furthermore, it remains unclear if the inherited thrombophilias directly predispose to stroke as they do to venous thrombosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=see_link&amp;anchor=H8#H8\">",
"     \"Evaluation of the patient with established venous thrombosis\", section on 'Screening for inherited thrombophilia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A case-control study found that one in seven patients with a first ever acute ischemic stroke tested positive for one of the inherited thrombophilias, but that the relationship was likely to be coincidental rather than causal in almost all cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/44\">",
"     44",
"    </a>",
"    ]. In a systematic review, the prevalence of inherited deficiencies of protein C, protein S, antithrombin III, or plasminogen was low in unselected patients with ischemic stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/45\">",
"     45",
"    </a>",
"    ]. The pretest probabilities of other coagulation defects in these patients were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lupus anticoagulant 3 percent (8 percent in patients &le;50 years)",
"     </li>",
"     <li>",
"      Anticardiolipin antibodies 17 percent (21 percent in patients &le;50 years)",
"     </li>",
"     <li>",
"      Activated protein C",
"      <span class=\"nowrap\">",
"       resistance/factor",
"      </span>",
"      V Leiden mutation 7 percent (11 percent in patients &le;50 years)",
"     </li>",
"     <li>",
"      Prothrombin mutation 5 percent (6 percent in patients &le;50 years)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The posttest probabilities of these abnormalities increased with increasing pretest probability and features of the patients' history and clinical presentation.",
"   </p>",
"   <p>",
"    In the absence of definitive data, it is my practice to obtain testing for hypercoagulable conditions in patients who have:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A personal or family history of systemic thromboses",
"     </li>",
"     <li>",
"      No clear etiology for ischemic stroke or TIA, despite cardiac and vascular imaging, especially when involving young patients",
"     </li>",
"     <li>",
"      Clinical findings that suggest systemic lupus erythematosus or the antiphospholipid antibody syndrome",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     Antiphospholipid antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of antiphospholipid antibodies (aPL) in the pathogenesis of ischemic stroke remains unclear. APL (usually measured as lupus anticoagulant or anticardiolipin antibody [aCL]) can be acute phase reactants; elevated levels may simply be a sequel to stroke and not related to its cause. On the other hand, aPL may be associated with a coagulopathy or cardiac valve abnormality that is the cause of stroke.",
"   </p>",
"   <p>",
"    The evidence is conflicting as to how to interpret positive aPL assays among the full complement of ischemic stroke patients, as illustrated by the following reports [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A large, prospective, cohort study (APASS) of 1770 patients with ischemic stroke found that the presence of aPL, either LA or aCL, did not predict increased risk for subsequent vascular ischemic events, including ischemic stroke; did not confer increased risk for subgroups of patients younger than 55 years or those with cryptogenic stroke; and did not predict a differential response to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/46\">",
"       46",
"      </a>",
"      ]. A small subgroup (120) positive for both LA and ACL had a tendency toward higher risk of vascular occlusive events at two years than those without aPL (31.7 versus 24 percent). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link&amp;anchor=H14#H14\">",
"       \"Clinical manifestations of the antiphospholipid syndrome\", section on 'Stroke'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with systemic lupus erythematosus, one study found that the levels of both aCL binding to beta 2 glycoprotein I, and anti phosphatidylserine antibodies binding to prothrombin were significantly higher in patients with a history of cerebral infarction compared with those who had no history of cerebral infarction [",
"      <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/48\">",
"       48",
"      </a>",
"      ]. Furthermore, lupus patients who were positive for both of these antibodies had a 77 percent prevalence of cerebral infarction (odds ratio 30.0, 95% CI 11-86). The presence of either antibody alone was not associated with a significantly increased stroke risk.",
"     </li>",
"     <li>",
"      In 2,712 women and 2,262 men in the Framingham Heart Study cohort who were free of stroke or TIA at the time of their baseline examination and were followed for 11 years, elevated serum concentrations of ACL independently and significantly predicted the risk of first ischemic stroke or TIA in women but not men [",
"      <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the absence of definitive data, I recommend obtaining antiphospholipid antibody testing in patients who have:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A history of lupus or symptoms compatible with lupus",
"     </li>",
"     <li>",
"      Features that suggest the antiphospholipid syndrome such as miscarriages, venous thrombosis, or migraine headaches",
"     </li>",
"     <li>",
"      Cryptogenic stroke or TIA at a young age",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma fibrinogen levels are risk factors for coronary heart disease and stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. However, the routine use of fibrinogen as a cardiovascular risk marker is limited by measurement variability. If fibrinogen is used clinically, three measurements should be obtained at each venipuncture and a minimum of two sets of fibrinogen measurements are needed. An elevated fibrinogen concentration may make a difference in the selection of cholesterol lowering medications in patients with hyperlipidemia.",
"   </p>",
"   <p>",
"    Other studies may include hemoglobin electrophoresis in patients suspected of having a hemoglobinopathy, and an erythrocyte sedimentation rate, tests for Lyme disease, syphilis, and HIV infection in selected patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h1\">",
"     EVALUATION OF PATIENTS WITH INTRACEREBRAL HEMORRHAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;CT scans usually define the size, location, and drainage pattern of intracerebral hematomas. Mass effect caused by the intracerebral mass, shift of midline structures, herniation of brain contents from one compartment to another [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/51,52\">",
"     51,52",
"    </a>",
"    ], and the presence of hydrocephalus are also easily seen on CT. MRI with echo-planar T2*-weighted (susceptibility) images can also show hemorrhages soon after the onset of symptoms. It is not necessary to perform both CT and MRI to exclude hemorrhage if echo-planar MRI scanning is available. A detailed description of the MRI characteristics of hyperacute ICH is found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29130?source=see_link&amp;anchor=H19#H19\">",
"     \"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis\", section on 'Brain MRI'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vascular malformations and brain tumor are better visualized on MRI. Echo-planar MRI can also show old hemorrhages not visible on CT scans. The location and appearance of the lesion as well as the history of the patient (eg, race, blood pressure, presence of known bleeding disorder, use of drugs) help determine the choice of additional diagnostic studies.",
"   </p>",
"   <p>",
"    No further diagnostic tests are necessary in the severely hypertensive patient with a well circumscribed and homogeneous hematoma that is located in a typical location for hypertensive ICH (eg,",
"    <span class=\"nowrap\">",
"     putamen/internal",
"    </span>",
"    capsule, caudate nucleus, thalamus, pons, or cerebellum); the clinician can be confident that the patient has a hypertensive hemorrhage in this circumstance (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29130?source=see_link\">",
"     \"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    ). Similarly, a traumatic etiology can be diagnosed with confidence in the patient who has had recent trauma and lesions in the appropriate location and with the appearance of contusion and traumatic hemorrhages (eg, anterior",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    orbital frontal lobes and temporal lobes at the surface).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Bleeding disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation for a bleeding disorder (platelet count, prothrombin time, international normalized ratio (INR), activated partial thromboplastin time for all patients, and thrombin time",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ecarin clotting time if the patient is known or suspected to be taking a direct thrombin inhibitor or a direct factor Xa inhibitor) should be performed in every patient with an intracranial hemorrhage, especially if the cause is not immediately clear. A bleeding tendency can cause or contribute to bleeding initiated by other etiologies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=see_link\">",
"     \"Approach to the adult patient with a bleeding diathesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Iatrogenic prescription of anticoagulants is the most common bleeding disorder contributing to brain hemorrhages. Oral anticoagulant-related intracerebral hemorrhage is often lobar [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/53\">",
"     53",
"    </a>",
"    ]. Compared with spontaneous intracerebral hemorrhages, anticoagulant&ndash;related hemorrhages are larger and associated with greater hematoma expansion and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?27/47/28410/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/12/27849?source=see_link\">",
"     \"Risk of intracerebral hemorrhage in patients treated with warfarin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Lobar or atypical hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amyloid angiopathy, bleeding into a tumor, and vascular malformations are likely etiologies of hemorrhages that are lobar or atypical in appearance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h3\">",
"     Cerebral amyloid angiopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemorrhages related to amyloid angiopathy are usually lobar and have a predilection to cluster in posterior brain regions, including the parietal and occipital lobes. The hemorrhages are usually multiple. T2* weighted (susceptibility) MRI images may show the presence of old small hemorrhages. Patients with amyloid angiopathy are typically over the age of 60 years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37001?source=see_link\">",
"     \"Cerebral amyloid angiopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h3\">",
"     Vascular malformation or brain tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other bleeding lesions should be excluded in patients under the age of 60 if the blood pressure is not sufficiently elevated to make a firm diagnosis of hypertensive lobar hemorrhage. A repeat MRI after the blood has been reabsorbed (four to eight weeks) may show residual vascular malformations or a brain tumor. Vascular imaging using CTA or MRA of the intracranial circulation is useful as a screening test for vascular malformations and aneurysms. Contrast angiography by arterial catheterization may be necessary in patients with a CTA or MRA suggestive of vascular malformation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/9/18584?source=see_link\">",
"     \"Vascular malformations of the central nervous system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32872?source=see_link\">",
"     \"Brain arteriovenous malformations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h3\">",
"     Cocaine use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with intracerebral hemorrhage after cocaine use (but not amphetamines) have a relatively high incidence of underlying aneurysms and vascular malformations. They require vascular imaging tests (eg, CTA, MRA,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    conventional angiography).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/34/22050?source=see_link\">",
"       \"Patient information: Hemorrhagic stroke (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=see_link\">",
"       \"Patient information: Stroke (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=see_link\">",
"       \"Patient information: Stroke symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19050479\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cerebrovascular disease is caused by one of several pathophysiologic processes (",
"      <a class=\"graphic graphic_table graphicRef69907 \" href=\"UTD.htm?42/25/43419\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef55099 \" href=\"UTD.htm?20/39/21117\">",
"       table 2",
"      </a>",
"      ) involving the blood vessels of the brain. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sudden loss of focal brain function is the core feature of the onset of ischemic stroke. However, patients with conditions other than stroke can present in a similar fashion (",
"      <a class=\"graphic graphic_table graphicRef69869 \" href=\"UTD.htm?26/51/27451\">",
"       table 3",
"      </a>",
"      ). The initial evaluation requires a rapid but broad assessment to stabilize vital signs, determine if intracranial hemorrhage is present, and decide if thrombolytic therapy is warranted for patients with ischemic stroke (",
"      <a class=\"graphic graphic_table graphicRef71462 \" href=\"UTD.htm?31/40/32397\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Initial general assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After completing the initial assessment, the goal of the subsequent evaluation is to determine the underlying pathophysiology of the stroke based upon the history, physical examination, and initial neuroimaging study (",
"      <a class=\"graphic graphic_table graphicRef69907 \" href=\"UTD.htm?42/25/43419\">",
"       table 1",
"      </a>",
"      ). Certain constellations of symptoms and signs can suggest a specific ischemic process (",
"      <a class=\"graphic graphic_table graphicRef75487 \" href=\"UTD.htm?27/15/27900\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Determining a presumptive diagnosis of stroke subtype'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Confirming the precise pathophysiologic process is aided by more directed diagnostic testing, including cardiac studies and neurovascular imaging. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Confirming the diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cardiac monitoring for at least the first 24 hours after the onset of ischemic stroke is useful to look for arrhythmias. All patients with suspected embolic stroke should have an echocardiogram. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Cardiac evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H37\">",
"       'Echocardiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of blood tests are indicated in patients with brain ischemia, including a complete blood count, platelet count, prothrombin time and partial thromboplastin time, and serum lipids. However, indications to test for hypercoagulable disorders are limited. Furthermore, it remains unclear if the inherited thrombophilias directly predispose to arterial stroke as they do to venous thrombosis. (See",
"      <a class=\"local\" href=\"#H39\">",
"       'Blood tests'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Evaluation for a bleeding disorder (platelet count, prothrombin time, activated partial thromboplastin time for all patients, and thrombin time",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ecarin clotting time if the patient is known or suspected to be taking a direct thrombin inhibitor or a direct factor Xa inhibitor) should be performed in every patient with an intracranial hemorrhage. (See",
"      <a class=\"local\" href=\"#H43\">",
"       'Evaluation of patients with intracerebral hemorrhage'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/1\">",
"      Caplan LR. Terms describing brain ischemia by tempo are no longer useful: a polemic (with apologies to Shakespeare). Surg Neurol 1993; 40:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/2\">",
"      Caplan LR. TIAs: we need to return to the question, 'What is wrong with Mr. Jones?'. Neurology 1988; 38:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/3\">",
"      Gorelick PB, Hier DB, Caplan LR, Langenberg P. Headache in acute cerebrovascular disease. Neurology 1986; 36:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/4\">",
"      Ginsberg MD, Busto R. Combating hyperthermia in acute stroke: a significant clinical concern. Stroke 1998; 29:529.",
"     </a>",
"    </li>",
"    <li>",
"     Caplan LR. Imaging and laboratory diagnosis. In: Caplan's Stroke: A Clinical Approach, 4th, Saunders, Philadelphia 2009. p.87.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/6\">",
"      Derex L, Tomsick TA, Brott TG, et al. Outcome of stroke patients without angiographically revealed arterial occlusion within four hours of symptom onset. AJNR Am J Neuroradiol 2001; 22:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/7\">",
"      Arnold M, Nedeltchev K, Brekenfeld C, et al. Outcome of acute stroke patients without visible occlusion on early arteriography. Stroke 2004; 35:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/8\">",
"      Caplan LR, Mohr JP, Kistler JP, Koroshetz W. Should thrombolytic therapy be the first-line treatment for acute ischemic stroke? Thrombolysis--not a panacea for ischemic stroke. N Engl J Med 1997; 337:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/9\">",
"      Schellinger PD. Editorial comment--outcome of acute stroke patients without visible occlusion on early arteriography. Stroke 2004; 35:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/10\">",
"      Moncayo J, Devuyst G, Van Melle G, Bogousslavsky J. Coexisting causes of ischemic stroke. Arch Neurol 2000; 57:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/11\">",
"      Barnett HJ, Gunton RW, Eliasziw M, et al. Causes and severity of ischemic stroke in patients with internal carotid artery stenosis. JAMA 2000; 283:1429.",
"     </a>",
"    </li>",
"    <li>",
"     Caplan LR. Diagnosis and the clinical encounter. In: Caplan's Stroke: A Clinical Approach, 4th, Saunders, Philadelphia 2009. p.64.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/13\">",
"      Caplan LR, Gorelick PB, Hier DB. Race, sex and occlusive cerebrovascular disease: a review. Stroke 1986; 17:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/14\">",
"      Petty GW, Brown RD Jr, Whisnant JP, et al. Ischemic stroke subtypes: a population-based study of incidence and risk factors. Stroke 1999; 30:2513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/15\">",
"      MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/16\">",
"      Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/17\">",
"      Kawachi I, Colditz GA, Stampfer MJ, et al. Smoking cessation and decreased risk of stroke in women. JAMA 1993; 269:232.",
"     </a>",
"    </li>",
"    <li>",
"     Kase CS, Caplan LR. Intracerebral hemorrhage, Butterworth-Heinemann, Boston 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/19\">",
"      Labovitz DL, Hauser WA, Sacco RL. Prevalence and predictors of early seizure and status epilepticus after first stroke. Neurology 2001; 57:200.",
"     </a>",
"    </li>",
"    <li>",
"     Caplan LR. Brain embolism. In: Practical Clinical Neurocardiology, Caplan LR, Chimowitz M, Hurst JW.  (Eds), Marcel Dekker, New York 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/21\">",
"      Glass TA, Hennessey PM, Pazdera L, et al. Outcome at 30 days in the New England Medical Center Posterior Circulation Registry. Arch Neurol 2002; 59:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/22\">",
"      Sarkar S, Ghosh S, Ghosh SK, Collier A. Role of transcranial Doppler ultrasonography in stroke. Postgrad Med J 2007; 83:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/23\">",
"      Mart&iacute;nez-S&aacute;nchez P, Serena J, Alexandrov AV, et al. Update on ultrasound techniques for the diagnosis of cerebral ischemia. Cerebrovasc Dis 2009; 27 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/24\">",
"      Saito K, Kimura K, Nagatsuka K, et al. Vertebral artery occlusion in duplex color-coded ultrasonography. Stroke 2004; 35:1068.",
"     </a>",
"    </li>",
"    <li>",
"     Caplan LR. Posterior Circulation Disease: Clinical Findings, Diagnosos, and Management, Blackwell Science, Boston 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/26\">",
"      Dittrich R, Ritter MA, Droste DW. Microembolus detection by transcranial doppler sonography. Eur J Ultrasound 2002; 16:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/27\">",
"      Gerraty RP, Parsons MW, Barber PA, et al. Examining the lacunar hypothesis with diffusion and perfusion magnetic resonance imaging. Stroke 2002; 33:2019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/28\">",
"      Wilterdink JL, Furie KL, Easton JD. Cardiac evaluation of stroke patients. Neurology 1998; 51:S23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/29\">",
"      Adams RJ, Chimowitz MI, Alpert JS, et al. Coronary risk evaluation in patients with transient ischemic attack and ischemic stroke: a scientific statement for healthcare professionals from the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association. Stroke 2003; 34:2310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/30\">",
"      Touz&eacute; E, Varenne O, Chatellier G, et al. Risk of myocardial infarction and vascular death after transient ischemic attack and ischemic stroke: a systematic review and meta-analysis. Stroke 2005; 36:2748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/31\">",
"      Calvet D, Touz&eacute; E, Varenne O, et al. Prevalence of asymptomatic coronary artery disease in ischemic stroke patients: the PRECORIS study. Circulation 2010; 121:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/32\">",
"      Amarenco P, Lavall&eacute;e PC, Labreuche J, et al. Prevalence of coronary atherosclerosis in patients with cerebral infarction. Stroke 2011; 42:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/33\">",
"      Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2013; 44:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/34\">",
"      Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation 2003; 108:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/35\">",
"      Horowitz DR, Tuhrim S, Weinberger JM, et al. Transesophageal echocardiography: diagnostic and clinical applications in the evaluation of the stroke patient. J Stroke Cerebrovasc Dis 1997; 6:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/36\">",
"      Harloff A, Handke M, Reinhard M, et al. Therapeutic strategies after examination by transesophageal echocardiography in 503 patients with ischemic stroke. Stroke 2006; 37:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/37\">",
"      McNamara RL, Lima JA, Whelton PK, Powe NR. Echocardiographic identification of cardiovascular sources of emboli to guide clinical management of stroke: a cost-effectiveness analysis. Ann Intern Med 1997; 127:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/38\">",
"      Sen S, Laowatana S, Lima J, Oppenheimer SM. Risk factors for intracardiac thrombus in patients with recent ischaemic cerebrovascular events. J Neurol Neurosurg Psychiatry 2004; 75:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/39\">",
"      Rauh R, Fischereder M, Spengel FA. Transesophageal echocardiography in patients with focal cerebral ischemia of unknown cause. Stroke 1996; 27:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/40\">",
"      Albers GW, Comess KA, DeRook FA, et al. Transesophageal echocardiographic findings in stroke subtypes. Stroke 1994; 25:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/41\">",
"      Leung DY, Davidson PM, Cranney GB, Walsh WF. Thromboembolic risks of left atrial thrombus detected by transesophageal echocardiogram. Am J Cardiol 1997; 79:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/42\">",
"      Markus HS, Hambley H. Neurology and the blood: haematological abnormalities in ischaemic stroke. J Neurol Neurosurg Psychiatry 1998; 64:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/43\">",
"      de Lau LM, Leebeek FW, de Maat MP, et al. Screening for coagulation disorders in patients with ischemic stroke. Expert Rev Neurother 2010; 10:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/44\">",
"      Hankey GJ, Eikelboom JW, van Bockxmeer FM, et al. Inherited thrombophilia in ischemic stroke and its pathogenic subtypes. Stroke 2001; 32:1793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/45\">",
"      Bushnell CD, Goldstein LB. Diagnostic testing for coagulopathies in patients with ischemic stroke. Stroke 2000; 31:3067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/46\">",
"      Levine SR, Brey RL, Tilley BC, et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004; 291:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/47\">",
"      Janardhan V, Wolf PA, Kase CS, et al. Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack: the Framingham cohort and offspring study. Stroke 2004; 35:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/48\">",
"      Nojima J, Kuratsune H, Suehisa E, et al. Strong correlation between the prevalence of cerebral infarction and the presence of anti-cardiolipin/beta2-glycoprotein I and anti-phosphatidylserine/prothrombin antibodies--Co-existence of these antibodies enhances ADP-induced platelet activation in vitro. Thromb Haemost 2004; 91:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/49\">",
"      Rothwell PM, Howard SC, Power DA, et al. Fibrinogen concentration and risk of ischemic stroke and acute coronary events in 5113 patients with transient ischemic attack and minor ischemic stroke. Stroke 2004; 35:2300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/50\">",
"      Fibrinogen Studies Collaboration, Danesh J, Lewington S, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005; 294:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/51\">",
"      Ropper AH. Lateral displacement of the brain and level of consciousness in patients with an acute hemispheral mass. N Engl J Med 1986; 314:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/52\">",
"      Ropper AH. A preliminary MRI study of the geometry of brain displacement and level of consciousness with acute intracranial masses. Neurology 1989; 39:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/53\">",
"      Cucchiara B, Messe S, Sansing L, et al. Hematoma growth in oral anticoagulant related intracerebral hemorrhage. Stroke 2008; 39:2993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/47/28410/abstract/54\">",
"      Flaherty ML, Tao H, Haverbusch M, et al. Warfarin use leads to larger intracerebral hematomas. Neurology 2008; 71:1084.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1083 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-CCFD8525CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_47_28410=[""].join("\n");
var outline_f27_47_28410=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19050479\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Transient brain ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Intracerebral hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Ischemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Thrombotic stroke",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Embolic stroke",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Systemic hypoperfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      INITIAL GENERAL ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Vital signs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Blood pressure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Breathing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      History and physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Ischemia versus hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Is the patient a candidate for thrombolysis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DETERMINING A PRESUMPTIVE DIAGNOSIS OF STROKE SUBTYPE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Clinical course",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Ecology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Previous transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Activity at the onset or just before the stroke",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Associated symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Neurologic examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      CONFIRMING THE DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Embolic stroke",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Vascular studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Artery-to-artery versus cardiac sources of embolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Small vessel (lacunar) stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Large vessel atherothrombotic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      CARDIAC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Cardiac monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - TEE versus TTE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      BLOOD TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Hypercoagulable studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - Antiphospholipid antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      EVALUATION OF PATIENTS WITH INTRACEREBRAL HEMORRHAGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Bleeding disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Lobar or atypical hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      - Cerebral amyloid angiopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      - Vascular malformation or brain tumor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      - Cocaine use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19050479\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1083\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1083|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/5/88\" title=\"figure 1\">",
"      Headache and vomiting in stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/3/13373\" title=\"figure 2\">",
"      Time course embolic stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/62/9197\" title=\"figure 3\">",
"      Time course thrombotic stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/54/25453\" title=\"figure 4\">",
"      Time course lacunar stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/23/6526\" title=\"figure 5\">",
"      Time course cerebral hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/18/12591\" title=\"figure 6\">",
"      Stroke mortality related to BP and age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/34/42531\" title=\"figure 7A\">",
"      Cerebral vascular territories",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/23/29049\" title=\"figure 7B\">",
"      Anterior cerebral artery territory",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/51/10042\" title=\"figure 7C\">",
"      Middle cerebral artery territory",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/17/21786\" title=\"figure 7D\">",
"      Posterior cerebral artery territory",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/41/13978\" title=\"figure 7E\">",
"      Inferior pontine syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/28/24010\" title=\"figure 7F\">",
"      Medullary syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/21/5465\" title=\"figure 7G\">",
"      Midpontine syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/10/31914\" title=\"figure 8\">",
"      Anterior circulation stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1083|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/25/43419\" title=\"table 1\">",
"      Characteristics of stroke subtypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/39/21117\" title=\"table 2\">",
"      Ischemic stroke classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/51/27451\" title=\"table 3\">",
"      Acute stroke differential dx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/40/32397\" title=\"table 4\">",
"      Criteria for treating acute stroke with tPA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/15/27900\" title=\"table 5\">",
"      Acute stroke syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17305?source=related_link\">",
"      Antihypertensive therapy to prevent recurrent stroke or transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=related_link\">",
"      Approach to the adult patient with a bleeding diathesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39689?source=related_link\">",
"      Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32872?source=related_link\">",
"      Brain arteriovenous malformations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1482?source=related_link\">",
"      Cardiovascular risk of smoking and benefits of smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37001?source=related_link\">",
"      Cerebral amyloid angiopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40216?source=related_link\">",
"      Clinical diagnosis of stroke subtypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40105?source=related_link\">",
"      Cryptogenic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18773?source=related_link\">",
"      Definition of transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/37/36439?source=related_link\">",
"      Differential diagnosis of transient ischemic attack and stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12361?source=related_link\">",
"      Echocardiography in detection of intracardiac sources of embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10809?source=related_link\">",
"      Embolism from aortic plaque: Thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31994?source=related_link\">",
"      Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9208?source=related_link\">",
"      Etiology and classification of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31033?source=related_link\">",
"      Evaluation of carotid artery stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=related_link\">",
"      Evaluation of the patient with established venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=related_link\">",
"      Initial assessment and management of acute stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10426?source=related_link\">",
"      Initial evaluation and management of transient ischemic attack and minor stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/61/2010?source=related_link\">",
"      Intracranial large artery atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6570?source=related_link\">",
"      Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4026?source=related_link\">",
"      Lacunar infarcts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21530?source=related_link\">",
"      Management of symptomatic carotid atherosclerotic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17290?source=related_link\">",
"      Neuroimaging of acute ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/24/9608?source=related_link\">",
"      Pathophysiology of symptoms from carotid atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/34/22050?source=related_link\">",
"      Patient information: Hemorrhagic stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=related_link\">",
"      Patient information: Stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=related_link\">",
"      Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39273?source=related_link\">",
"      Posterior circulation cerebrovascular syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41098?source=related_link\">",
"      Reperfusion therapy for acute ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/12/27849?source=related_link\">",
"      Risk of intracerebral hemorrhage in patients treated with warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=related_link\">",
"      Risks and side effects associated with estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/61/30682?source=related_link\">",
"      Secondary prevention of stroke: Risk factor reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29130?source=related_link\">",
"      Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/9/18584?source=related_link\">",
"      Vascular malformations of the central nervous system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_47_28411="Outcome ART v natural conceived";
var content_f27_47_28411=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53754&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53754&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of selected pregnancy outcomes after ART and natural conception",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Outcome",
"       </td>",
"       <td class=\"subtitle1\">",
"        ART, mean percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Natural conceptions, mean percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital anomalies [1]",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spontaneous preterm birth before 37 weeks [2,3]",
"       </td>",
"       <td>",
"        11 to 12",
"       </td>",
"       <td>",
"        5 to 6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spontaneous preterm birth before 32 to 33 weeks [2,3]",
"       </td>",
"       <td>",
"        2 to 3",
"       </td>",
"       <td>",
"        0.7 to 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low birth weight (&lt;2500 g) [2,3]",
"       </td>",
"       <td>",
"        10 to 11",
"       </td>",
"       <td>",
"        4 to 6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Very low birthweight (&lt;1500 g) [2,3]",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ART: assisted reproductive technology.",
"    </div>",
"    <div class=\"reference\">",
"     Data from studies matching for maternal age and parity",
"     <br>",
"      1. Hansen, M, Kurinczuk, JJ, Bower, C, Webb, S. N Engl J Med 2002; 346:725.",
"      <br>",
"       2. Helmerhorst, FM, Perquin, DA, Donker, D, Keirse, MJ. BMJ 2004; 328:261.",
"       <br>",
"        3. Jackson, RA, Gibson, KA, Wu, YW, Croughan, MS. Obstet Gynecol 2004; 103:551.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_47_28411=[""].join("\n");
var outline_f27_47_28411=null;
var title_f27_47_28412="FISH classification MM";
var content_f27_47_28412=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F83079&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F83079&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Revised primary molecular cytogenetic classification of myeloma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        FISH abnormality",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percentage of myeloma patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trisomy(ies) without IgH abnormality",
"       </td>",
"       <td>",
"        42",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        IgH abnormality without trisomy(ies)",
"       </td>",
"       <td class=\"sublist1_start\">",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        t(11;14)",
"       </td>",
"       <td class=\"sublist_other\">",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        t(4;14)",
"       </td>",
"       <td class=\"sublist_other\">",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        t(14;16)",
"       </td>",
"       <td class=\"sublist_other\">",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        t(14;20)",
"       </td>",
"       <td class=\"sublist_other\">",
"        &lt;1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Unknown partner/deletion of IgH region",
"       </td>",
"       <td class=\"sublist_other\">",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        IgH abnormality with trisomy(ies)",
"       </td>",
"       <td class=\"sublist1_start\">",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        t(11;14)",
"       </td>",
"       <td class=\"sublist_other\">",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        t(4;14)",
"       </td>",
"       <td class=\"sublist_other\">",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        t(14;16)",
"       </td>",
"       <td class=\"sublist_other\">",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        t(6;14)",
"       </td>",
"       <td class=\"sublist_other\">",
"        &lt;1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Unknown partner/deletion of IgH region",
"       </td>",
"       <td class=\"sublist_other\">",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Monosomy 14 in absence of IgH translocations or trisomy(ies)",
"       </td>",
"       <td>",
"        4.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other cytogenetic abnormalities in absence of IgH translocations or trisomy(ies) or monosomy 14*",
"       </td>",
"       <td>",
"        5.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The table describes the distribution of various abnormalities detected by fluorescent in situ hybridization (FISH) in a population of 484 patients with newly diagnosed symptomatic multiple myeloma.",
"    <div class=\"footnotes\">",
"     <p>",
"      *&nbsp;These included primarily monosomy 13 and p53 abnormalities.",
"     </p>",
"    </div>",
"    <div class=\"reference\">",
"     This research was originally published in Blood. Kumar S, Fonseca R, Ketterling RP, et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood 2012; 119:2100. Copyright &copy; 2012 American Society of Hematology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_47_28412=[""].join("\n");
var outline_f27_47_28412=null;
var title_f27_47_28413="Management of anticipated difficult airway in pregnant women";
var content_f27_47_28413=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78812&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78812&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Management of anticipated difficult airway in pregnant women",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 309px; height: 302px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     LMA: laryngeal mask airway; ILMA: intubating laryngeal mask airway.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_47_28413=[""].join("\n");
var outline_f27_47_28413=null;
var title_f27_47_28414="External ear pediatric algorithm";
var content_f27_47_28414=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    External ear causes of ear pain in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 418px; height: 358px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_47_28414=[""].join("\n");
var outline_f27_47_28414=null;
var title_f27_47_28415="Variable incidence of Ewing sarcoma";
var content_f27_47_28415=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F81715&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F81715&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Geographic and ethnic variation in incidence of Ewing sarcoma family of tumors",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 386px; height: 547px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Striking differences in the incidence of Ewing sarcoma are well documented and are graphically evident in this illustration. The well-known near-total lack of incidence in native Africans (Zimbabwe and Nigeria with no reported incidence) as opposed to striking incidence in whites (Los Angeles, white, 3.4) fails to convey the entire story. Surveillance, Epidemiology and End Results (SEER) network data clearly document an even greater incidence in Spain and Israel (approximately 3.5) as well as in in at least two Polynesian populations, the New Zealand Maori and the Hawaiian Polynesian, with a similar incidence. At the same time, considerable variation among Asian populations is evident: China has the lowest reported incidence (0.1), Korea is intermediate (0.5), and Japan is the highest (1.0). These striking ethnic differences are not paralleled by any childhood malignancy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data adapted from: Triche TJ, Sorensen PHB. Molecular pathology of pediatric malignancies. In: Principles and Practice of Pediatric Oncology, 4th ed. Pizzo PA, Poplack DG (Eds), Lippincott Williams and Wilkins, Philadelphia 2002. p. 163.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_47_28415=[""].join("\n");
var outline_f27_47_28415=null;
